Sponsored By
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Glioblastoma Multiforme

NCT Trial Name# of Centers


  Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme


  Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery


  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme


  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme


  Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma


  Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme


  Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma


  Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors


  Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma


  Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma


  Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)


  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)


  Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients


  Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer


  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma


  The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma


  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)


  A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 )


  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)


  An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)


  A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy


  A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma


  A Study in Recurrent Glioblastoma (GB)


  Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme


  An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)


  Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma


  A Study of TAS-120 in Patients With Advanced Solid Tumors


  Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors


  Study of Palbociclib in MLL-rearranged Acute Leukemias


  International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)


  A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma


  Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma


  Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma


  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III


  Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)


  Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme


  A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma


  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)


  A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors


  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas


  Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme


  Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma


  Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors


  Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme


  Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors


  Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme


  DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma


  Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)


  Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2)


  Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas


  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects


  A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma


  Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects


  Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme


  Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.


  Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma


  Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients


  Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.


  Phase I Study of APX005M in Pediatric CNS Tumors


  Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma


  Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers


  Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma


  Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy


  p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors


  A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma


  Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas


  Post-approval Study of NovoTTF-100A in Recurrent GBM Patients


  A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma


  Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors


  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients


  A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma


  Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma


  Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma


  Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma


  Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies


  A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies


  Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma


  Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma


  A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma


  Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma


  Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma


  A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma


  Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma


  A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)


  Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)


  Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients


  Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme


  Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma


  Phase 2 Study of MEDI4736 in Patients With Glioblastoma


  Pembrolizumab +/- Bevacizumab for Recurrent GBM


  Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma


  HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma


  MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma


  Disulfiram in Recurrent Glioblastoma


  First in Patient Study for PF-06840003 in Malignant Gliomas


  Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme


  A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)


  Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme


  INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)


  A Study of Abemaciclib in Recurrent Glioblastoma


  Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer


  Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma


  A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)


  Using Genomic Analysis to Guide Individual Treatment in Glioblastoma


  Nativis Voyager for Newly Diagnosed GBM


  A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients


  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma


  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma


  Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma


  Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma


  Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma


  Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma


  Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma


  Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma


  A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma


  PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation


  Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas


  Lenalidomide and Radiation Therapy in Treating Young Patients With Pontine Glioma or High-Grade Glioma


  Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma


  A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma


  GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients


  A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer


  This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)


  Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies


  A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma


  Regorafenib in Relapsed Glioblastoma


  A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas


  A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma


  Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer


  Safety and Efficacy of TTFields Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma


  Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma


  Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)


  AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme


  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma


  Surgery for Recurrent Glioblastoma


  A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor


  Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers


  INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme


  VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM


  Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab


  An Efficacy Study Of Ortataxel In Recurrent Glioblastoma


  Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma


  Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas


  Clinical Study of WT2725 in Patients With Advanced Malignancies


  Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma


  Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma


  Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma


  Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma


  LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma


  MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme


  Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas


  A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab


  EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation


  Timely End-of-Life Communication to Parents of Children With Brain Tumors


  PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma


  Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas


  A Trial With Dose Optimization of OTX015 in Recurrent Glioblastoma Multiforme (GBM) Patients


  Everolimus for Children With Recurrent or Progressive Ependymoma


  Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma


  Feasibility Study on LITT for Newly Diagnosed Glioblastoma


  Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma


  A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)


  Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma


  mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme


  Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma


  Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma


  Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma


  Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma


  AMG 595 First-in-Human in Recurrent Gliomas


  Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis


  Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients


  Improving Goals of Care Discussion in Advanced Cancer Patients


  Prevention of Thrombocytopenia in Glioblastoma Patients


  Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma


  Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2


  Easing Psychosocial Burden for Informal Caregivers


  Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme


  Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma


  Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma


  A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)


  Safety and Efficacy Study in Recurrent Grade IV Glioma


  Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma


  Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma


  INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)


  Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme


  Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects


  ONC201 in Adults With Recurrent H3 K27M-mutant Glioma


  Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma


  Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children


  Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma


  Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas


  Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma


  A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma


  Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors


  An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse


  Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme


  A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma


  A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas


  Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery


  Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors


  Vorinostat and Radiation Therapy Followed By Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Pontine Glioma


  BIBF 1120 for Recurrent High-Grade Gliomas


  More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery


  Safety Study of MGA271 in Refractory Cancer


  Low Dose Radiation Therapy for Glioblastoma Multiforme


  Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma


  Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors


  Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)


  Gene Expression, Immunological Status and Metabolome in Glioma Patients


  R04929097 and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma


  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma


  Amgen 386 for Recurrent Glioblastoma


  Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma


  Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma


  A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma


  Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer


  Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme


  Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide


  Bosutinib in Adult Patients With Recurrent Glioblastoma


  A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors


  A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas


  CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM


  NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma


  Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study


  Bevacizumab and Lomustine for Recurrent GBM


  Derivation of Tumor Specific Hybridomas


  Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas


  A Phase 2 Study of BGJ398 in Patients With Recurrent GBM


  MRSI to Predict Response to RT/TMZ ± Belinostat in GBM


  TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors


  A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma


  Glioma Modified Atkins-based Diet in Patients With Glioblastoma


  Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma


  TH-302 in Combination With Bevacizumab for Glioblastoma


  Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner


  Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery


  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma


  Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas


  Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma


  Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)


  Seizure Treatment in Glioma


  Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma


  Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma


  A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102


  Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma


  Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors


  MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas


  qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.


  Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma


  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma


  Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475


  Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors


  TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma


  A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme


  A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)


  Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma


  Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma


  Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme


  Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients


  The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells


  Curcumin Bioavailability in Glioblastoma Patients


  Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma


  TRC105 for Recurrent Glioblastoma


  Bevacizumab With or Without Surgery for Adult Glioblastomas


  AZD7451 for Recurrent Gliomas


  Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis


  Evaluation of [18F]-FMISO for Non Operated Glioblastoma


  Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme


  AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme


  Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab


  A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas


  Additive Homeopathy in Cancer Patients


  A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma


  Pilot Immunotherapy Trial for Recurrent Malignant Gliomas


  Cilengitide Imaging Trial in Glioblastoma


  The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells


  Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme


  A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection


  Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer


  I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers


  A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)


  Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon


  I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD


  Glioblastoma Platelet Activation Study


  uPAR-PET/MRI in Glioblastoma Multiforme


  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers


  Bioavailability of Disulfiram and Metformin in Glioblastomas


  Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer


  Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme


  Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study


  Safety Study of Afatinib for Brain Cancer


  Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model


  IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma


  Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma


  Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas


  Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme


  Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)


  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens


  Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma


  TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma


  Enhancing Optune Therapy With Targeted Craniectomy


  Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma


  CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas


  A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma


  Integrative Analysis of Human Glioblastoma Multiforme


  Non Invasive Cancer Test (NICT): a Proof of Principle Study.


  BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab


  Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma


  Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma


  Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over


  FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma


  Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients


  Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma


  Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme


  Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma


  Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification


  Temozolomide Chronotherapy for High Grade Glioma


  Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma


  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients


  Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA


  Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)


  The Addition of Chloroquine to Chemoradiation for Glioblastoma


  Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis


  Determination of Immune Phenotype in Glioblastoma Patients


  Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma


  HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors


  Tumor Hypoxia With HX4 PET in Several Diseases


  Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma


  VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma


  Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma


  Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM


  Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.


  Evaluating Therapeutic Response to Novo-TTF


  Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy


  Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme


  A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)


  A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)


  89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme


  Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas


  Metformin And Chloroquine in IDH1/2-mutated Solid Tumors


  Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors


  Fluorescence Spectroscopy Guided Surgery


  Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients


  Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma


  Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma


  Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma


  Neoadjuvant Nivolumab in Glioblastoma


  DC Migration Study for Newly-Diagnosed GBM


  MRSI Guided Dose Escalated Radiation in Glioblastoma


  A Feasibility Study of the Nativis Voyager™ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia


  Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma


  Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme


  Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma


  NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse


  T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma


  Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy


  Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas


  CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor


  Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid


  Brain Glioma Registry Combining Clinical and Imaging Information


  Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients


  Cancer Stem Cell High-Throughput Drug Screening Study


  Spatial Analysis and Validation of Glioblastoma on 7 T MRI


  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas


  Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma


  Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)


  Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma


  Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma


  Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery


  A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy


  Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma


  Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme


  Radiomics for Prediction of Survival in GBM


  Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma


  Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker


  Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma


  BrUOG 329 GBM Onyvide With TMZ


  NCT Neuro Master Match - N²M² (NOA-20)


  Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM


  Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma


  Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma


  Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma


  A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin


  A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer


  Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma


  Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM


  EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)


  Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma


  Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy


  Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)


  Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma


  Chronic Convection Enhanced Delivery of Topotecan


  LITT Palliative Treatment for Patients With Malignant Gliomas


  HMPL-813 in Treating Patients With Glioblastoma


  Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme


  Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma


  Prognosis and Therapeutic Biomarkers for Glioblastoma Patients


  Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)


  Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer


  Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma


  SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors


  Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma


  Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)




  Phosphorus 32 in Treating Patients With Glioblastoma Multiforme


  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade


  Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields


  Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma


  A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas


  HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors


  Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors


  Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer


  AMG 102 and Avastin for Recurrent Malignant Glioma


  Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients


  Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer


  Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.


  Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy


  Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma


  Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers


  [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers


  Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy


  Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)


  3D-Prediction of Patient-Specific Response


  Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma


  Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment


  A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas


  HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM


  HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM


  Predictive Role and HuR Mechanisms of Regulation in the Brain Tumours


  GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification


  Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma


  Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM


  Exercise in Patients With Glioblastoma


  Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma


  Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma


  FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy


  A Trial of KB004 in Patients With Glioblastoma


  Restricted Calorie Ketogenic Diet as a Treatment in Glioblastoma Multiforme


  Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)


  Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI


  Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor


  Phase I EGFR BATs in Newly Diagnosed Glioblastoma


  PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme


  TTFields In GErmany in Routine Clinical Care


  Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma


  Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)


  Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)


  Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide


  Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children


  Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma


  Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma


  A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma


  5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme


  Spectral Analysis Probe to Identify Glioblastoma Cells


  Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients


  Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation


  Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.


  NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma


  Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma


  Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.


  Glioma Microenvironment an Exploratory Study


  NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy


  Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma


  Hypofractionated Radiation Therapy for Glioblastoma


  Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients


  Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM


  HUMC 1612: Optune NovoTTF-200A System


  Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma


  NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery


  INtraoperative photoDYnamic Therapy of GliOblastoma


  Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.


  A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma


  Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI


  Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma


  A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients


  Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme


  Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?


  Ketogenic Diets as an Adjuvant Therapy in Glioblastoma


  A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme


  A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas


  Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas


  Safety of BBB Opening With the SonoCloud


  A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas


  Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma


  Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas


  SmartCare: Innovations in Caregiving Interventions


  Preoperative Chemoradiation for Glioblastoma


  Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)


  Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme


  Trial of Hypofractionated Radiation Therapy for Glioblastoma


  Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed GBM.


  Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma


  Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme


  CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR


  Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme


  Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma


  Image-derived Prediction of Response to Chemo-radiation in Glioblastoma


  Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study


  Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)


  Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma


  Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme


  The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma


  DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors


  TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM


  A Phase 0 Study of AZD1775 in Recurrent GBM Patients


  Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma


  Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)


  Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma


  A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70


  Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas


  Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme


  A Pilot Trial Testing the Feasibility of Molecular Profiling in Recurrent/Progressive Glioblastoma


  Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma


  Bevacizumab w / Temozolomide PET & Vascular MRI For GBM


  Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma


  Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma


  Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured Compared to Avastin/Irinotecan


  Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma


  ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme


  Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma


  INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study


  Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid


  Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma


  MET-PET for Newly Diagnosed Glioblastoma


  Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma


  Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma


  Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96


  FMISO PET Study of Glioblastoma


  Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM


  Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters


  Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors


  Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)


  Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy


  Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma


  Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme


  Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas


  Procarbazine and Lomustine in Recurrent Glioblastoma


  Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients


  Bevacizumab Beyond Progression (BBP)


  A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients


  Carbon Ion Radiotherapy for Recurrent Gliomas


  Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)


  BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)


  A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma


  Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study


  Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme


  Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA


  Tivozanib for Recurrent Glioblastoma


  18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy


  Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma


  Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma




  Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM


  A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme


  Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma


  FET-PET for Evaluation of Response of Recurrent GBM to Avastin


  Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme


  Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22


  A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma


  Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide


  Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma


  Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma


  A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma


  Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure


  NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme


  Virus DNX2401 and Temozolomide in Recurrent Glioblastoma


  Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma


  3T MRI Biomarkers of Glioma Treatment Response


  Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia


  Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma


  Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors


  A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors


  Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma


  Immunophenotyping From Blood of Patients With Malignant Gliomas


  Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery


  Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1


  Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma


  Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial


  MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme


  Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors


  Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)


  A Phase I/II Study of the Photon Radiosurgery System


  Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain


  PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform


  Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme


  BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor


  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas


  Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma


  Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)


  Radiosurgery Plus Bevacizumab in Glioblastoma


  Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors


  Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors


  Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)


  A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas


  Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma


  Magnetic Resonance (MR) Imaging Study Using Ferumoxytol to Assess Early Tumor Response in Patients With Glioblastoma Multiforme


  Establishment of a Brain and Spinal Tumor Tissue Bank


  Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours


  Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma


  Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma


  Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma


  Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme


  Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme


  Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme


  Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma


  Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA


  Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA


  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma


  Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme


  Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors


  A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas


  Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA


  Vitamin D for Treatment of Glioblastoma Multiforme


  iMRI Guided Resection in Cerebral Glioma Surgery


  CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII


  Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)


  Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas


  PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma


  Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma


  Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma


  A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma


  Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients


  A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma


  Biomarkers for Prognosis of Glioblastoma (GBM)


  Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents


  HYPAZ: Hypertension Induced by Pazopanib


  Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma


  E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)


  Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection


  Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma


  Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene


  Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.


  Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab


  Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas


  Carbon Ion Radiotherapy for Primary Glioblastoma


  Dendritic Cell Vaccine for Patients With Brain Tumors


  A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma


  Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme


  O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma


  Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)


  O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas


  Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide


  Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma


  Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma


  Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors


  Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme


  Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme


  Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma


  Carboplatin in Treating Patients With Recurrent High-Grade Gliomas


  Dexanabinol in Patients With Brain Cancer


  Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma


  NOA-12: BIBF1120 and R-RT in Glioblastoma


  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma


  Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence


  Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors


  Imaging Study of Glioblastomas Treated With Avastin


  Study of DC Vaccination Against Glioblastoma


  Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas


  Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma


  Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma


  Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme


  PVSRIPO for Recurrent Glioblastoma (GBM)


  Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma


  Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors


  Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients


  Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma


  Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)


  ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Glioblastoma

Brain Tumor News Articles About Glioblastoma Multiforme

  1. [05/16/2019] Optune Open Houses  These meetings are for anyone who uses or is thinking of using Optune.  Most of these are live but there are some broadcast on the web!  

  2. [05/09/2019] Medicare proposal to cover Optune for Glioblastoma  We need to fight this.  I will provide details next week!

  3. [04/29/2019] The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.  I am a fan of the CUSP 9 protocol.  Might be worth considering adding it to whatever else your plan is.  

  4. [04/29/2019] Optune Open House  Here is an updated list of the Optune Open Houses.   These meetings are interesting and a lot of fun for everyone who has  a brain tumor.

  5. [04/27/2019] Correlation of Tumor Treating Fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the Phase 3 EF-14 randomized trial.  This is a very technical article but basically it boils down to showing that there is a dose-response curve.  The higher the dose the better the patient does.  The dose is determined by the arrangement of the arrays around the tumor, as well as the average compliance time - which is the % of time the machine is turned on! The differences in survival are pretty significant.  The doctor has to determine the positioning of the arrays (and articles like this will help optimize that), but the patients can work on the second part: compliance.   I find that most patients do not understand the importance of high compliance. The doctors usually say to try for about 70% compliance, but the evidence says if you can get to 90% or better, there is a big improvement.  Unlike drugs which work for days or weeks after you take them, Optune stops working the second you turn the machine off - and starts again when you turn it on.  

  6. [04/20/2019] Cancer and the dopamine D2 receptor: a pharmacological perspective.  Interesting article.  They are correct that the D2R receptor family (also known as  DRD2) is very important in many types of cancers, including brain tumors – especially in tumors of the midline and brainstem.

    However, they are incorrect when they say there is no useful way to target this. The drug Onc201 is a very selective antagonist to DRD2 and is now in clinical trials for brain tumors.    Although it is too early to tell how well it works, I have seen a few remarkable responses to it already. This article talks about trying to repurpose older drugs that are NOT selective.


    Disclaimer:  The Musella Foundation was an early supporter of Onc201 and we are involved in funding the compassionate use program for this treatment.

  7. [04/15/2019] Use of metformin and outcome of patients with newly diagnosed glioblastoma - pooled analysis.  This study did not show a significant imporvement in outcomes when using Metformin.  Metformin is a drug used to control high blood glucose in diabetics but has been used off label to try to treat cancers including brain tumors.  More research needs to be done before we write this off.

  8. [04/09/2019] Optune Open Houses

    This is a chance to learn about Optune - or for those of you using it - to meet others using it and swap tips and ask the experts any questions you have!  Most are live but the last one is a webinar.

  9. [04/03/2019] High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.

    We already knew that there is a high frequency of this mutation in the pediatric thalamic tumors but this study shows that 60% of adult thalamic tumors have this mutation.    Glioblastoma in this area have the worst prognosis. This article shows why - all are MGMT unmethylated, and most have the H3K27M mutation.    The good news about all of this is that now we have options that we did not have before:

     For the H3K27M mutation, the experimental drug Onc-201 can be tried. There are trials available for it and if you do not fit the trial, we are involved in a compassionate use program for it - call us.  

     For the unmethylated MGMT, there is a different experimental drug - Val-083 which is in trial that is similar to Temodar but works in a different area of the DNA so it is unaffected by the MGMT status.


  10. [04/03/2019] New Glioblastoma Vaccine Shows Promising Results in Phase 1b Clinical Trial  This is an interesting new type of vaccine.  These are early results but looks good.

  11. [03/28/2019] New Strategies Take On the Worst Cancer—Glioblastoma  This opens another option for people about to have a brain tumor surgery.  This article describes how they give a cocktail of drugs  a few days before the surgery then when they do the surgery they can measure if the drugs got into the tumor and if they have shown efficacy.  If yes, they continue with that cocktail, if not, they switch to something else.    This prevents you from wasting time with an ineffective cocktail.  This team is also open to experimenting with different cocktails based on prior lab results. The article says that this team treats more glioblastomas than any other center in the country!

  12. [03/20/2019] Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.  This is one of the more exciting treatments in the pipeline, but unfortunately this trial did not show good results for most of the patients.  2 patients out of 18 did well.   There are many variations of CAR-T cells, using many different targets. This doesn't mean all Car-t cell trials won't work.

  13. [03/14/2019] Optune Open Houses
    These are informative and fun meetings. Some of them are webinars available online for those not close to a live meeting.  All are free.  They are sponsored by Novocure and the Musella Foundation is not involved - I am just letting you know about them because they are important!  

  14. [03/13/2019] Newly Diagnosed Glioblastoma: A Review on Clinical Management  Excellent review of glioblastomas and how to treat them.

  15. [03/12/2019] A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma  I was really hoping this trial would turn out well but it failed to meet it's endpoints.   This is a different way of using vaccines - it makes a lot of sense.  However, they chose to try it on recurrent glioblastomas, which might have been too late. 

  16. [03/10/2019] Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.  This looks good for recurrent GBM.  It is too small of a study to tell for sure but the survivals compare very well to historical survivals.  We need to follow all patients who use Optune to see which combinations are the best, and this opens the door for more research on using Optune for recurrent GBM.

  17. [03/09/2019] Optune Open House These are nice meetings if you are using Optune or are considering it!  

  18. [02/23/2019] Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.  This shows what we already assumed:  getting treated in a academic center with a high volume of brain tumor patients will result in a better outcome.

  19. [02/22/2019] Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
    This is the results of a relatively small randomized study comparing Temodar to Temodar plus Lomustine for Newly Diagnosed GBM with MGMT methylation.  Results look very good - a significant increase in overall survival - about 17 months. However, I would like to see this study repeated with a larger number of patients, and possibly include Optune use.
     One problem I have is that the treatment was limited to about 6 months of therapy.  Looking at the graphs, there is really no difference between the groups for the first 2 years.  Only 2 patients at the end of the trial make the plots diverge.  These 2 patients may have had different treatments after finishing the trial treatments or may just have been lucky. 

  20. [02/22/2019] Tocagen is looking for patients with recurrent high grade glioma (glioblastoma or anaplastic astrocytoma) and caregivers to participate in an advisory board event in San Diego from March 20-21st.  From our friends at Tocagen!  Sounds like an exciting meeting!

  21. [02/13/2019] Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema.  This is another way to beat the edema from a brain tumor without using steroids. These researchers used an antibody that blocks the protein that causes the swelling in the first place!  Again - too early but this is something to keep an eye on!

  22. [02/13/2019] Race influences survival in glioblastoma patients with KPS =?80 and associates with genetic markers of retinoic acid metabolism.
    This study shows a very large racial disparity - this time favoring African Americans.  They identified a set of genes that differed between the two groups, which may be responsible.   This difference is larger than most clinical trials would report as a successful treatment. It may be worth reporting clinical trial results by race and/or this group of genes now.
    Historically, African Americans have been way underrepresented in clinical trials – as shown by this study.  Out of almost 1,000 patients, only 6% were African American -  while in the USA African Americans make up about 13% of the population.   We are working to try to correct that – and other – disparities.  

  23. [02/13/2019] Progesterone is more effective than dexamethasone in prolonging overall survival and preserving neurologic functions in experimental animals with orthotopic glioblastoma allografts.  An alternative to dexamethasone is badly needed, especially when using immunotherapies or Optune.  This may be one such alternative but the experiment was done in rats.  Need to wait until it is tested in people before using it.  

  24. [02/13/2019] Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation
    Interesting experiment. Of course it is too early to tell if it will help people with a GBM, but something like this should be easy to pick up in our virtual trial.   For those of you who are participating, and take aspirin on a regular basis,  go back in and enter it!
    Warning:  Talk to your doctor before taking Aspirin.  It can also increase the chances of bleeding. It might also help prevent blood clots - but this is a delicate balance.

  25. [02/12/2019] Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

    This article intended to be a balanced article on the plusses and minuses of Optune.  Unfortunately it is loaded with errors and bias.  For example,


    1. They say:   They did a survey between January 2015 and July 2015 and found only 41% of doctors had access to the device.  Optune was approved for newly diagnosed in July 2015.  So they did the survey before the device was available for newly diagnosed. (The recurrent data was not great). This article was published in 2019.  Optune is now available at just about every major medical center in the USA. Their website, says there are 700 certified treatment centers that offer Optune in the USA.  They should have repeated the survey but instead used an old one that made Optune look bad.


    2. They harp on the fact that there was no sham device in the control group.  That would have been ridiculous.  Imagine having to shave your head twice a week and carry around the old version of the device (which was twice as heavy and bulky as the current version), and risk getting skin problems without a chance to benefit from it? I would not want to do that.  The endpoint was overall survival. Placebos cannot show such an increase in overall survival.  The Temodar studies did not use a placebo and nobody faulted the study for that. The Avastin trials did use a placebo but the placebo group did not do better than the treatment group (which means placebos do not help  glioblastomas). This is absolutely not an issue.


    3. They say Optune is not covered by Medicare or many other insurance companies. The second part of that statement is not true.  Over 90% of non-medicare insurance companies pay for Optune. They go on to say Medicare has now agreed to reconsider coverage – which only happened a few weeks ago so there is no reason to be so far behind on the statistics. That statement was true in 2015 but not in 2019. Hopefully by the end of this year all insurances including Medicare will be paying for it.  In the meantime, Novocure has said they would not let a patient not get access to this treatment due to being unable to afford it. They very generously gave it for free or at a very reduced rate to those on Medicare or who did not have insurance that covered it. 


    4. They keep talking about patients being reluctant to wear the device and shave their heads. This is too subjective. Of course patients would prefer not to shave heads or have to wear a device that constantly reminds them of the disease.   However, having to use a wheelchair, or being unable to speak, at a much sooner time are not great alternatives. It is a personal decision that the patient has to make.


    5. Finally – they complain about the price. At least they do point out that other new treatments are way more expensive.  I doubt we will ever see a new brain tumor treatment priced less than Optune.  Optune is about half of the price of Avastin, and the trials showed a big increase in survival for Optune, and no increase in survival for Avastin (although they did show a nice improvement in progression free survival and patients feel better on it). I never heard the complaint that Avastin was too expensive.  Hopefully we will have a few new treatments approved in the next year or 2.  We have no idea what they will cost but to put it in perspective:  The cheapest gene therapy on the market (for other diseases) is $373,000 for the one treatment. Most expensive now is over $1 million for the one treatment. A new one that is under review might be $4 million for the 1 dose. As for vaccines, the only one approved in the USA (for prostate cancer) cost about $93,000 for a 6 week course of treatment.    The only way to bring these prices down to earth is a major change in regulatory policy – but that is for another day.


  26. [02/12/2019] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.  I posted this a while ago when it was presented at the SNO meeting but it was just published so I am posting it again. One of the more important papers of the year. They were able to double survival just by starting the pembrolizumab (Keytruda) before surgery instead of after surgery the way it was always tried in the past.  This is important enough to print out and save it - if you ever need a brain tumor surgery ask your doctors about starting Keytruda before the surgery. Show them the article.

  27. [02/10/2019] Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55 Exciting results for this experimental treatment which is in clinical trials for recurrent GBM.  This is give  one time, using convection enhanced delivery.  May be worth considering if you have the correct marker: Type II interleukin-4 receptor (consisting of the IL4Rα  and IL13Rα 1)

  28. [01/26/2019] Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells.  This is a very technical article that says that adding a calcium channel blocker to TTFields (Optune) may work better than TTFields alone.  There are many calcium channel blocking drugs available, approved as medications to treat high blood pressure. The authors used Benidine, which is approved in Asia but not the USA. They suggest, but did not try, Nifedipine may also work. This is available in the USA for high blood pressure and is easily available. This is perfect for our Virtual Trial project.   (See  click on Virtual trial for details and to join). We can observe patients who are using Optune and compare those who also report using Nifedipine compared to those who do not report using Nifedipine.   We do not have any patients reporting that combination yet - so we need more participants!  All brain tumor patients should participate so when things like this come up we can just press a few keys on the keyboard and have the answer!    

  29. [01/26/2019] The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma.  This is a pretty technical article but basically it says that  you need to target both pathways (NOTCH and PI3K)  at the same time to have a major effect.  There are a few drugs approved for PI3K  inhibition and  a few experimental NOTCH inhibitors in clinical trials.  These have to be tried in combination for GBM.  

  30. [01/26/2019] Effect of health disparities on overall survival of patients with glioblastoma.  This article shows what we already knew:  If you do not have insurance and you are diagnosed with a GBM, you are going to have trouble getting treatments and you will not have any chance to beat it.  80% of the uninsured patients did not even get the standard of care treatment.  This is not acceptable. The system has to be changed.  

  31. [01/26/2019] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial This is probably the most important article about Optune.  It updates the data reported the prior year and shows a little better results.  If you can maintain over 90% compliance, the  % of patients alive at 5 years was 29.3% compared to 4.5% in the control group which was Temodar and whatever else the doctor and patient wanted to use.  This is the best survival rate ever reported in a large brain tumor trial and should finally put to rest any resistance to it's use.  At this point, Optune (plus Temodar)  should be considered the new standard of care.

  32. [01/22/2019] Dexamethasone—Friend or Foe for Patients With Glioblastoma?

    This is a very important article. It says that using Dexamethasone hurts the immune system.  Sometimes we need it - it is used to treat swelling of the brain which can cause death, but we should be careful and consider other treatments if possible,   Temozolomide has a similar effect.  This means it might be best to start immunotherapies before starting Temozolomide, and before the surgery that necessitates the use of Dexamethasone. And also keep the dosage of Dexamethasone to a minimum if possible NOTE: Dexamethasone is the one drug that you can NOT just stop cold turkey - that can kill you. There is a weaning schedule that has to be followed closely so you can not adjust the dose yourself. You need to talk to your doctors about this.

  33. [01/19/2019] Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma.  This article talks about the role of DRD2 in GBMs.  Looks like it may play an important role.   Onc-201 is an experimental drug in clinical trials for brain tumors. It is a DRD2 antagonist. This may explain it's method of action.

  34. [01/18/2019] Optune Open House, Newton, MA  These are great get togethers for any brain tumor patient or anyone who knows a brain tumor patient!  

  35. [01/09/2019] Musella Foundation awards 2 grants! The first grant is for the development of a new type of vaccine for the treatment of brain tumors.  The second is a project to try to make it easier to find the correct clinical trials.  It is not just a matching service - it is a system where clinical trials will be explained and reviewed so we have more information to go on when selecting a clinical trial!  

  36. [01/09/2019] ERC-USA Initiates Therapy Under Right to Try Law With First Patient In California Using Investigational Compound ERC1671 for Treatment of Glioblastoma  This is the first case I heard of where a brain tumor patient was able to get a treatment under the "Right To Try" laws.  I do not know what the costs are (if anyone finds out - please let me know).  This is one of the more exciting vaccines. It is made with fresh tumor sample from the patient AND with tumor samples from 3 other people with the same tumor type. The idea is that should allow the vaccine to hit any of the current targets in your tumor, but also prevent the tumor from mutating around the vaccine - since the most common mutations were picked up from the donors!

  37. [01/07/2019] Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

    They should have done this a long time ago. I hope this becomes available for patients soon.  The delivery method should be approved separately from the drugs used - so we can mix and match drugs based on a patients' genetic profile.

  38. [12/24/2018] Identification of a novel role of IL-13Ra2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway

    This article shows that most GBMs overexpress IL-13Rα2  and that this may be involved in making the tumor invasive, proliferation and angiogenesis.  There are a few experimental treatments that target this marker.  ICT-107 was a vaccine that showed remarkable results in a few subgroups of patients but "failed" their pivotal trial  and is no longer in development.  GB-13 is in preclinical testing and hopefully will get into clinical trials soon..

  39. [12/19/2018] Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. I have written a lot about this drug (Onc-201) lately - I am excited about it and we (the Musella Foundation) have a special interest in it because we gave grants to help them get this far!  This study shows that it may also be good to treat many other types of tumors that overexpress the target!  Right now for brain tumors it is in clinical trials for DIPG and high grade gliomas that have the H3 K27M mutation - which usually occurs in younger people with tumors in the midline of the brain.

  40. [12/15/2018] An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. Voyager is an experimental  device that is worn on the head and is used to treat the brain tumor.  This small study shows that the device is safe, but we can't tell if it helps yet.  They have a very impressive list of authors on the paper, so I know the research will be done correctly.

  41. [12/13/2018] Tumor treating fields increases membrane permeability in glioblastoma cells.  This show a different possible method of action for Optune.

  42. [12/03/2018] Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.  I am a big fan of Optune, and think almost all GBM patients should be on it. It is the best treatment currently available, but it is not good enough by itself.  We need to find what to add to it so that it works for everyone.  This article presents one such combination.   There are hundreds of other combinations that also need to be tested and the only way we are going to find the best combination is for us to track the outcomes of every patient who uses Optune.  We are now tracking patients in our virtual trial project. Go to and click on virtual trial to learn about it and join. It is free - but you need to commit to posting update monthly for as long as needed.  All brain tumor patients should be participating, but especially if you are considering Optune.

  43. [12/03/2018] Help Us Better Understand Glioblastoma Multiforme - Paid survey!  This is from our friends at Pinpoint Patient Recruiting.  They are doing a survey about GBMs. They want GBM patients or caregivers to participate in an online survey, and are offering you $75 for your time.  They will also make a donation to the Musella Foundation! Please let us know if you do the survey and your experiences with it!

  44. [11/22/2018] The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma.  This paper shows that it is worth traveling to a major brain tumor center.

  45. [11/22/2018] Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target  This is one of the most important articles of the year. It opens the door for improving response to immunotherapies in brain tumors.

  46. [11/20/2018] Musella Foundation 2018 Highlights  As the year comes to a close, we reflect back on what was accomplished.  This was a really exciting year for brain tumors.  We feel that we are on the cusp of a major breakthrough. Everything is coming together - many clinical trials are reporting long term survivors in a small % of patients.  Our goal is to speed up the approvals for these treatments so doctors can combine them in cocktails and get long term survivors for most  brain tumor patients!

  47. [11/11/2018] Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.  Mebendazole is an old, cheap, easily available drug approved for  treating worm infestations.  This paper (and many others) suggest it might be useful for treatments brain tumors, especially when combined with radiation. This article is about meningiomas but other articles mention GBM and Medulloblastomas!  

  48. [11/10/2018] The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma.  In the case presented, the patient had a GBM but was allergic to Temodar so they had to try something different.   They tried erltinib and Optune, which has resulted in stable disease for at least 9 months after radiation.  It is only 1 case but shows brilliant thinking on the part of this patient's team. They chose Optune, which is the obvious choice, but since the patient overexpressed EGFR, they also added erlotinib.  More research needs to be done on such combinations of Optune and therapies personalized to the patient!

  49. [11/08/2018] Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.  Adding Valproic Acid to the standard radiation and Temodar for GBM might help a lot without adding any more long term problems.

  50. [10/12/2018] Bevacizumab: Is the lower the better for glioblastoma patients in progression?  This one is hard to interpret.  The authors say that a low dose is just as effective as the standard dose of Avastin, but with less side effects (and less cost).   They should have included the control gorup of patients who do not use Avastin. But it is something to think about.

  51. [10/12/2018] Checkpoint Blockade Reverses Anergy in IL-13Ra2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.  This type of treatment worked miracles in other types of cancer. The first attempt in human glioblastoma wasn't spectacular but these researchers may have found a way to make it work at least in dogs and rats.  Lets hope it translates to people! 

  52. [10/04/2018] Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018

    This shows that Optune has finally hit the mainstream.  55 presentations at the major European brain tumor conference.  Many of these are looking at ways to improve the outcomes, including new types of arrays, new placement of arrays for tumors lower in the skill and for pediatric patients.

  53. [09/17/2018] Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.  I love this type of research.  Invadopoia are small projections from the edges of tumnor cells that help allow them to move.  Without the ability to move, the tumor is much less dangerous and more sensitive to normal treatments. This is a highly underappreciated target and they found 2 existing drugs which may target this.  Of course, it is just theory now and needs to be tested but it is a promising approach!

  54. [09/14/2018] Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.  I am a big fan of Optune. It is the most effective approved treatment for gbms,  but it is not good enough by itself. We need to find ways to make it work better.  There are about 16 clinical trials going on now that involve Optune and ways to make it work better.   Any of these trials are worthwhile to try.  Experiments like this are needed to identify candidates for the trials. 

  55. [09/10/2018] Intra-tumoral treatment with oxygen-ozone in glioblastoma: A systematic literature search and results of a case series  Interesting results, but in a small number of patients.

  56. [09/06/2018] KKCO - Daybreak Anchor Sarah Schwabe`s Connection To Glioblastoma  A video segment about glioblastoma

  57. [08/29/2018] Optune open house Seattle, WA  These are always very interesting and worth going for anyone dealing with a brain tumor.

  58. [08/27/2018] Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib impairing VEGF-related signaling.  Interesting study - but it is only in the test tube. We follow Aspirin in the virtual trial but nobody has recorded it - I know many people must be taking it long term for heart protection - they just aren't recording it. If you are in the virtual trial and take long term Aspirin , please go back and post an update so we can see if it helps!

  59. [08/24/2018] New glioblastoma clinical trial: mTOR inhibitor ABI-009  This is a new trial for newly diagnosed GBM or recurrent high grade glioma in adults (age 18+).

  60. [08/23/2018] Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.  This drug has a strange past - it did very good in early trials for breast cancer but failied in the large phase 3 trial.  It seems to have lottle toxcicity and the early brain tumor trial showed good results so it is worth a try again

  61. [08/22/2018] Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients This is another type of analysis of the latest Optune trial for newly diagnosed GBM. Unlike most results that are published, this is for an evaluation of the health economics where they use a mathematical model to predict how long patients will live in each arm of the trial if they were observed over the course of 15 years instead of about the 5 years covered by the trial. This reports the average survivals, not the median survivals that were already presented.  The main difference is the median survival is the point at which the person at the midpoint of the trial dies. For example, if there were 500 patients, it is the point at which patient number 250 dies.  This allows them to report the information in a reasonable amount of time, but it doesn't give any insight into the long tail - patients who live for a long time. The average adds up all of the survival times and divides by the number of patients. This is impossible to do when patients live for a long time, so this study is using a model to estimate it.   This takes into account the long term survivors.   There are a few amazing numbers presented here.  IF you survive the first 2 years on Optune, you will have about a 17% chance of living to 15 years.  In the temodar group, that number is 8.7%.   The average life expectancy for the Optune group was 4.2 years vs. the control arm of temodar alone at 2.4 years.  An increase of 1.8 years!

  62. [08/01/2018] Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.  At least we now know you do not have to physically remove the pacemaker to use Optune.  Unfortunately you still have to turn it off.  Hopefully there will be more testing done so that we can keep it turned on.

  63. [07/27/2018] Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells. This study shows that Metformin MIGHT be useful to help other treatments work better. We know that by itself it is not going to cure a brain tumor, but the evidence shows it inhibits motility and invasion at least in the test tube.  Might be good to watch how it interacts with other treatments in the virtual trial

  64. [07/25/2018] The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma.  This study says that for a small group of patients (we have to be careful trusting results in small groups), overall survival was doubled by adding Avastin during or right after radiation ends for gbm patients who progress through radiation.

  65. [07/16/2018] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.  About 1/2 of the USA population has high blood pressure - so it may be worthwhile to consider this drug if you have a gbm, are taking Temodar and also have high blood pressure.  This is a perfect combination to observe in the virtual trial!  

  66. [06/30/2018] Returning to work after multimodal treatment in glioblastoma patients  This should be a key endpoint for clinical trials for glioblastomas.  In this study, only 18% of the patients went back to work after surgery, radiation and Temodar.  Out of these who did go back to work, most were not able to resume full time work. Only about 8 out of the 125 patients were able to return to work full time.    Some of the new experimental treatments such as DCVAX and Tocagen  not only had some long term survivors, but had people working full time in high level jobs 5+ years after diagnosis.  That is really what we want to see, even more than merely "surviving".

  67. [06/26/2018] Recurrent Glioblastoma Treated with Recombinant Poliovirus  See my editorial under the link to the full text of the article!  This is a major breakthrough and must read article!

  68. [06/13/2018] Musella Foundation awards 7 brain tumor research grants!  A big thank you to our amazing volunteers and participants in the National Walk To End Brain Tumors!  These projects are going to make a difference fast!

  69. [06/02/2018] Returning to work after multimodal treatment in glioblastoma patients.

    Returning to work after multimodal treatment in glioblastoma patients.         This is one of the most important outcome of brain tumor treatments. It should be considered an important primary endpoint for clinical trials: what % of patients  are able to work full time at the level of their previous job at 1,2,3 year point? What % of patients can work at least part time at any job at 1,2,3 years.  This is important because for the first time, we are seeing long term survivors of GBMs who can actually work full time at high level jobs, many years down the line.  Even if a treatment only improves median survival by a small amount, but allows those who do survive to engage in meaningful work - that is a breakthrough. For example, many years ago there were reports of a high % of long term survivors with intense radiation.  However, it caused so much damage that most survivors were bedridden for the rest of their lives.  More recently, with DC-Vax, ICT-107, Toca 511 / Toca FC, and others, we see some long term survivors who are functioning at the highest level - executive jobs, having families, driving and enjoying life.   That is what we strive for. So it should be a formal endpoint!

  70. [05/29/2018] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
    This article is so important that I am placing my editorial comments into the full text part of this entry so more people see it, along with a link to the full article.

  71. [05/25/2018] Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.  This is only 1 case report but it shows great results using an old drug in a new way.

  72. [05/24/2018] Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.  This study says that for glioblastoma patients with unmethylated MGMT, adding Temodar to radiation does not improve survival or progression free survival.    This is a retrospective study that does not control for other factors, but it is interesting. It opens the door for experimenting with other treatments for newly diagnosed MGMT unmethylated patients, such as perhaps substituting Val-083 instead of Temodar.

  73. [05/24/2018] Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.  Pretty good results, but it is in a small trial.   

  74. [05/23/2018] MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma  Excellent results with a simple shot in the arm -and minimal side effects. This is the type of treatment that we need access to now - not years from now.

  75. [05/13/2018] When did the glioblastoma start growing, and how much time can be gained from surgical resection? A model based on the pattern of glioblastoma growth in vivo.  Fascinating. We get this question all of the time. The answer is it takes about a year for the gbm to grow to the size where it causes symptoms and you notice it.   And there is a big gain from removing 99% of the tumor compared to 95%.  If they only remove 50% of the tumor, it will grow back before the surgery heals.

  76. [04/24/2018] Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas  Carboxyamidotriazole Orotate is an experimental treatment, given orally.  It is made by Tactical Therapeutics.  Visit their website at for details on how it works.  Looks promising but too early to tell for sure.

  77. [04/19/2018] A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma  Nothing we did not know before, but now this impressive journal has an article that says Optune should be the standard of care for GBMs.  This should help get insurance coverage for those few plans that still deny it.

  78. [04/18/2018] New Technology Crosses Blood-Brain Barrier To Fight Glioblastoma Cells Directly Interesting new drug - apparently did well in phase 1 testing.

  79. [04/18/2018] Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

    This study definitively proves what we already knew, that you do better if the entire tumor is removed. At a recent FDA advisory committee meeting I attended, the FDA said they did not believe that is the case.  Next time they will believe this study.  

  80. [04/12/2018] CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China  This is a new approach . They are running trials in China for newly diagnosed and recurrent GBM patients.

  81. [04/06/2018] Phase II clinical trial starts evaluating new drug for glioblastoma GDC-0084 (RG7666) which is a novel BBB-penetrating PI3K/mTOR inhibitor displaying a high brain-to-plasma ratio (1.9–3.3). It remarkably impedes the proliferation of five GBM cell lines and suppresses the growth of U-87 MG GBM xenografts through decreasing Akt phosphorylation 

  82. [03/31/2018] The Musella Foundation For Brain Tumor Research & Information, Inc awarded a brain tumor research grant today!  This is an important project because the drug being studied is approved for Lung Cancer. so if they find it useful for glioblastomas, it can immediately be used off label!

  83. [03/20/2018] NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma  This is great news.  The NCCN basically sets the standard of care for cancer treatments. The NCCN treatments classification is:

    NCCN Categories of Evidence and Consensus

    • Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
    • Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
    • Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
    • Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
    Not only does this set the standard of care as including Optune, but it should make it impossible for insurance companies to deny it.

  84. [03/15/2018] Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 That is an impressive number of presentations, and means that Optune has finally been accepted by the research community.  

  85. [03/13/2018] OURBRAINBANK: PEOPLE-POWERED, TECH-ENABLED START-UP TO TACKLE BRAIN CANCER  This is from our friends at "OurB Brain Bank".  It is an app that records your information to be used in research and helps match you with clinical trials.   We have similar projects going - the brain tumor virtual trial, and our clinical trials matcher, but it is good to get other points of view

  86. [03/09/2018] Optune Open House  This is from the people at Novocure.  It is a facebook event where you can learn about and ask questions about Optune!

  87. [03/03/2018] Help Us Understand Glioblastoma Multiforme (GBM) Patient Experiences better through a quick survey:  One more time...  only a few slots left for patients and caregivers.  You get $75 for responding to the survey, and the Musella Foundation gets a donation! Let me know if you do it!

  88. [02/28/2018] Advantages and disadvantages of combined chemotherapy with carmustine wafer and bevacizumab in patients with newly diagnosed glioblastoma: A single institutional experience.  This is a small study - so it can't be relied on completely. However, it shows that adding both Gliadel and Avastin to the standard Temodar for newly diagnosed GBM added 9 months to average survival and doubled progression free survival. Another tidbit - more than half of patients operated on in this hospital in Japan received Gliadel wafer.  

  89. [02/24/2018] Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.  Very interesting.   If this is true,  this may lead to big gains in immunotherapies.  One of the problems was the lack of CD8+ Killer T Cells in the area of the tumor. Apparently, Gliadel wafer may attract these cells to the tumor bed.  So we need to watch combinations of Gliadel with immunotherapies! Very exciting!

  90. [02/19/2018] Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Glioblastoma of the Corpus Callosum.  This may be another option for patients whose tumors are in the corpus callosum.  

  91. [02/14/2018] Help Us Understand Glioblastoma Multiforme (GBM) Patient Experiences better through a quick survey:  I have sent this before but now they only need a few more patients.  They already had enough caregivers.   If interested, they pay you $75 and give us a donation. (So let me know if you do the survey!)

  92. [02/10/2018] Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?  Unfortunately, this report says there is no effect.

  93. [02/08/2018] Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.  This trial shows why we need to test treatments in kids and not just assume that they will work the same as in adults.  This trial compares the standard of radiation and temodar with and without Avastin,  for newly diagnosed high grade glioma.  In previously reported trials on adults, there was a pretty good increase in progression free survival with just about no increase in overall survival.  In this study with children, they found that adding Avastin decreased both the progression free survival and overall survival, and there were more side effects in the Avastin group. [Disclosure: Genetech is a sponsor of our organization]

  94. [02/01/2018] Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial  JAMA is one of the most respected journals. The  conclusion: Considering the net clinical benefit, our HRQoL (healthcare related quality of life)  data support the addition of TTFields to standard therapy in patients with glioblastoma

  95. [02/01/2018] BTB Foundation Expands Giving with Academic Scholarship Opportunity (Chicago Area Only)  This scholarship is for students in the Chicago area affected by a brain tumor.

  96. [01/31/2018] ONC201 Trial Begins at NYU for Children with H3 K27M Mutant Glioma  This is an important trial for patients who have this mutation. Check your pathology report for the H3 K27M mutation, or if your child has a DIPG and did not have a biopsy - they most likely have this mutation.

  97. [01/31/2018] Please help Us Better Understand Glioblastoma Multiforme (GBM) Patient Experiences through a short, online survey:  I sent this out a few weeks ago.. They need just a few more patients.  

  98. [01/30/2018] Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.  This sounded like a great idea, but unfortunately it did not pan out in this study.  That is why we can't just go by theory - it has to be tested in trials.  

  99. [01/29/2018] Optune Open House, Santa Anna, CA  This is from the people at Novocure. These meetings are a perfect introduction to Optune for brain tumor patients thinking about trying it or those who are using it!  

  100. [01/17/2018] High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.  Very interesting.  In our virtual trial, we have 10 glioblastoma patients who tried the combination and they did a lot better, on average, than those who took Temozolomide without Metformin.

  101. [01/17/2018] Help Us Understand Glioblastoma Multiforme (GBM) Patient Experiences better through a quick survey:  This is only for patients (and caregivers) where the patient was diagnosed with a GBM in the last 15 months.  If that fits your situation, please take the survey.  You will get $75 for your time, and a donation will be made to the Musella Foundation.  (If you do the survey, let me know).  

  102. [01/11/2018] Drugs targeting the cells circadian rhythm offers hope for glioblastoma

    This article is a little complicated to follow, but it may lead to a breakthrough. Excellent work.

  103. [01/10/2018] Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage Glioblastoma  This is a trial for recurrent glioblastoma patients who have failed Temodar and Avastin.  There is another trial of Val-083 for newly diagnosed MGMT unmethylated patients.  Val-083 is a chemotherapy similar  to Temodar but works at a different location on the DNA of the tumor cells.  It should theoretically not be affected by the MGMT status and may work even when the tumor is resistant to Temodar

  104. [01/06/2018] Help Us Understand Glioblastoma Multiforme (GBM) Patient Experiences better through a quick survey:  We have worked with this company before, and they do pay the $75 to you, and also send a donation to the Musella Foundation!

  105. [12/27/2017] Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme  This is my favorite trial for newly diagnosed inoperable glioblastomas! They had some impressive results in the early trials - particularly among inoperable tumors.

  106. [12/26/2017] DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma  Great news!  This is one of my favorite experimental treatments.  Fast track designation will speed up the approval process!  

  107. [12/19/2017] JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma  This is the final report of the Optune trial for newly diagnosed GBM.  It should set the new standard of care for GBM to include Optune.

  108. [12/03/2017] Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.  This was only in mice, but it shows that using morphine might make temodar work better.  

  109. [12/03/2017] Correction regarding dose of Avastin in an old article  This correction just came out. In this article about Avastin for GBMs from 2008, they used the wrong units for the dosage calculation. The correct units are mg per kilogram, not the mg per square meter of body surface area that they originally reported.  The difference is huge. For a typical 200 pound 6' tall patient, at 5mg per square meter, the incorrect dose would be about 10mg of Avastin.  Using the correct formula, 5mg per kg,  it would be about 450 mg.   Note that the correct dose of Avastin is not really known. Some use 5mg per kg, some 10mg per kg and some higher doses.

  110. [12/02/2017] SNO 2017: No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators  The package inserts warns against using Optune if you have an implanted defibrillator  or a programmable shunt.  However, they looked at patients in the trials who had these devices implanted and used Optune anyway, and found that there were no safety problems.

  111. [12/02/2017] Researchers identify vulnerability for glioblastoma subtypes  This type of research is the key to finding the cure.  All of the treatments that have failed phase 2 and 3 trials should be retested to try to figure out why there was enough success in the phase 1 trial to justify the phase 2, then having the subsequent trial fail.  Most likely there is a subtype of tumor that IS sensitive to the treatment.  

  112. [11/24/2017] Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma  I love combinations like this. I believe that it might be impossible to cure GBMs with just a single approach. 

  113. [11/21/2017] Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.  This showed no benefit of adding Gliadel when 5-ALA was used to guide the surgery. Surprising results. 

  114. [11/21/2017] Lomustine and Bevacizumab in Progressive Glioblastoma. These results were disappointing.  Last year, the data was presented that this combination worked very well. This year they are saying that although there is a a relatively large improvement in progression free survival (from 1.5 months with the Lomustine (CCNU) alone to 4.2 months with the combination of Lomustine and Bevacizumab (Avastin), there was little (less than a month) improvement in overall survival.

  115. [11/21/2017] High compliance with Optune linked to greatest survival benefit for glioblastoma  There is a dose response curve. (Which also should convince the naysayers that the device is effective)   The better the compliance, the better the patients do. They have been saying 75% is the target compliance rate but the new data shows that 90% should be the target.  Those patients who had a compliance rate of 90% or more, had a survival rate of 29.3% at 5 years, compared to the control group (temodar) which had a 4.5% survival rate, an almost 650% increase in survival rate.
       With a compliance of 70-80%, the 5 year survival rate drops to 19.9%.   Still much better than the control group... so don't stress too much if you can't hit the 90%, but try.

  116. [10/30/2017] Health Beat: MDNA trial for glioblastoma  Video explains the trial.

  117. [10/11/2017] Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells  This is the type of research and thinking that can lead to major breakthroughs. Figuring out why treatments fail, and putting together intelligent combinations is the path to breakthroughs.  This research is in mice, hope they try it on people soon.

  118. [10/07/2017] ABC²`s Research Showcase: INSIGhT - The First-Ever Adaptive Clinical Trial for Glioblastoma  This is the wave of the future in clinical trial design. They will be broadcasting the event on facebook.  

  119. [09/27/2017] Amazing increase in survival for newly diagnosed GBM by adding CCNU  This study shows an amazing increase in survival by adding ccnu to Temozolomide.  These treatments are already available and may be worth asking your doctors about now. 

  120. [09/24/2017] Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients  The 5 year results for Optune just came out and they were unbelievably good.  This is a large study in newly diagnosed GBM patients so the results are significant. Bottom line: 5 year survival rate was 13% for the Optune (plus Temodar) group and only 5% for the Temodar alone group.  That is a major step forward.

  121. [09/14/2017] Treatment nonexistent for some glioblastoma patients

    This is why we are always telling our patients to seek care at a major brain tumor center. You need experienced people taking care of you. I cringe when people tell me they are being treated at a small community hospital. Many times when staff at a community hospital calls us to ask about our copayment assistance program and we explain the covered treatments, they say "what is Optune?".  You do not want to be treated at a center that doesn't keep up.

  122. [09/11/2017] DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme  For GBM patients with unmethylated MGMT, the standard Temozolomide has a much worse chance of helping. This may be an alternative. It works similar to how Temozolomide works, but at a different spot on the chromosomes so it is not affected by the MGMT repair enzyme.

  123. [09/11/2017] "Treatment Options for Glioblastoma and other Gliomas" Ben Williams` Aug 2017 Update  Ben Williams is a 22+ year GBM survivor who wrote an excellent book on his thoughts on how to approach a serious diagnosis.   The book talks about a lot of treatments - so it is out of date as soon as it is published.  So he puts together an update every year to keep it fresh.  Starting last year, our medical editor, Stephen Western, has taken over the updates - with Ben's approval of all changes.  We host these updates on  as a free service!  It is one of the more important articles on brain tumor treatments.   This years update is 138 pages! We discuss this on the braintumor treatments online group:

  124. [09/07/2017] Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas  This sounds exciting - it is a new target which is not usually found on normal brain but is found in GBM cells - especially cancer stem cells

  125. [08/18/2017] Reengineering Immune System Cells to Fight Glioblastoma  This may lead to a breakthrough in the treatment of most cancers!

  126. [08/16/2017] VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme  This vaccine showed very good results in early trials!

  127. [08/15/2017] Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas  This targets Oligo2, which sounds like it might be a great target 

  128. [08/14/2017] Options to Treat a Glioblastoma  I was asked for my opinion on what I would do if I had a newly diagnosed gbm.. here is my response.  We can discuss it in the braintumor-treatments online group  

  129. [08/14/2017] Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.  This is a very rare, but very serious,  side effect of checkpoint inhibitors. Although it is only 1 patient, keep this in mind if you hear of this side effect.

  130. [07/29/2017] Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.  Very interesting study. It says that starting radiation therapy earlier than we usual do actually is worse for the patient. The study was performed just by looking at billing records.  I would like to see more research on this. Perhaps look at the reasons radiation was started earlier. Maybe those patients had a lot of residual tumor so they were rushed into radiation as there was less space for recurrence? Or had some other medical reasons.

  131. [07/24/2017] Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma  All new trials should consider adding an Optune arm. Currently, a few interesting trials are not allowing patients to use Optune at the same time as the trial.  I feel that is not ethical. Optune has been shown to more than double the 5 year survival rate for adult GBM.  If you have to make a choice between trying Optune with a proven benefit and minimal side effects to trying an experimental therapy with no track record and inknown side effects, I would choose Optune.  [Disclaimer: Novocure is a sponsor of the Musella Foundation]

  132. [07/23/2017] Glioblastoma: New tools against brain cancer This is one of my favorite new treatments. It is too early to tell how well it works, but it looks promising.  Disclaimer: I am on the patient advisory board at the Brain Tumor Center at Duke (but have no financial involvement in this treatment)

  133. [07/19/2017] Human CAR-T Cell Glioblastoma Trial Generates Clues for Improving Treatment  This was too small to tell if the treatment works, but it did prove that these cells can cross the blood brain barrier- which is a major step forward.  CAR-T cell therapy is one of the most exciting new therapies available. Recently the first CAR-T cell therapy for leukemia was approved by the FDA, after trials showing very high long term remission rates after a single injection!

  134. [07/06/2017] Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.

    Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.         Gliadel wafer is a biodegradable implant that slowly releases chemotherapy at the tumor site.  It was approved on 1995 and it's popularity has waned. One of the main reasons is that many clinical trials said that using Gliadel wafer makes you ineligible for the trials.  Some major brain tumor centers use this routinely on everyone who has a glioblastoma surgery, and others almost never use it.  It is worth asking your surgeon about.  This report shows that it is associated with longer progression free survival and overall survival.

  135. [07/06/2017] Optimizing bevacizumab dosing in glioblastoma: less is more.

    The "standard" dosage of Avastin for brain tumors was not determined by a trial.  Other cancers used 10mg/kg.  The original small trials for brain tumors used 5mg/kg because of a worry about causing bleeding in the brain - which didn't happen, and it worked well. Then when larger brain tumor trials started up they went with the standard 10mg/kg dose other cancers use.  Some brain tumor doctors still use the 5mg/kg lower dose and feel it works as well or better with less side effects. This study goes a step further and says  less than 3mg may work as well or better with much less side effects. May be worth considering. They had a big increase in survival but there weren't enough patients to say that is significant statistically  


  136. [07/06/2017] Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme.

    Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme.         6 months of Temozolomide for newly diagnosed patients became the standard because the original trials specified 6 months. That was done to speed up the trials. They didn't try various lengths of time and picked the best. This study looks at using 6 vs 12 months or Temozolomide.  It is a small study - so you have to be careful, but using the 12 months of temozolomide increased overall survival by over 50% but did triple the chances of having toxicity.

  137. [06/21/2017] Looking Ahead: Combination Offers New Hope For Glioblastoma They are talking about the  combination of Tarceva and Thalidomide.  Looks good in the lab but needs to be tested in people.  Both parts are approved for other diseases so they should be easy to get.  I checked our virtual trial results. We had 2 glioblastoma  patients who reported using that combination. (and 2 patients with other tumor types) . One died after 24 months, the other is alive at over 10 years.  That is good - but you can not go by just 2 patients. If you try the combination, please join the virtual trial first so we can track it.

  138. [06/16/2017] Researchers assess pinworm medication for adults, children with glioblastoma  Very interesting, because if it is found to help, it can be used immediately as it is already approved for other uses and can be used off label.  

  139. [06/12/2017] First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma  Interesting combination.  I would guess the concept they are going after is that Avastin, when it fails, doesn't just stop working - it just doesn't work enough but still is slowing down the tumor.  If you add Optune, perhaps the combination could be strong enough to stop the tumor.  Hate to say, but it may make more sense to just start Optune at the start - right after radiation - on newly diagnosed people.  For those that missed that opportunity, this trial makes sense. [Disclaimer: Novocure is a sponor of our organizaiton]

  140. [06/07/2017] Medicenna’s Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology  [Disclosure - this company is a sponsor of the Musella Foundation|    It looks like the technology to get the drug in the correct spot at the right concentration is finally here. Follow the link in the press release to the background info on the delivery system.  And this may be the right drug to use. In an earlier study, in recurrent GBM patients, they had a few complete responders, with some still  alive 4 years later.  

  141. [06/01/2017] Musella Foundation awards 7 brain tumor research grants!  I would like to thanks all of the volunteers and participants in our "Natioanl Walk To End Brain Tumors" who made this possible, as well as the donors to our organization and the families that named us for memorial donations.

  142. [05/30/2017] Efficacy Results for ONC201 in Recurrent Glioblastoma Published
     Impressive results in a few patients. Interesting about the  histone H3 tumor mutations - it has been shown that brainstem gliomas commonly have that mutation. Unfortunately only adults are getting access to this compationate use program now. Maybe they will expand it to children after a few adults do well.
    The Musella Foundation funded the early work on this new treatment!

  143. [05/25/2017] Four Neuro-Oncology Experts to Lead New Glioblastoma Research Center at NewYork-Presbyterian  These are some of the brightest minds in the field. Great to see them working together!

  144. [05/20/2017] Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Until recently, this did not matter much, but as we get closer to treatments that can work on patients with unmethylated MGMT, this becomes of utmost importance.    To recap:  MGMT is a repair enzyme that can fix the damage caused by Temozolomide, making the cells resistant to Temozolomide. "Methylation of MGMT" means that the gene that codes for the MGMT repair enzyme is blocked so it cannot make the MGMT enzyme - which gives a better result for Temozolomide.   "Unmethylated MGMT" thus means that the gene is not blocked, and it makes the repair enzyme, so Temozolomide has much less chance of helping.  The controversy is that most tests do not say you are 100% methylated or unmethylated.  It is open to interpretation of where the cutoff between methylated and unmethylated lies.  Pathology labs should show the % of methylated cells in addition to the label of unmethylated or methylated, as this cutoff value can change.

  145. [05/19/2017] Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy  This is one of the most exciting treatments in the pipeline, but it is only 1 patient.  We will keep an eye on this.

  146. [05/14/2017] Tumor treating fields in pediatric high-grade glioma.  This is proof of concept - that kids (aged 10-20) can at least tolerate the treatment. 

  147. [05/14/2017] Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.  This is a different way to give Avastin - directly into an artery.  One case doesn't prove anything but it is very nice to see.

  148. [05/11/2017] First spherical nucleic acid drug injected into humans targets brain cancer  A completely new approach. I wish them luck. Looks very interesting!

  149. [05/08/2017] DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)  This is a very important trial - hopefully it will allow GBM patients who happen to have the "bad" markers to do as well (or better) than the current standard of care does with GBM patients who have the "good" markers!

  150. [04/19/2017] Effect of gross total resection (GTR) in WHO grade II astrocytomas: A SEER based survival analysis.  It is obvious that a gross total resection helps, and this study quantifies it.

  151. [04/17/2017] CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence  This study shows that Optune should be continued after the first recurrence, and use it in addition to a second line therapy.  Patients who had a recurrence and remained on Optune therapy did 31% better than those that discontinued Optune.

  152. [04/14/2017] Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial  This is an exciting trial.  Early (small)  trials had a few complete responses after a single treatment. Disclaimer: Medicenna is a sponsor of our organization

  153. [04/14/2017] Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination  This small  study had amazing results.  Compared to matched historical controls, median progression free survival was  25.3 months in the vaccine group vs.   8.0 months in the historical control group and  median overall survival was 41.1 vs. 19.2 months.  Only 1 patient had significant side effects, an allergic reaction to the immune stimulant they used - which was discontinued and she was able to continue on the vaccine. Disclaimer: I (Al Musella, DPM) am on the patient advisory board at The Preston Robert Tisch Brain Tumor Center.

  154. [04/06/2017] Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.  This is the second recent study to suggest that 6 months of Temozolomide might be optimal.  However, this was not a randomized prospective trial.  I would think each case is different and if things are going well, it may be worth using Temozolomide longer. If not, try something else.

  155. [04/05/2017] DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting  This is one of my favorites. It may become a drop in replacement for Temodar in patients who have unmethylated MGMT, and it might also do better in other situations.

  156. [04/05/2017] Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma  I did not really expect it to do well by itself. I feel that it may be part of a combination approach with other immune therapies. We are funding such a combination trial now!

  157. [03/29/2017] MGH/Dana Farber Initiate Expansion of ONC201 Glioblastoma Trial  Exciting news- the trial was expanded.   We (the Musella Foundation) gave a grant to help with the early development of this new drug!

  158. [03/20/2017] Is it time for "Conditional Approvals"?  I have been working on this plan for a while, but I think now is the time for it to actually be approved. Everything is coming together - like the perfect storm: 1. We finally have a few experimental treatments in the pipeline that look really good. 2. The new president is slashing regulations and calling for faster FDA approvals and for slashing drug prices. 3. Computer technology  and biostatistics have reached the point where our plan for a registry trial can be just as reliable - maybe more so - than traditional phase 3 trials. IF this plan is put into effect, I predict we would have an immediate breakthrough in the treatment of brain tumors, and the possibility of a cure in a few years, instead of the decades it would take on the current path. I need the support of other organizations now, and in a few weeks I may need everyone to be writing letters and making phone calls.  I will send out details when it is time!

  159. [03/17/2017] Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.  This article says that using more than 6 months of Temozolomide is not better than using 6 months of it as far as survival goes. That is counter-intuitive.  I would like to see larger studies to confirm it.

  160. [03/10/2017] Clinical Trial Announcement Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression  Disclosure: the company that makes this is a sponsor of the Musella Foundation This is an exciting trial.  It is similar (although it uses a different target) to a trial done a long time ago that failed because the state of the art in convection enhanced delivery at that time did not allow the drug to get to the entire tumor.  Now the technology has improved to the point where it can deliver the drug to just about anywhere we want it to go!  A major advantage of this type of treatment over other immunotherapies is that it does not rely on your immune system to help it. The fusion protein binds to the IL-4 receptor (which about 80% of glioblastomas over-express, and normal cells do not express), and carried the toxin to those cells - which makes this a smart bomb type of approach - it should theoretically kill tumor cells and not normal cells.

  161. [03/10/2017] Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.  Good project, but I disagree with their conclusion.  They found that 25% of the time, the methylation status changes between the first and second surgery.   They conclude that it is insignificant and we shouldn't bother testing the second time as it provides no useful information.  They are correct for now, but  that should change very shortly as there is now a drug in clinical trials that can work on unmethylated patients. This makes the methylation status very important to determine, and for those 25% of patients with the changed status, it can be a life altering test.

  162. [03/09/2017] Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization  This is a hot topic.  Some researchers are reporting 100% of GBMs have cytomegalovirus. Other researchers are reporting none have it. I would love to see a roundtable discussion with both groups getting together, discuss the methods they use, and finally figure it out. It has profound consequences.  Some early results of targeting CMV in small trials has showed some success, so I lean toward the group that says there is CMV in GBMs.  More research is needed.

  163. [03/08/2017] Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.  General consensus is that Optune is now the standard of care for newly diagnosed GBM patients, and a good option for recurrent GBM patients!

  164. [03/07/2017] Help us better Understand Patient Experiences with Glioblastoma Multiforme  I am sending this out again as they still have a few more spots open.  It is an easy way to make $125!  We heard back from some of our members who tried it and they did get the money, and we also got a donation from them.

  165. [02/23/2017] Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma  This is very exciting news. I have always felt that it is almost criminal that most patients do not have access to treatments like this.  They have shown that the treatment is safe, and early results show impressive results - at least a doubling of average survival with some patients still doing perfectly for a long time.  This breakthrough therapy designation will speed up the process of approval.  It opens the possibility  that FDA approval could come based on the phase 2 trial which has completely enrollment and results should be available within a year, which means that FDA approval might be possible by the end of next year.  Unfortunately not soon enough for anyone who has a brain tumor now. We still have to work on ways to make it available now to people who need it - possibly using compassionate use or the right to try laws.  

  166. [02/22/2017] UPDATED: Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII  Unfortunately, this trial failed. It may have failed because the vaccine was started too late - at the time of recurrence. It makes a lot more sense to try it for newly diagnosed healthier patients.  Adding in a checkpoint inhibitor should also help. Lastly, with other vaccines, the early readings of the trial did not look good, but as time goes on, there was a small group of patients who do well for a much longer time than expected.

  167. [02/21/2017] Help us better Understand Patient Experiences with Glioblastoma Multiforme  This is a survey from a market research group.  If you participate in a phone call, they will send you $125, and the Musella Foundation also gets a donation!    This is only for GBM patients or people who care for a gbm patient.   Let me know if you participate!

  168. [02/09/2017] Trials Open for Enrollment: Phase II Study of VAL-083 in Patients with MGMT-unmethylated Bevacizumab-naïve Recurrent Glioblastoma Multiforme  I have talked about Val-083 a lot over the last year. The trial is finally open.  This is a great option for recurrent GBM patients with unmethylated MGMT.

  169. [02/09/2017] TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma  Unfortunately, the trial failed.

  170. [02/06/2017] NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA There is no mention of why there was a hold in the first place. It makes no sense to me that they have to wait for 233 people to die before they can analyze the data.  If we ever have a cure, these methods insure that we will never see it because the trials would never end.

  171. [02/04/2017] FDA Grants New Clearance for Brain Surgery Technology  These 2 new approvals should help make brain tumor surgery safer, and also may turn some inoperable tumors into operable ones!

  172. [01/26/2017] Out of Warburg Effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH.  I like the approach. We had a few articles recently on this approach. Maybe combining some would make sense.

  173. [01/25/2017] Combination therapy for glioblastoma shows promising results in early-stage research  This project is funded, in part, by the Musella Foundation! It shows that that the vaccine can be enhanced significantly by using other immune modulating drugs.  The  full text of the article is not available for free, only the abstract is free.  The full text shows how strong the effect is when using each treatment separately, then in all combinations.  It is a major improvement. This project also shows, I think for the first time, that the immune suppression caused by PD-L1 is created by tumor-infiltrating myeloid cells and not directly by the tumor cells, which is what I always assumed.  The huge significance of this is that doing a biopsy of a tumor  and testing for PD-L1 on the tumor cells shouldn't make any difference to how the treatment would work.   I would love to see this being done in humans.

  174. [01/25/2017] Antiangiogenic treatments prolong OS in glioblastoma subgroup  This is exciting.  They found that  Avastin can more than double the survival for patients who have highly vascularized tumors.  The test they use - perfusion MRI is readily available.  This shows how antiquated our clinical trial system is.  It is going to be very hard to find a single treatment that cures everyone.  Until we find that, we have to use what we have.  That is many treatments that each help a small group  tremendously, helps a little in a larger group, and not at all in others.  Avastin failed when they did a trial mixing all patients.  The best way to have run the trial is to test early to see how the treatment is doing, and figure out which subgroups benefit and which do not. At that point, they should stop accruing patients that they know will not do well - let them try other trials.  But we are not doing that now. (There is some work going on to try this - called adaptive trial design - but it is not widespread).   Obviously, the best way is to get as many of these treatments approved so we can use them in rational combinations. Figure out which treatments will help YOUR particular tumor, and combine the few that look best. 

  175. [01/25/2017] DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)  This is one of the more promising trials.  Val-083 is a new chemotherapy that works similar to the way Temozolomide works, except at a different location, so the MGMT repair enzyme can not undo the damage.  If there is a lot of MGMT repair enzyme around, (sometimes pathology reports call this unmethylated MGMT genes)  temozolomide has a much smaller chance of helping, so something else is needed.  

  176. [01/24/2017] Quick Survey For GBM patients Now that Optune is FDA approved for both newly diagnosed and recurrent GBMs, we would assume all Glioblastoma patients would at least be offered it as a choice but I am hearing from some patients who were never told about it.  If you (or a loved one) were diagnosed since Jan 1, 2016 with a GBM, please take this quick 1 question survey!  Then we can figure out if more education is needed!

  177. [01/19/2017] Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.  That is amazing, as doctors have to take a course to get certified in the use of Optune. This means that practically every major brain tumor center in the USA can offer Optune to their patients.    There was a 70 percent increase in the survival rate at 4 years for newly diagnosed GBM patients, and Optune is now considered the standard of care for newly diagnosed gbms!

  178. [01/19/2017] Glioblastoma Treatment Breakthrough: `Untreatable` Brain Cancer Tumor Stabilized With Malaria Drug  Chloroquine is a cheap drug approved for treatment of Malaria, and is now being tested against many types of cancer.  This article talks about success with 3 patients, and all 3 benefitted.   In our brain tumor virtual trial registry, we have 8 patients who tried it.  5 out of the 8 lived over 2 years, and 3 went on to become long term survivors.  Note that they also took many other treatments besides Chloroquine, so it is impossible for us to tell if it was due to the Chloroquine, but it may be worth looking at closely

  179. [01/19/2017] New Study Aims to Extend TTFields Beyond Grade IV Brain Cancer Domain  It would make sense to use Optune with grade 3 brain tumors - would be nice to see the proof. Good luck with the trial!

  180. [01/19/2017] Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine  This is an exciting trial. I love the combination. Hope it works!

  181. [12/31/2016] Top Brain Tumor News Stories for 2016  2016 was an exciting year - but I think 2017 will be the year we see big steps forward! Happy New Year! BTW: The copay program will open again very soon - maybe Monday or Tuesday. Will announce it as soon as it opens!  

  182. [12/31/2016] Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.  This study shows that CMV is NOT associated with GBMs. Other studies show 100% of GBMs have it.  It is very important to get the 2 sides together and work out why one group finds it and the other group doesn't. Perhaps have both labs test the same samples, and also have them compare methodology.

  183. [12/31/2016] A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastomas.  We (the Musella Foundation) are partially funding this work!  Good luck to them.

  184. [12/31/2016] Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.  This suggests that stereotactc radiosurgery may be worth consdering for recurrent gbm. This is another controversial issue in the field.  Some doctors I talk with never use it, and others use it a lot.  This is why it is so important to get second opinions.

  185. [12/25/2016] Some glioblastoma patients benefit from `ineffective` treatment, Stanford researchers say  This is the problem with clinical trials.. if the average patients doesn't benefit, they call it a failure.  They do not identify the patients who do benefit. In this case, they identified a group of patients who would benefit from Avastin, even though an average patient doesn't. I have seen many patients with a huge benefit from it, which makes no sense when you look at the trial results. This may explain why. They should go back to the original Avastion trials,  and see if this group of patients did better,

  186. [12/25/2016] ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results  It's a great sign that they expanded the trial to include more patients and has shown signs of helping patients as well as of not hurting them.

  187. [12/25/2016] First patient enrolled in brain tumor trial combining 9 repurposed drugs - CUSP9v3 project  This is the 3rd version of CUSP9... it appears that they are only taking patients from Germany at this time, however, since all of the treatments are already approved and readily available, it can be done outside of that trial. If you try it, please register for our virtual trial project first at That way we can track results. 

  188. [12/19/2016] Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.  Aside from the mechanism of action these authors proposed, perhaps the theories about cytomegalovirus playing a role in GBMs are valid, and this drug also fights the CMV, just like Valcyte does.

  189. [12/13/2016] Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel  We have a lot of members from Israel asking about coming to the US for clinical trials - now they have one of my favorite trials available there!

  190. [12/13/2016] Medicenna Announces Initiation of Phase 2 Clinical Trial of MDNA55 for the Treatment of Recurrent Glioblastoma  (Disclosure: Medicenna is a new sponsor of the Musella Foundation).   This immunotherapy had some very impressive results in a small early trial. Of course we have to be careful when there are small numbers involved - sometimes that doesn't pan out when the large trials are done, but it is a good sign.  In a group of patient with recurrent gbm who did not have a resection at the time of recurrence, just one infusion of this new treatment, they had 20% complete response rate.  That means the tumor disappeared after just one infusion.  The response rate was 56% and if you include stable disease, the benefit rate (Stable + partial response + complete response) was 68%.   They were no serious safety problems. This treatment is a fusion protein which targets Interleukin-4 which is overexpressed on 3/4 of GBMs, and 100% of brainstem gliomas. It carries along a toxin that can kill the cells which overexpress IL-4. Normal cells have a low level of IL-4. Delivery is via convection enhanced delivery.  Prior trials involving CED have failed, mainly because the early versions of CED were not accurate - they couldn't get the drug to the target.  The Tocagen trials proved that CED is now at a point where they can routinely get the treatment 

  191. [12/09/2016] NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

    Very exciting news.  Nobody knows why the trial was placed on hold. Usually that is a bad sign but there are many reasons a trial can be placed on hold that have nothing to do with how good a treatment is.  See .  I doubt it is for safety reasons, as there were no safety issues at all in the first few trials and in similar trials. That is the one we would worry about if it were true.  There are many other reasons. One possibility is that the FDA thinks that the trial will not prove anything.  There has been arguments back and forth about appropriate endpoints. At one time the FDA allowed progression free survival as an endpoint, but then the Avastin trial showed excellent progression free survival but no increase in overall survival, so the FDA changed its stance and said it wanted overall survival as an endpoint and that progression free survival is not enough. This happened after the trial was designed. The primary endpoint is progression free survival.  This trial allows patients in the control group to cross over and get the vaccine when they have a recurrence.  This messes up the endpoint of overall survival because you will be comparing people who get the vaccine to people who get the vaccine.  The FDA may think it is futile to try with the current design and may want the trial redesigned and done over again, which would probably be too expensive and lead to abandoning of the treatment.  I would protest that it is unethical to not allow cross over for the control group. (Let alone that it is unethical to have a control group in the first place).


    Anyway - this press release says they have stopped enrollment in the trial and will just analyze the results they have.  They already enrolled 331 patients, which should be enough to tell how it looks. IF it shows a progression free survival benefit, we will be fighting to get it approved based on this trial and hopefully not have to go through another phase 3 trial.

  192. [12/07/2016] First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.  The FDA approval for Optune limited it to use in patients 22 and old because that was the youngest patient in the trial and it hasn't been tested on younger patients. Obviously, it should help younger people.  It can be prescribed for pediatric patients, off label, but insurance companies might try to reject it based on that FDA label restricting age.  Reports like this help us fight the insurance companies! I think the only real limit is the size of the head - the arrays are large and won't fit on a young child.

  193. [12/07/2016] Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.  Unfortunately, the trial failed to show a benefit.

  194. [11/25/2016] Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13R?2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology  CAR T Cell therapy has been one of the most promising therapies in other types of cancer (although a large CAR T Cell trial for leukemia was recently placed on hold due to a few treatment related deaths). Here the researchers bring it to GBMs, and shows early signs of it helping.  More work needs to be done to optimize the delivery and the targets (Other researchers are using CAR T Cells targeting EGFRvIII see .  This study targeted IL13Rα2, which is another good target, but neither target is presnet in 100% of tumors. Perhaps combining them would reach the majority of patients.

  195. [11/23/2016] Help Us Better Understand Glioblastoma Multiforme (GBM) Patient Experiences  This is from our friends at the Patient Alliances. They are looking for patients or caregivers to fill out a survey.   Please help out! They are making a donation to the Musella Foundation to encourage people to help!  If you contact them, tell them the Musella Foundation referred you!

  196. [11/18/2016] Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates  This is what we have been waiting for. The final results of the Optune trial for newly diagnosed GBM.  There was some resistance to accepting Optune as the standard of care because the results presented 2 years ago were "just preliminary". The final results are actually better than the preliminary results! Now the next step is getting insurance to pay for it. Already most non-Medicare plans do pay for it, but Medicare has been hesitating. We had a petition a while ago to help nudge Medicare toward paying for it.  I presented it to them and we did come close and I think it did help - but we had that problem of results being preliminary.  We are going to try again. I resurrected the survey - and updated it to show current results.  Please sign it and have your friends and family members sign it.  IF you already signed it last time - you do not need to sign it again - it is still valid.  If you aren't sure, email me your name and address and I will check it for you.  Go to for details and to sign! 

  197. [11/09/2016] DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA  This is an exciting combination.  The immunotherapies have had some impressive results in some patients, but not everyone was helped.  Adding a checkpoint inhibitor may allow more - or all - patients to be helped!

  198. [11/07/2016] United Healthcare Issues Positive Coverage Decision for Optune This has been a big battle to get insurance to pay for Optune.  United Healthcare was basically the last private insurance that didn't pay - now almost all do.  Next up is the Medicare battle.  I have been working on that one for a while and getting closer. I may need your help soon - we are thinking of another petition campaign!

  199. [11/07/2016] Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology  It looks like Optune is finally getting the respect that it deserves. When it was first introduced, I would say most neuro-oncologists dismissed it without looking at data, based solely on preconceived notions that it couldn't possible work.  Now, most seem to at least allow their patients to try it, if not encourage them to try it.  The holdouts tell me that the data is preliminary and they will wait for the full report. Well - that will come out next week!  I did not see it yet, but I assume from this press release that it is favorable.  Hopefully that will remove the last doubt that this should be part of the standard of care for newly diagnosed Glioblastomas. It is very significant that most of the presentations are from researchers not associated with the company.  That shows broad acceptance in the field. 

  200. [10/25/2016] Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature. This is a reminder that we have to be careful of the treatments we use. If you think an alternative treatment is strong enough to stop a glioblastoma, then it may be strong enough to cause other severe problems.

  201. [10/23/2016] The Musella Foundation announced that it has awarded a $25,000 brain tumor research grant to Dr. Robert Prins of UCLA.  In keeping with our efforts to collaborate with other organizations to speed up brain tumor research, we partnered with Voices Against Brain Cancer to fund this $50,000 grant request.  Each organization paid ½ of the total amount.  This is a very special project, which I think has the potential to make a big impact. It will combine a checkpoint inhibitor with a custom made vaccine.  The vaccine by itself has had remarkable success in a few patients - with some GBM patients alive and doing well after 6 years, but it didn't help other patients. This project will try to figure out how to make the vaccine help more - or all - of the patients.

  202. [10/22/2016] Patient-Tailored Immunotherapy Shows Promise in Treating Brain Cancer  Pretty good results in a large phase 3 trial.

  203. [10/20/2016] An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.  This may be a new target for GBM treatment, which may use a few drugs already approved for other diseases. Should be quick and easy to prove... Might be a perfect project for our brain tumor virtual trial registry.

  204. [10/09/2016] CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times  Impressive results in a large controlled trial.

  205. [10/09/2016] Darren Daulton Battling Brain Cancer Through Charitable Foundation  This organization offers brain tumor (and brain injury) patients up to $5,000 per year to help with expenses! Great work!

  206. [10/09/2016] Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha This drug, Val-083, might just be the next big step forward.  Late stage trials are about to start. It already had been approved in China for other diseases, and over 1,000 patients took it and have shown that toxicity is not a problem. It might especially be useful for gbm patients who have unmethylated MGMT.   The article may have missed a little on the statistics. I doubt if 200,000 GBMs are diagnosed a year. They say "less than 200,000" but it is more like 20,000.  

  207. [10/05/2016] Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy  Pretty good results.  20% of the patients in the trial responded, but those that responded  remain alive at 21-42 months. This means that the median survival they reported,  14.3 months, will go up as time goes on - assuming these patients continue to do well for a while! In the past, I have seen numbers reported of about 8 to 9 months average survival for recurrent gbms.. (this press release doesn't break down the % with anaplastic astrocytoma), but that is with everyone dead at the end of the trial. And they mention the Musella Foundation as funding part of the work.  Your donations at work! :) We are starting a new fundraiser to raise money specifically to speed up approval for this treatment. For details, go to

  208. [10/01/2016] Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. The MGMT status did not have much effect on the use of Avastin with newly diagnosed gbm patients.    It is good to see research on this topic, because people with unmethylated MGMT are usually relatively resistant  to Temodar.

  209. [10/01/2016] Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.  Excellent results.. in a small group of patients.  Average survival of 30.5 months for newly diagnosed GBM patients is pretty good. More research needs to be done.

  210. [10/01/2016] Pioneering Studies Apply New Immunologic Insights to Glioblastoma  This is a completely new way of trying to treat brain tumors by suppressing cells in the blood that travel to the brain tumor and inhibit the immune system.  We (The Musella Foundation) funded part of the project!  This is YOUR donations hard at work! Thanks  

  211. [09/30/2016] Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioblastoma Multiforme  It is a shame that the connection to illegal marijuana has severely delayed research and acceptance of a promising treatment for brain tumors.  It is great that this drug company is taking it on even though it isn't politically correct to do so.

  212. [09/28/2016] Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy  Explains how Optune works. 

  213. [09/28/2016] Glioblastoma: Overview of Disease and Treatment.  This is a good overview of the basics of what a glioblastoma is and how it is treated.  

  214. [09/21/2016] The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.  Excellent article. Apparently, when the MGMT methylation status test results show inconsistent methylation, it really should be thought of as being unmethylated.  For background:  MGMT is a gene that codes for an enzyme that repairs damage to the DNA caused by Temodar.  If your MGMT genes are methylated, that means they are inactive and can not produce the repair enzyme.  This makes Temodar work much better.  However, if your MGMT is unmethylated  (or apparently now - even inconclusive), the repair enzyme is produced which reverses the damage caused by Temodar, making it not really work. This really didn't matter much until recently when a new drug, Val-083, was created which works similar to Temodar but on a different part of the DNA so that this repair enzyme can not reverse the damage. This drug is about to start phase 3 clinical trials. Worth considering for those whose test show unmethylated MGMT. 

  215. [09/19/2016] CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma This should make the treatment work better - especially for those offices that do not have a lot of experience with using Optune

  216. [09/08/2016] Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1?/PKM2 axis in glioblastoma cells.  The concept of cytomegalovirus being associated with GBMs is controversial.  Some researchers say 100% of GBM samples have it, others say none of them have it. I tend to agree with the ones that say it is very common in GBM samples.  IF that is true, this study may show how CMV can promote the formation of tumors. And that opens the door for treatments. There is already an approved drug that fights CMV, and there is a brain tumor vaccine under development that targets the CMV. Preliminary results look good. This study also identifies other downstream targets which may be exploited.

  217. [09/08/2016] Monteris Medical Receives IDE Approval From FDA To Evaluate NeuroBlate® In Patients Newly Diagnosed With Glioblastoma Multiforme  This trial will be for patients with newly diagnosed GBM who are told the tumor is inoperable. This is a form of laser surgery where a small hole is made in the skull and a special probe is inserted to destroy the tumor. It can sometimes be done in locations that were though impossible to treat using regular surgery. The Neuroblate system is already available all over the USA.  You can find a doctor near you at    [Disclosure: Monteris is a sponsor of the Musella Foundation]

  218. [09/07/2016] DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer  Val-083 is an experimental treatment (actually it is approved in China for other types of cancer) for brain tumors. It is similar  to Temodar, but works at a different site which is not affected by the MGMT status of the patient.  The VAL-083  trial for recurrent GBM should be considered for patients who have unmethylated MGMT.  This press release talks about combining VAL-083 with Temodar or BCNU, and implanting it at the time of surgery to increase the dosage of the drugs at the site of the tumor. Sounds exciting.

  219. [09/07/2016] The fourth weapon in the battle against cancer  Nice story about one of the members of our online support group (Brain-novocure)! To join the group, go to and select brain-Novocure

  220. [09/01/2016] Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis.  Another abstract on Optune showing a good effect in the test tube.

  221. [09/01/2016] Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation.  This brings up an exciting possibility. Optune is not used during radiation now, for theoretical reasons - the radiation can irritate the skin and cause delayed healing, which may make the irritation from the electrodes worse. As far as I know it was never tried. Might be worth trying.

  222. [08/31/2016] Kadmon launches mid-stage study of lead oncology candidate in brain cancer  This oral treatment crosses the blood brain barrier. 

  223. [08/31/2016] Immunotherapy, Vaccines Offer Promise in Glioblastoma, But Data is Still Preliminary  This is exciting but going too slow!  I am trying to speed up the process! I am saving up to fund a brain tumor research project that combines a checkpoint inhibitor with a vaccine in a human trial!

  224. [08/24/2016] Update published for "Treatment Options For Glioblastoma and other Glioma"  This is the most important article on our website and is updated once a year..  Ben Williams originally wrote the book: Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About" in 2002. Since treatment change so rapidly, it needed an update every year, and Ben graciously allowed us to host the yearly updates to distribute for free. This year, for the first time, our medical editor, Stephen Western, helped Ben update it.  New this year is an easy way to see changes from previous editions - they are now in red.  They did a great job and this is a must read for anyone who is interested in Brain Tumors.

  225. [08/23/2016] Curcumin Changes the Polarity of Tumor-Associated Microglia and Eliminates Glioblastoma.  This is only in mice now but looks exciting.

  226. [08/18/2016] Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.  This article is scary. The big hope was that by finding the genetic mutations in a tumor, a cocktail of drugs could be prescribed to personalize the treatment plan for each person's tumor.  This small study shows that we are not there yet. A lot more research needs to be done before the concept should be discarded.

  227. [08/18/2016] Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.  There has always been the fear that using Avastin would cause the tumor to become more invasive as the blood supply to the tumor gets cut off.  This article shows in a large number of patients that this fear is not justified.

  228. [08/18/2016] Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma.  I had a relative do great for over 5 years with high dose tamoxifen for her gbm.  It was relatively popular before Temodar came into use. Studies showed that it helped a small % of patients, but when it helped, it helped a lot. And it had minimal side effects.  This article  might explain why it helps some patients and not others. More research needs to be done.

  229. [08/16/2016] Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13 This should make the Optune system easier to use.

  230. [08/10/2016] Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.  This may be why the vaccines do not work in some patients.  Worth further study.

  231. [07/26/2016] Musella Foundation awards $149,992 in 3 brain tumor research grants.  These 3 projects can make a big impact in this disease, quickly.   The first project is a pilot human trial for kids with brain tumors using the polio virus vaccine made famous on a recent 60 minutes episode. This is the first time it will be tried on children and if successful, will lead quickly to a larger trial, then hopefully FDA approval so all kids would be able to get access to this promising treatment.  The second project involves a new way to get drugs to the tumor at a higher concentration and for a longer period of time. This is a mouse experiment to see if this new delivery method can make a significant difference in outcome. If it does, it will lead quickly to a human trial.  The third project combines an immunotherapy that is already approved for other types of cancers with stereotactic radiosurgery in a mouse model. Since both parts are easily available today, this can lead to immediate use in patients if successful.  I would like to thank all of the volunteers and donors who made it possible for us to give these grants out!  

  232. [07/26/2016] NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma  I sent a story about this in a recent news blast but this is the press release from Novocure and their take on the topic!

  233. [07/13/2016] Musella Foundation Request for Donations!  Most of the funds for this round of granting come from our National Walk To End Brain Tumors.  I would like to thank all of the volunteers who made it possible!

  234. [07/13/2016] Novocure Receives FDA Approval for Second Generation Optune System  I have seen the new system, and it is much nicer. Smaller, lighter, looks much more modern, and is easier to use.  

  235. [07/04/2016] Scientists just discovered we`ve been looking at cancer growth all wrong. This could change everything.  This is still preliminary work, but raises an important point: that we should recheck everything that we thought we knew about these tumors.  The technology we have now is amazing compared to what was available in the 1950s when it was decided that brain tumors use glucose as the main energy source. This article points out that by culturing the tumor cells in blood, you change the tumor cells to use what is most common in the blood, which is different than what is in the brain. On the other hand, they also mention that PET scans show where glucose is being used - and the tumors do use a lot more glucose than non tumor brain.

  236. [06/29/2016] The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.  These are puzzling results.  Avastin increased the time to progression by over 100% compared to chemotherapy, but the overall survival time was about 30% less. This doesn't make sense.  This brings up the question of quality vs quantity of life. Patients did well for twice as long using Avastin, but died sooner. What is worth more?  I would like to find out why the people in the Avastin group didn't live as long as those in the chemotherapy group.  I wonder if the chemotherapy group used Avastin after recurrence?

  237. [06/29/2016] Rapid regression of glioblastoma following carmustine wafer implantation: A case report.  You can never make decisions based on individual case reports but they are nice to see.  Gliadel has been neglected by some medical centers.  On average, it adds a little extra time before the tumor progresses, sometimes allowing time for other treatments to have a chance at working. It was never meant to be a cure by itself.  We do not have enough patients in our brain tumor virtual trial ( to make a statistically significant statement about it, but taking a look at just our  long term (over 5 year) GBM survivors,  5 out of the 21 (24%) have used Gliadel as part of the plan. Looking at all GBM patients, 36 out of 469 (8%) have used Gliadel. To me this means that if Gliadel had no effect, you would expect the same % of patients who used it as the % of long term survivors who use it. But we see a tripling of the %, which means Gliadel does have a big increase (possibly tripling) in the chances of becoming a long term survivor, and it should be studied more in depth.  

  238. [06/29/2016] Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.  This study shows that it might be OK to avoid radiation therapy for high grade gliomas in young children, or at least delay it until they are older.  Radiation in young children can cause permanent problems like a lower IQ.  These results are still not good enough but are similar to the treatments that do include radiation, so the lucky few who survive are presumably in better condition. A better way needs to be found.

  239. [06/24/2016] Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology  Impressive results.

  240. [06/24/2016] Extended Survival Reported in Brain Cancer Patients Treated With Viral Gene Therapy  This treatment is now in a phase 2/3 trial for recurrent gbm, available in over 35 centers across the USA and Canada!  Go to for details!

  241. [06/23/2016] ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma  Great news!  This is one of my favorite trials, and they are now open! This is a stock vaccine - which means you do not need fresh tumor tissue to make the vaccine.  It is a relatively simple blood draw and shot in the arm.

  242. [06/01/2016] Study Published in Science Translational Medicine Reports Favorable Safety and Extended Survival for Brain Cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy  This is impressive results from a small study.  There is a large multicenter trial going on now for recurrent high grade glioma and they will soon start one for newly diagnosed. And they acknowledge the Musella Foundation (and other brain tumor foundation)  grant support for this project!  This is your generous donations at work!

  243. [05/31/2016] Novocure Receives IDE Approval to Initiate METIS Trial  This sounds like a great combination. Radiosurgery can usually control an individual brain met over 90% of the time, however the patient usually still develops new mets in the brain - because the radiosurgery doesn't do anything for the little islands of tumor cells that you can't yet see on the scans.  The TTFields might be able to stop those islands from developing into new tumors.  

  244. [05/24/2016] Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.  I thought that Avastin crossed the blood brain barrier but this experiment, in mice, shows that opening up the blood brain barrier using a relatively simple application of focused ultrasound leads to vastly improved outcomes and much higher concentration of Avastin in the brain.  There is a trial in humans now of administering Avastin via intra-arterial infusion directly into the tumor. We do not have the results yet, but this experiment gives hope that the principle of increasing the dosage to the tumor may work in people!

  245. [05/19/2016] What `60 Minutes` Still Isn`t Saying About The `Miracle` Glioblastoma Drug  This is the counter point to the 60 Minutes story on the polio vaccine for glioblastomas.  She has a few good points. It is way too early to say this is a miracle cure.  However, I think it has the potential to be a big step forward.  Contrary to what this reporter says, I do think that IF it works for GBMs, it is very likely that it will work for most other types of cancer. There wasn't enough time to talk about it on the show but I was at Duke a few weeks ago where it was discussed at length and they discussed how they tested the other types of cancer in the test tube and animal models, and it is the same mechanism of action. In the GBM trial, there were some deaths relating to increased swelling in the brain as the immune system kicked into high gear.  That causes a problem because in the head, the skull has a limited volume and can not expand, so swelling causes a rise in the intracranial pressure which causes all sorts of problems.  We do not have that problem in the rest of the body- swelling can be accommodated  easily.  So it may work better outside the brain.  We are lucky they are working on the brain first. 

  246. [05/10/2016] The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.  This is the new classification for brain tumors. They now recognize that GBMs with and without the IDH mutations are very different tumors - they were lumped together before, but they behave so differently that you can't compare them. All trials from now on should seperate out the data by IDH status. For more details see

  247. [05/08/2016] Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting Very good results. An article at says average 12 month survival for recurrent gbm is 14%. This trial is reporting 61%. This project was supported, in part, by the Musella Foundation (as well as the other organizations listed in the article!).  Thanks to those whose donations allowed us to help get this project going!

  248. [05/08/2016] Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Unfortunately, this treatment did worse than the control group - which was the standard of care.

  249. [05/08/2016] Entrectinib Achieves High Response Rate Across Solid Tumors  This is an experimental treatment of a new targeted drug which hits 3 targets: NTRK, ROS-1 and ALK.  Might be worth trying this trial (or trying to get it on compassionate use if you do not fit the trial) if your genomic report mentions you have 2 or 3 of these targets overexpressed. Go to for the current trials with this drug.

  250. [05/06/2016] Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma  They did a nice jobe with the website. Take a look at the stories there. I never heard of ThunderClap before but it also looks like it can be very useful to raise funds for research and awareness for brain tumors. This is a perfect way to try it out. Follow the instructions below.  You will have to give your permission for the Thunderclap program to post a one time message to your facebook page.  It is safe to allow that. They can't see your username or password.  You do that now and then at the specified time, Thunderclap posts a message supporting brain tumors to everyones' facebook (and other social media) pages. By everyone sending it at same time, a huge number of people will see it and it might trend on twitter.

  251. [05/05/2016] Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.  This sounds like an ideal treatment for small recurrent gbms. They had local control (of the treated tumor) in over 90% of the tumors, although most people eventually died of tumors growing outside of the treated areas.   None had radiation necrosis which happens frequently with single fraction sterotactic radiosurgery.  This may work well in combinations with other treatments to give them time to work.

  252. [04/27/2016] Research findings could lead to treatment for deadly brain cancer  Sounds like an exciting new approach

  253. [04/27/2016] Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.  Looks like Optune should now be available to just about everyone.

  254. [04/05/2016] Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.  This makes sense. When the AVAglio trial was reported, it showed that Avastin improved progression free survival but not overall survial. This did not make sense to me, as I interact with a LOT of brain tumor patients and we track them in our brain tumor virtual trial registry. I always felt that Avastin does increase overall survival. Looking closer, it appears that the trial was designed to allow patients in the control  group who had progression to take Avastin after the progression.  So in effect, they were comparing patients who took Avastin to patients who took Avastin and there was no difference. Duh. This analysis seperates out those who did not have Avastin or other treatments after reccurence and it showed that there is an overall survival advantage for Avastin.  

  255. [03/17/2016] Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Impressive gain in progression free survival. These trials should NOT even try to report on overall survival. They say 83% of patients in the control group took Avastin at the time of recurrence.  So they are comparing patients who took Avastin to patients who took Avastin and found no difference in overall survival. Duh.  

  256. [03/17/2016] Tocagen to Present at Three Oncology Conferences  It is impressive that so many of the brain tumor foundation (including the Musella Foundation:) have come together to support this promising research.

  257. [03/07/2016] Data Safety and Monitoring Board Recommends Celldex`s Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease  This is a huge shock. Celldex is stopping development of thier vaccine treatment for GBMs. Apparently, the patients in the control group did a lot better than they were expected to do. These patients all  were EGFRvIII+, which would usually make them have a worse prognosis. In this trial, they compared the standard of care PLUS the vaccine, against the standard of care plus the drug KLH.  KLH is an immunostimulant which is actually a part of the Celldex vaccine.   The result was the control group has about a 21 month average survival for newly diagnosed.  This compares to the results of the Novocure trial's control group which was the standard of care as well as a mix of other clinical trials and avastin - which yielded an average survival of 16.6 months.  Perhaps more work needs to be done on KLH alone, and  I still feel the Celldex vaccine is worthwhile.  It still had a 20% improvement over historical controls and is a simple shot in the arm with minimal or no side effects, which may be a building block for a cocktail that actually works.  

  258. [03/05/2016] The Curcumin Analog C-150, Influencing NF-?B, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.  I would love to see human trials of this.

  259. [03/04/2016] Dbait: An innovative concept to inhibit DNA repair and treat cancer  This was not in brain tumors but the same mechanism may cause resistance to Temodar in brain tumors - so perhaps this would help.

  260. [03/03/2016] Humana Issues Positive Coverage Decision For Optune  Humana insures 10 million people in the USA, and now all of these people have access to Optune if they need it!    

  261. [02/21/2016] Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.  I love this type of project.  These researchers tried adding the drug valganciclovir (Valcyte) to the treatment plan for recurrent gbm patients who were using Avastin. The concept behind this is that most or all GBMs have a virus in them called Cytomegalovirus. (Some researchers disagree and say NONE of the GBMs they tested have the virus).   It is not known if the virus triggers the tumor to form, or if it makes the tumor more aggressive, or if it is just a bystander and doesn't affect the tumor. Valcyte is an oral antiviral drug which slows or stops the virus from reproducing. This study (although it is too small to be considered proof) shows that adding Valcyte increases overall survival and progression free survival. This implies that the CMV plays a role in making the tumor grow. Using it in combination with Avastin was a great idea, since Avastin also slows down the tumor growth using a different pathway (VEGF).  I think that hitting either pathway alone allows the tumor to find a way around the treatment, but hitting it on multiple pathways may be the answer. Perhaps adding 1 or 2 other treatments, hitting the tumor from another pathway, may make even a larger difference.

  262. [02/21/2016] Photodynamic Therapy for Malignant Brain Tumors. Photodynamic therapy for malignant brain tumors involves giving the patient a dye right before surgery and then shining a laser light at the tumor at the time of surgery.  It has been approved in Japan and this article shows that it may increase the time to progression, at least in the treated area, but a lot. There was no control group so we don't know for sure but compared to historic controls, it looks pretty good. As far as I know, the clinical trials for photodynamic therapy of brain tumors in the USA are completed and we are waiting for the results.

  263. [02/21/2016] Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series.  I do not think this was the best way to set up the study.  The better way of doing it would have been to start Optune a few weeks  after radiation is over, and perhaps try Avastin in a pulse dosing form  - either as newly diagnosed at the same time you start the optune, or at the time of recurrence.  Withholding Optune from a newly diagnosed patient for the purpose of entering a trial like this sounds unethical to me. It shows a lack of understanding of how Optune works. It is a slow, gentle treatment. The time to start it is not when you have a recurrence as it needs a few months to kick in.  The effect of slowing tumor growth starts immediately but it takes time before the tumor starts to shrink.   The trial using it for newly diagnosed patients did much better than the one that started at recurrence. Having said that, the results show that Optune does help when used this way, but I would like to see more trials using it the correct way. For those that missed out on the opportunity to use it when newly diagnosed, this shows that it is worth trying at the time of recurrence.

  264. [02/14/2016] Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.  Excellent result. For the group with total resections, this  increased the chances of being alive at the 3 year point from 6% in the control group to 32% in the gene therapy group. Amazing.

  265. [02/14/2016] ABT-414, an Antibody Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.  This is very exciting. They found a way to target the EGFR in tumors and not in normal tissue. There are a few trials going on now for this treatment. Check for details.

  266. [02/14/2016] Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma

     Great news.   

    Now that the 3 largest private health insurance carriers in the USA cover Optune, the rest should follow suit soon!  This is a major victory in the fight against brain tumors. We thought the hard part was going to be getting FDA approval because it is a completely new type of treatment, but that actually was easy since the data supported it.  Once that happened, I assumed patients would be able to just get it but the timing was terrible. Insurance companies have just started fighting back against expensive treatments and started denying all new treatments as a way of saving money until they are forced to pay for them. It was a long, hard battle but the people at Novocure persevered and won the battle with the private insurers.

    Next up is Medicare. I had multiple meetings with Medicare and they are getting close to approving payment. The people I met with at Medicare understand that brain tumor patients need this treatment and they are trying to find a way to pay for it. Having the majority of private insurance companies paying for Optune, along with the recent publication of data in the Journal of the American Medical Association, should allow patients to appeal Medicare rejections successfully. IF you have a problem with a Medicare rejection, call me at 888-295-4740 and maybe I can write a letter for you to help with the appeal.

  267. [02/10/2016] Brain tumor movie - looking for volunteers!  These people are trying to create a movie about brain tumors and are asking for help - they need patients and doctors to volunteer to be interviewed..  

  268. [01/23/2016] The Musella Foundation announced that it has awarded a $5,000 Brain Tumor research grant to Ninh Doan, MD, PhD, of the Medical College of Wisconsin.  We gave a $50,000 grant last year to this researcher and the project is looking good. He wanted to expand it to include Medulloblastomas, which is a mostly pediatric brain tumor type.  Hopefully, if succesful, it should also help many other tumor types.

  269. [01/21/2016] Oncoceutics Begins Fifth Clinical Trial for ONC201  This is a new clinical trial for recurrent GBMs.  This is a new approach, with a new target. It is an oral medication. See for details on the mechanism.   I will be watching this closely - as the Musella Foundation gave them a research grant a few years ago to help do the preclinical work on this new drug - which came out pretty good!    

  270. [01/06/2016] Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System  I saw the new system, and it looks like it will make using the system a lot easier!

  271. [01/05/2016] Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies.  Looks like we need more research on this. Very interesting

  272. [01/05/2016] Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.  This is a controversial topic in the brain tumor world. Studies have shown that most or all gbm samples contain this virus. However, other studies show that few or none have it.  That difference may be related to the ability of the lab to detect it. There needs to be a standardized way of detecting it so we can settle that once and for all. There has been a human study of an anti CMV  drug (Valcyte) that has shown very good results, but the study was questioned by others saying it wasn't designed properly.  My thoughts are we need more studies on anti-CMV therapies, but in the meantime it might be worth adding it to the planned treatment regimen.  It would be best to track patients who try this in our brain tumor virtual trial so we can quickly tell if there is any effect - good or bad.

  273. [01/05/2016] Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.  This article shows that intra-arterial administration - either with or without disruption of the blood brain barrier may be too toxic to use.

  274. [12/21/2015] Recurrent venous thromboembolism in glioblastoma.  As if we didn't have enough things to worry about: this report says about 1/3 of patients with a gbm developed blood clots.  This topic needs more research to weight the risks vs the benefits of putting all gbm patients on long term drugs to prevent blood clots.  The symptoms to watch out for are: acute (sudden) shortness of breath, chest pain,  coughing up blood, fainting, swelling of the legs, tenderness of the back of the legs, and warm legs.  These symptoms are an emergency and you have to see the doctor the same day. If your doctor isn't available, it is worth going to the emergency room.  

  275. [12/15/2015] Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma  This may be the most important article of the year. It is the report on the phase 3 clinical trial for newly diagnosed GBM trial comparing Optune and the standard of care vs the standard of care alone.  Excellent results - best of any large phase 3 GBM trial. Better than the results that made Temodar the standard of care.  The trial was stopped early by the FDA when they saw the Optune group did so much better than the control group, and they allowed the control group to cross over into the treatment group. This is the first time (that I am aware of) this happened for brain tumors!  Hopefully this will remove all doubt that Optune works and should be included in the standard of care for newly diagnosed gbm.

  276. [12/12/2015] First Patient Enrolled in Toca 5, Tocagen’s Phase 2/3 Clinical Trial in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma  This is an interesting trial.  We (the Musella Foundation) helped fund earlier versions of it!

  277. [12/12/2015] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.  Unfortunately another negative trial. Adding Enzastaurin to Avastin did not help.

  278. [12/08/2015] Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients  Great news - you can use the Optune system even if you have a non-programmable shunt installed!   They aren't sure yet about programable shunts or pacemakers - they had a few patients who used Optune with these without problems but not enough for the FDA to remove the warning on the package insert.

  279. [11/27/2015] Experimental brain cancer treatment offers family hope  This is super selective intra arterial infusion.  There is an older video with more details at

  280. [11/27/2015] Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme  As far as I know, this drug is not yet approved for humans. It is approved for dogs and is pretty inexpensive, so it is easily available.  I would love to see a human trial of it.

  281. [11/25/2015] The Musella Foundation announced that it has awarded a $50,000 brain tumor research grant to Ninh Doan, MD, PhD, of the Medical College of Wisconsin.  This is an exciting project, looking at a new target to treat Glioblastomas. This is the 81st brain tumor research grant awarded by the Musella Foundation! Thanks to the many donors who made it possible for us to fund these amazing projects!

  282. [11/23/2015] Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO) Exciting reports from the SNO meeting!   Highlight is almost a  doubling of survival time for patients using Toca511 compared to historical controls. These were small uncontrolled trials but they show enough promise that they justify a large phase 2/3 trial which is starting right now!  (disclaimer: Tocagen is a sponsor of our organization)

  283. [11/23/2015] Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS  We need to have a discussion about the value of increasing progression free survival (PFS) without increasing overall survival.  (The braintumor treatments group is the best place to discuss it). My thoughts are that  obviously, increasing PFS is good - you feel good for a longer period of time, but perhaps it may be better to try other things instead.  Shoot for increasing both PFS and overall survival.  There are a few interesting trials going on for recurrent GBM, and the Optune device has been shown to increase both PFS and OS.

  284. [11/22/2015] Groundbreaking Global Brain Cancer Trial Planned

           I tried to get something very similar off the ground years ago, but couldn't raise the money needed for it.  I had the major brain tumor centers and another brain tumor foundation willing but it was too expensive for us.  I hope this group does well. I think it is the fastest and cheapest way to find the best drugs and combinations.

  285. [11/21/2015] ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma  Impressive long term survival state presented at the SNO conference of Rindopepimut plus Avastin vs. Avastin alone for recurrent Glioblastoma patients. Highlight: at 2 years the Rindopeimut + Avastin group had 25% of patients alive. The Avastin alone group had 0% alive.   This is just a simple shot in the arm which adds no significant side effects - just local reaction at the injection site like a flu shot.

  286. [11/20/2015] ImmunoCellular Therapeutics Ltd Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015  Good  news from the SNO meeting: Although they did not hit the original target of overall survival for all patients in the trial, they found a subgroup of patients where the vaccine worked very well. Newly diagnosed GBM patients with a blood type of HLA-A2+ did very well. If the MGMT methylation status was positive, there was a 58% increase in survival compared to the control group. If the MGMT status was negative, there was a 34% increase in survival.  This is for a treatment that is just a simple shot in the arm and once approved, could just be added to other treatments. They just started a new phase 3 trial that will require patients to be HLA-A2+.  This should show a big improval.

  287. [11/20/2015] New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence  This is a new report on combining Optune with Avastin. Both are approved for recurrent GBM. The combination reduced the chance of dying by 39% compared to Avastin alone.  This should be the standard for recurrent gbm and investigated for newly diagnosed.

  288. [11/20/2015] Celldex vaccine improves long-term brain cancer survival in study  Amazing results.  25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group!  The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.

  289. [11/18/2015] CURE Media Group’s Heroes of Glioblastoma Announced Today  Congratulations  to the four heroes!  

  290. [11/17/2015] Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data Amazing number of presentations for Optune. So glad to see the brain tumor community finally embracing this new treatment option!

  291. [11/17/2015] Drug That Could Limit Spread of Deadly Brain Tumours  This should be tested in combination with Avastin. Might make a big impact!

  292. [11/07/2015] Toca5: A Phase 2/3 Randomized, Open Label Study of Toca 511™, a Retroviral Replicating Vector, Combined With Toca FC™ versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma  The Tocagen trial has just opened!  Our website and do not have the details yet, but if you are interested in this trial, call them and ask where it is being done.  This is for people with recurrent GBM or Anaplastic Astrocytoma, who are going to have surgery.  There is a video on how this works at  This is one of my favorite new trials.  (Disclaimer: Tocagen is a sponsor of the Musella Foundation)

  293. [11/07/2015] Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.  This is just theoretical, but it makes sense to me. Might be worth trying to add Dapsone if you are on Erlotinib.  At the least it will help the rash, and at best might kill the tumor better!

  294. [10/30/2015] Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.  This has an interesting result: Using Temozolomide right after surgery compared to waiting until radiation starts resulted in a big increase in median overall survival, but a decrease in progression free survival.  It makes a lot of sense to me to start the Temozolomide right away (although we have to study the effect on wound healing), but more research is needed to see why the progression free survival goes down while the overall survival goes up. 

  295. [10/30/2015] Swedish Medical Center in Seattle announces a clinical trial in humans for the treatment of glioblastoma  This is a very exciting trial.  It is now open and will show up on our website and in a few days but you can contact them directly if you are interested. It is for newly diagnosed gbm patients only.

  296. [10/11/2015] Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.  This is only in the test tube and in mice, so more research is needed. This is a perfect use of the brain tumor virtual trial... we have 7 patients who used Metformin in addition to Temodar, and they seem to be doing better than average. That is not enough patients to even consider using it but it is a good start. If everyone reading this joined the virtual trial project, we would have enough data to say it is worth using - or not.  Go to and click virtual trial to join and for details. It is free and easy - we do not tell you what to do - we just observe the outcome.

  297. [10/08/2015] VBI Vaccines Announces Development of a Novel Glioblastoma Immunotherapy Candidate  This will target the cytomegalovirus, which some researchers say is associated with 100% of GBMs, so it should make a great target.

  298. [10/05/2015] FDA Expands Optune`s Glioblastoma Multiforme Indication  Fantastic news! The FDA acted quickly! They approved Optune for Newly Diagnosed Glioblastoma to be used in addition to the standard treatment!  It results in "the risk of progression or death was reduced by 37 percent "

  299. [10/01/2015] Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients This is a relatively new, FDA approved robotic laser surgery. This article mentions the ability to target tumors in very hard to reach areas.

  300. [09/28/2015] International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.  This reports on a clinical trial comparing a shorter course of radiation for the elderly with glioblastomas.  There was no difference when they cut the radiation to 1 week compared to 3 weeks and the total dose of radiation cut by about 45%.  Both resulted in short survival and progression free survival times and had equal quality of life, so it seems that for the elderly (or frail) patients, we can cut the radiation to just 1 week which is a lot easier for the patient, without changing the outcome.

  301. [09/20/2015] Caffeine inhibits the growth of glioblastomas through activating the caspase-3 signaling pathway in vitro.  Finally some good news - Caffeine may help!    

  302. [09/20/2015] EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients  Sounds interesting

  303. [09/12/2015] Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies  This updated the results that were presented last year.  They still look great!

  304. [09/08/2015] Novocure Announces Optune® Now Available at more than 200 Leading Cancer Centers across the United States  This is a big milestone for the Optune system.  This treatment is now available in most areas of the USA. If it isn't available near you, you can ask your doctors to get certified.

  305. [09/01/2015] Oncoceutics Awarded Grant for Phase II Brain Cancer Trial We helped fund the early work on this (They mention us in the press release!).  For details on how this drug works, go to:

  306. [09/01/2015] UCLA Researchers Develop a Likely New Combo Treatment for the Deadliest Form of Brain Cancer  This is an amazing concept. Hope it works out.

  307. [08/29/2015] Computed modeling of alternating electric fields therapy for recurrent glioblastoma.  It is always great to find out why a treatment fails, and how to make it work better. Novocure now has a system in place where the doctor can shape the field by determining placement of the electrodes to better hit the tumor compared to the first generation of the system

  308. [08/26/2015] Treating Brain Tumor with Microbeam Radiation Generated by a Compact Carbon-Nanotube-Based Irradiator: Initial Radiation Efficacy Study.  We funded some of the earlier studies mentioned. This is a big step toward human trials.

  309. [08/25/2015] FDA Grants Orphan Drug Designation for Tocagen`s Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma  Great news for brain tumor patients!

  310. [08/24/2015] Update posted for Ben Williams` "Treatment Options for Glioblastoma and other Gliomas"  Ben Williams is a 20+ year GBM survivor and has written a book about his experiences.  Every year he writes an update to keep it current. This is a must read. It outlines all of the treatment options available for Glioblastoma and other high grade gliomas.   New this year, Stephen Western, who is the medical writer for, helped Ben organize and format this free e-book. There is now a table of contents and a list of the major changes from last year. This is a living document - you can discuss it in our braintumor treatments online support group - point out errors / omissions or if anything is not clear, and we can fix it for the next version.

  311. [08/24/2015] NW Bio Confirms Phase III Trial of DCVax®-L for GBM Brain Cancer Is Ongoing Patients In Trial Continuing To Be Treated Per Protocol, Including In Germany  There have been a lot of rumors flying around. What we now know is that the DC-Vax trial has stopped screening new patients for inclusion in the trial but will continue treating and observing the patients already enrolled. The company that makes it says it is a temporary suspension while they have to file some regulatory paperwork.  Some of the financial websites have painted it as a much worse event - implying that it might be permanent.    I think that this is one of the most promising treatments in the pipeline - not only for brain cancer but possibly most types of cancer. I can not see it closing down at this point when they are so close to the finish line. Let's hope it is just a paperwork thing and will reopen soon.

  312. [08/14/2015] ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma This vaccine therapy trial should open soon. Looking forward to it. 

  313. [08/14/2015] Cleveland Clinic researcher awarded National Cancer Institute`s Outstanding Investigator Award  Congratulations  to Dr Rich!  He is one of the bright stars in the brain tumor world and this grant should help speed up the search for the cure!

  314. [08/12/2015] Can a Lung Cancer Drug Fight Brain Tumors?  I love the concept of testing drugs approved for other types of cancer. 

  315. [08/09/2015] New Consensus Recommendations Announced for Standardized Imaging Protocol in Brain Tumor Clinical Trials        This new standard should be used for all new clinical trials, and if possible, even for brain tumor patients outside of clinical trials. It will allow for a better comparison from scan to scan by minimizing the differences between MRI scanners. Currently, you can do a scan in 1 MRI machine, and immediately do another scan in a different machine and the results could be off by as much as 20-25%. This makes it impossible to tell if you are doing better, worse or no change.   This standardization effort was the result of the Jumpstarting Brain Tumor Drug Development Coalition, which was started by the National Brain Tumor Society. The Musella Foundation, as well as ABC2 and the Society For Neuro-oncology are also participants in the coalition.        

  316. [08/05/2015] Colchicine derivative as a potential anti-glioma compound.  I thought about this a long time ago.. Colchicine is a drug that stops cells from dividing by stopping the cell cycle at a specific point. It would make sense that it would be useful for cancer but it is too toxic at high doses. I always thought it might be a good drug to try for brain tumors using it directly in the brain, not systemic so you don't get the systemic side effects.  Perhaps combining it with something like the Optune system would work much better as more tumor cells would be in the middle of the cell cycle where Optune works the best.  Creating derivatives of it that aren't as toxic is worth trying.

  317. [07/27/2015] A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. This is a small study - so we can't be sure the results are correct, but it seems to have minimal side effects, it can prevent seizures, and elevate mood. And it might make the Temodar and radiation work better!   May be worth trying. It is readily available.

  318. [07/18/2015] Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.  This article shows that adding Gliadel wafer at the time of the initial surgery for glioblastoma adds about 2 month to the progression free survival as well as to the overall survival.  2 months might now sound like a lot, but it may buy enough time for something else to work.  I am surprised that they aren't used more frequently.

  319. [07/18/2015] ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma.  This is one of the most important articles of the year.  Rindopepimut is a simple off the shelf vaccine given as an injection under the skin (not into the brain).  Apparently it has minimal side effects. In this study, the early results for using it on recurrent glioblastoma shows an improvement of more than doubling the 6 month progression free survival rate and there are twice as many patients still progression free in the vaccine arm than the control arm. This is just one of a few clinical trials testing this vaccine. All have been showing good results. Let's hope this treatment gets FDA approval quickly so all eligible patients can benefit. (You need to be EGFRvIII positive to benefit from the vaccine).  

  320. [07/18/2015] Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis.  This article says that hyperbaric oxygen may make the tumor grow faster.  There are some experiments which showed the opposite but this raises a red flag that we have to look into this treatment closer.

  321. [07/13/2015] FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma  Exciting news.  This will hopefully speed up the approval of this immunotherapy for brain tumors!  Notice that they mention the Musella Foundation!  

  322. [07/06/2015] An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. This should be included in the standard of care for newly diagnosed glioblastomas. (Disclaimer: Novocure, the company that makes Optune, is a sponsor of our organization).    

  323. [07/06/2015] Epigenetic Driver of Glioblastoma Provides New Therapeutic Target  Brilliant research. This type of thinking may lead to a major advance quickly. There is research on using this approach for ovarian cancer (in the test tube) that showed good results.

  324. [07/05/2015] Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.  Although it is a small study, impressive results. Sounds similar  to a treatment that was done at Duke years ago which also showed good results but for unknown reasons development was stopped.

  325. [07/05/2015] Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.  This study says that adding carboplatin to Avastin actually is worse than using Avastin alone for recurrent gbm.

  326. [06/27/2015] IBTA Newsletter  From our good friends at the IBTA

  327. [06/20/2015] New City Of Hope Clinical Trial Harnesses The Power Of The Immune System To Fight Brain Cancers  This is a very exciting new trial. it has done very well with other types of cancers. We hope it will work the same for brain tumors.

  328. [06/18/2015] Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics  This is a hot topic in neuro-oncology now. The current issue of the Journal of Neurooncology has this article, as well as an editorial about it and a letter in response from Dr Cobbs - who first announced that CMV is present in most GBMs.  This article says there is no CMV in brain tumor samples.  The editorial says it is a controversy and they are leaning towards CMV not being associated with GBMs. The letter from Dr Cobbs explains how they found the CMV and showed that the methods used in this article did not have a chance of finding the CMV.  I tend to think Dr Cobbs is correct and he found a method that can find the CMV. Researchers at Duke were able to confirm the presence of CMV in most or all GBM samples. Other labs were also not able to detect it. What is needed is a standardized test where any lab can do it with the same results. Until that happens, the controversy remains. This is a very important topic because IF CMV is associated with most GBMs, it presents a target to be used to fight GBMs.

  329. [06/03/2015] Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met  This is great news. Rintega has shown significant advantage in overall survival for recurrent GBMs. Let's hope the FDA approves this quickly.

  330. [06/03/2015] Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.  This type of research is brilliant. It is only in a mouse model, so we do not yet know if it applies to humans.  They looked at tumors that became resistant to BCNU and Temodar and found that the changes that allowed the resistance  to these drugs opened the door for different drugs to work.   Doxorubicin has been shown to be effective against brain tumor cells in the test tube but it is hard to get a high level of it in the brain so it is not used much today. 10 years ago there was a paper ( reporting on using Doxorubicin wafers implanted into rat brain tumor and they did pretty well.  It may be time to look at this again especially for recurrent GBMs that became resistant to temodar.


    The National Walk To End Brain Tumors raised over $230,000 this month for the Musella Foundation to use for research. We awarded $210,000 this round and will save the remaining $20,000 to use with the next round of grants.  These events were run by individuals who are committed to helping speed up the search for the cure. None of them had prior experience! They all did a fantastic job.  If you would like to host a fundraiser for us, just contact me at

  332. [05/31/2015] Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial  This confirms the good results they reported in the interim analysis a few months ago. 2 year survival for newly diagnosed GBM patients went up from 29%  in the standard therapy group to 43% in the standard + Novocure group.  More of the details will come out on June 2, 2015.  When I discussed the interim results with neuro-oncs , many took the cautious viewpoint of "wait for the full results - it can't be that good".  Well - these are the full results and almost as good as the interim results.  They also had concern that perhaps a major difference in prognostic factors between the control group and treatment group might account for the difference. Hopefully we will find out in a few days when more details are released. 

  333. [05/28/2015] Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community  This sounds like a lot of fun and a great idea! It is a contest with nice prizes to create tools to help GBM patients. [Disclaimer: Novocure is a sponsor of our organization]

  334. [05/28/2015] Adding Bevacizumab (Avastin) Has No Impact on Quality of Life in Glioblastoma  This article is confusing. They first say adding Bevacizumab  (Avastin) to the standard of care has no impact on quality of life, then they say "Adding bevacizumab to radiotherapy with temozolomide (RT/TMZ) resulted in statistically longer deterioration-free survival across all health-related quality of life items."  In my view, they are intentionally being misleading with the headline. In the fine print at the end they say "there is no impact on quality of life DURING the progression free period." I take that to mean the until there is progression, quality of life in both groups was relatively good. Once quality of life deteriorates, there is progression. So of course there won't be much difference in the period before progression - how can you get better than good?  They downplay the part about statistically significant longer deterioration free survival.  To me that is very important and a good reason for using Avastin for newly diagnosed.  By having the same quality of life with and without Avastin, that means adding Avastin does not have a negative impact on quality of life - no more serious side effects than the placebo. And you have a longer period of feeling good.  [Disclosure - the company that makes Avastin is a sponsor of our organization)  

  335. [05/28/2015] Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan  Optune is now available in Japan!

  336. [05/26/2015] Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation  When Gliadel was first approved, there were rumors that it caused brain infections. There were reports that it happened much more frequently with inexperianced neurosurgeons, but not with the experienced  ones.  This article shows that there is no link between the wafers and infections. The long term data with Gliadel looks good. It is surprising that it isn't used more often.

  337. [05/25/2015] Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.  This is a surprising finding.. the standard dosing for Temodar does as well as the dose dense schedules with less chance of serious side effects.

  338. [05/19/2015] Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors  This trial may be a good option for kids with high grade brain tumors. 

  339. [05/16/2015] Help us to better understand Glioblastoma Multiforme patient experiences: (And get $100 for your time) I sent this a few weeks ago and it worked out nicely. There are still a few more spots left in the study - you can get $100 for your time on a phone meeting!  They need GBM patients or caregivers. 

  340. [05/15/2015] Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies  Excellent news. This treatment is very elegant. They inject a virus into the tumor - in 1 of 3 different ways - this virus can only infect cancer cells (see for how that works). When it infects them, it inserts a gene that encodes for an enzyme which converts a nontoxic oral fungus medication into a powerful chemotherapy - only in the cancer cells theoretically leaving normal cells alone. They let the virus spread for a month or so, then give the oral medication.  This kills the cancer cells that have enough copies of the gene.  The cells that were infected but did not get enough copies of the gene acts as a reservoir to start the cycle again.  They wait another month and repeat the oral medications.   If that sounds scary, they did build in a safeguard. They designed the virus to be very sensitive to oral anti-viral drugs so that if something bad did happen (and it hasn't yet), they can give a drug and clear the virus from your system in about a day. Also the virus can't live in normal healthy cells.   The Musella Foundation has funded a small part of these studies.

  341. [05/15/2015] The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme  This shows a major difference in outcome between GBM patients who had "radical" surgery vs. thos who did not.  They used a criteria of 1.5cm in diameter of residual tumor as the cutoff from radical to non radical surgery.  They did not go into detail on outcomes from patients with total resections but it looks like extent of surgery - even on a rough look like this - makes more of a difference than anything else.  This goes to show that selecting the right neurosurgeon and medical center - with the most experiance and the best tools, is the most important decision you can make.

  342. [05/15/2015] Agenus (AGEN) Provides Update on its Brain Cancer Vaccine By itself the increase in survival doesn't sound like a lot but this adds a new possible tool to the toolkit that can be used to put together a cocktail that might have a long lasting effect.   Best part is it is well tolerated with no serious side effects.  

  343. [05/13/2015] Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.  This is only in the test tube, so it is too early to get excited about it, but I love the methodology of this research and it can be used to identify other approved drugs which can be repurposed to fight brain tumors!  Thioridazine used to be used in the USA mental disorders but was stopped because it had a bad side effect of causing heart problems.

  344. [05/13/2015] NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma Novocure  This is a good first step but way too little. The NCCN guidelines should have made it a standard treatment for both newly diagnosed as well as recurrent glioblastoma. The upgrade from Category 3 to Category 2B will help with insurance coverage issues, but again, they are too conservative and should have upgraded it to a Category 1, which should eliminate all insurance issues and allow access to everyone who needs Optune..  Hopefully when the results of the recent phase 3 trial for newly diagnosed GBM patients is published, they will revise the guidelines again and give it a Category 1 for both newly diagnosed as well as recurrent GBM.

  345. [05/13/2015] GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin  It's a great sign that they expanded the trial!

  346. [05/11/2015] ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain Cancer  Another gene therapy trial is starting up for recurrent GBM and Anaplastic Astrocytoma.  I love the concept and will be watching this one.

  347. [05/11/2015] FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma  This is great news.  Hopefully the FDA will quickly approve the Optune system for newly diagnosed GBM patients. Right now it is only approved for recurrent GBM patients but with results like this ( a 48% increase in 2 year survival rate), of course newly diagnosed patients should be using it. Newly diagnosed patients can use it now off label.  I just had a patient request my help in fighting his insurance company - they rejected the claim for Optune for his newly diagnosed GBM saying it is experimental for newly diagnosed.  I sent a nice letter along with the research and they reversed the decision, saying they will now pay for it.  Getting the FDA - then the NCCN - to support it's use for newly diagnosed will speed things up and avoid that problem.

  348. [05/06/2015] Help us to better understand Glioblastoma Multiforme patient experiences:  You can get $100 to participate in this phone conversation!  

  349. [05/05/2015] Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community  We will be participating in most of these events!  

  350. [05/01/2015] Brain Tumor Survey We are working with Novocure to help create resources to help brain tumor patients.   The first step is a survey of what is needed.  Please fill out this survey!

  351. [04/29/2015] The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. There has been predjuduce against marijuana as a treatment for cancer simply because in most states it is illegal.  Removing the psychoactive components should immediately remove that barrier.

  352. [04/25/2015] Investigational Brain Cancer Vaccine Produces Strong Immunological Response  Pretty good results!

  353. [04/25/2015] New Optune You-Tube Video Channel  There is a new video on that page which shows the effect Optune has on dividing cancer cells. They show cancer cells in culture dividing, the ones on the left are treated with Optune, the ones on the left are not treated.  Aside from the amazing video of showing cells blow up when they try to divide, the end result is a huge reduction in the number of tumor cells at the end.

  354. [04/20/2015] Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer  (Disclaimer: I am on the  advisory board of the Brain Tumor Biotech Center at the Feinstein Institute).  The new brain tumor biotech center at the Feinstein Institute on Long Island, NY is designed to speed up the process of pre-clinical and clinical studies of new treatments for brain tumors, and to do it at a lower cost than traditional methods!  I would love to see more of these partnerships!

  355. [04/14/2015] Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response.  Metformin is a cheap, easily available drug used to treat type 2 diabetes.  Sounds interesting.

  356. [04/09/2015] PharmaCyte Biotech`s Novel Approach to Brain Cancer  Sounds interesting.

  357. [03/15/2015] New clinical trials at JFK Brain Tumor Center in Edison, NJ  I usually do not list trials at an individual brain tumor center, but this one is special. These are 4 of my favorite  trials, all done at one medical center, and they are also certified to use the Optune treatment as well.  For more information, look at  click on LEARN ABOUT then Tocagen, then Learn About and Vaccines.

  358. [03/15/2015] Y Combinator backs cancer drug combo testing service Notable labs was created by a friend of mine. They have a great concept: they grow a patient's tumor in the lab and try thousands of combinations of existing drugs on it to pinpoint the best combination to try.  They will be starting a clinical trial of it soon to prove the concept works.  Good luck to them!

  359. [03/14/2015] Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).  I had high hopes for this trial.  Previous trials that used targeted drugs against 1 target failed, so the thinking was to try targeting multiple targets. Dasatinib is active against 4 targets, and did not work.  Hopefully the concept is  correct and this mix of targets was wrong.

  360. [03/11/2015] Study: Tetanus Shot May Aid Treatment of Deadly Brain Cancer  Great results.  Of course it is too small to prove it works but it looks like it has no side effects and may have a huge benefit.   Hope the larger trial opens soon.  Perhaps the tetanus vaccine could help boost the other vaccines in trial now also. There will be a segment on cbs evening news tonight about it

  361. [03/07/2015] IBTA e-News From our friends at the IBTA 

  362. [02/26/2015] Cancer drug first tested in pet dogs begins human trials  This will soon start trials in brain tumors in dogs soon. hopefully it works and will start up in people!

  363. [02/26/2015] NW BIO`S PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER APPROVED TO PROCEED IN CANADA AND UNDER WAY AT TWO SITES  I frequently get calls from Canadians asking how to get into this trial, and now it is available in Canada! Great news.  

  364. [02/26/2015] New clinical trial for Glioblastoma using immunotherapy  This is an exciting new trial for gbm patients either at first recurrence or if there is residual tumor after the initial surgery and radiation. Patients must be EGFRviii positive.  This type of treatment has shown fantastic results in other types of cancers and they are now trying it for GBM patients.

  365. [02/26/2015] Israeli Company Develops Device to Fight Tumor Growth with Electric Fields  (Disclosure: Novocure is a sponsor of our organization) We have talked a lot about this recently - I include this article because it points out that 2,000 patients have used it for gbms.  That is a lot of experience. It also says that tumor treating fields are now being tried on ovarian and pancreatic cancer.

  366. [02/25/2015] UCLA 15th Annual Brain Tumor Conference  This is always an excellent program - well worth going to!

  367. [02/23/2015] Celldex`s Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma  Great news.  That is an excellent sign that things are going well.

  368. [02/21/2015] End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma  This is sadly the end of the drug Cilengitide. We all had high hopes for it. They tried many different combinations and all of the trials failed, so they are giving up on it.  It is sad because it seemed to make a lot of sense, which we thought would translate into a benefit but it didn't work out. 

  369. [02/21/2015] Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.  This is one of my favorite trials now.  It is for people with Glioblastoma multiforme who have the EGFR vIII mutation.  It can be done at the time of recurrence or for newly diagnosed if they have residual tumor. For details go to:

  370. [02/13/2015] Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma This is a study of Temozolomide alone and in combinations with 3 different drugs that have been popular with brain tumor patients.  I think this study is too small to really tell what is happening but it is interesting for 2 things:  1. The design of the trial is impressive - it is a new way to test multiple treatments. Great start and this is how trials should be run, but there were not enough people in each group. 2. Overall, there was no or minimal benefit to any combination tested over the Temodar alone. However, the group using isotretinoin (accutane) did much worse than all other combinations or even just Temodar alone.  This shows that trials are always needed even when it seems to make sense to try adding something to the standard therapy. IF it is strong enough to help, it is also strong enough to hurt and a trial is the only way to tell if the benefits outweigh the risks. There have been other trials showing a benefit to adding Accutane to the standard treatment, so more research needs to be done.

  371. [02/10/2015] Could There Be a Gleevec for Brain Cancer?  Sounds very exciting. The protien is a  FGFR-TACC fusions in IDH wild type glioma

  372. [01/31/2015] Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.  The results for Gliadel wafer are impressive when you consider it is just a 1 time insertion of wafers. These wafers have been vastly underutilized at some brain tumor centers. The reason stated is usually that they would prevent you from entering some clinical trials but if you look at the history of clinical trials in the past, most did not result in a gain as good as Gliadel would have given.  The restriction on prior use of Gliadel wafer for clinical trials should be removed immediately. It is not ethical to withhold a known benefit. At the very least, it should be required to at least discuss the risks and benefits of Gliadel before any brain tumor surgery.

  373. [01/22/2015] IBTA e-news  From our friends at the IBTA

  374. [01/20/2015] CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)  Sounds very promising. It is rare to get a complete response in recurrent gbm

  375. [12/21/2014] Neuro-oncologists discover cancer cells can burn acetate for fuel I love projects like this - those that challenge the current thinking. It may open up a ne target not only for treatments but for diagostics.


  376. [12/21/2014] Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States  There are now  over 150 centers certified to use Optune, including some of the best in the world, now making it much easier to find a center close to you  

  377. [12/17/2014] Novogen Announces Breakthrough Discovery in the Treatment of Melanoma    Sounds like an interesting drug for brain tumors but it also looks like this company doesn'[t have the resources to develop it. Hopefully another company will come along and partner with them to develop the brain tumor version.

  378. [12/02/2014] Novocure Announces FDA Approval of an IDE Supplement Allowing All Control Patients in its Phase III Trial in Newly Diagnosed GBM to Cross Over to Receive Tumor Treating Fields  This is amazing -  that the FDA has moved so quickly. The data from this trial was released less than 3 weeks ago and the FDA has already acted on it. (As far as I know) This was the first time in history that the FDA allowed a brain tumor trial to stop the control group and move them into the active treatment group because the results were so good in the control group that it is unethical to continue a contril group!

  379. [11/29/2014] Personalized vaccines, next frontier in cancer treatment, to begin clinical trial  This is one of the most exciting concepts...   see this video: for details on how it works. Basically they start out with a general vaccine against the most common targets on the tumor. They then do a complete genetic profiling of the tumor.  Using that information, they construct a cocktail using about 5 of the 72 vaccines they already made to specific targets, using the ones your tumor expresses the most.. When it is ready, they stop the general vaccine and start this new cocktail which is individualized for your tumor.   We are funding part of the USA trial of it!

  380. [11/19/2014] Quality-of-Life Issues Important in Neuro-Oncologic Treatment  Quality of life IS the most important factor and has taken a back seat to other measures of success for too long. In our brain tumor virtual trial project, we try to rank treatments based on not only how long people live but also how well they live.  I feel that living 10 years with poor QOL is not as important as living 5 years with high QOL.

  381. [11/19/2014] Al Musella`s Brain Tumor Blog on SNO2014  This is my thoughts on the exciting news from SNO this week!

  382. [11/15/2014] Novocure Announces the EF-14 Phase III Clinical Trial of Tumor Treating Fields in Patients with Newly Diagnosed Glioblastoma has been Terminated at the Interim Analysis due to Early Success

    This is historic.  As far as I know, and I have been involved with brain tumors for 22 years, this is the first time a GBM trial was ever stopped early because it actually worked!  Optune – the new name for the FDA approved Novocure tumor treating field device, has finally shown what it can do.   This was a large phase 3 randomized trial comparing the standard “Stupp Protocol” to the standard + the Optune device.  There are many ways to look at the results (see the article for the rest)  but keep in mind the numbers given are from the time the trial started, not from the date of diagnosis. The trial started around 3.8 months after diagnosis.  There was an increase of about 50% in the number of patients alive at 2 years after starting treatment ( about 27.8 months after diagnosis) ,  from 29% in the Temodar group to 43% in the Optune group.  Overall survival increased by about 3 months, from 16.6 to 19.9 months after trial started ( or about 20.4 to 23.7 after diagnosis).   

    Dr Stupp presented the data and then said "a new standard of care for patients with GBM has been established", and  "A new cancer treatment modality has been born".  He called it a paradigm shift.

    The last time the standard of care changed was in 2005  when Dr Stupp presented his data on using Temodar at the same time as radiation, in addition to the old way of using Temodar.  That resulted in a gain of 2.5 months, from 12.1 months to 14.6 months from diagnosis.

    My opinion is that this is a big step forward, with very little downside. This is the first non-toxic therapy ever to succeed in a phase III trial for newly diagnosed cancer patients.  I agree it should be the new standard of care.  Of course a lot more work needs to be done but we have to go with the best we have at the time and this is it. I hope to see more trials combining other treatments with Optune – hopefully also with no or low toxicities.  This brings us a step closer to our goal of a cure.

    Talking to many of the doctors present at the meeting, there were still a few who said they wouldn’t use it. The main objection now is that it may interfere with clinical trials.   I would suggest designing trials to allow for the use of Optune just as they had to do when the standard of care changed 9 years ago.  I am a huge supporter of clinical trials but if there is a choice between using Optune and having minimal or no additional side effects with a known average benefit of a 50% better chance of living at least 2 years, vs. a clinical trial which has unknown side effect profile and unknown benefit in survival, I would probably choose the Optune. 

     If you decide that you want to try this treatment, ask your doctor about it but if they seem resistant to the idea, go to to find a doctor in your area that is trained to use it and get another opinion. This treatment has been FDA approved for recurrent glioblastoma, but it can be prescribed off label for newly diagnosed. Clearly the earlier you start it the better the outcome.  Hopefully the FDA will approve it for newly diagnosed GBM soon!


         Disclaimer: Novocure is a sponsor of the Musella Foundation but I have never personally received anything of value from them.

  383. [10/30/2014] CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia  This is a report on the preclinical results of this new experimental treatment. They are running a phase 2 trial of it for GBM patients. See for details on the trial.  CytRx is a new sponsor of our website.

  384. [10/26/2014] Cancer-killing stem cells engineered in lab  This is a clever approach but not used in people yet.  Something to keep an eye on.

  385. [10/26/2014] Yours for $2 million: Place on cancer drug trial

    This brings up an interesting ethical question:   Is it OK to buy your way directly into a clinical trial? At first glance, I would say no, but then upon further consideration, the trial wouldn't be able to start for anyone if those first patients didn't pay the $2 million... so it is helping others.    In the past, wealthy people have approached me and have asked for help in getting unapproved treatments.  My response was always that it had to be done within a standard clinical trial. They would donate money to the Musella Foundation, and I would then find a researcher willing to design and run a clinical trial of the treatment we wanted, with liberal enough entry criteria that the donor would qualify.  However, it had to be open to other patients as well. This has worked out pretty good and I do not think it has the moral issue of a patient paying directly to get into a trial.  There is more oversight - our medical advisory board has to approve of the project, and we are able to watch and make sure the trial really opens for others, and the money is well spent and accounted for.  This has resulted in new treatments that are now being used for many other patients.

  386. [10/26/2014] Cavion and Yale University Announce First Patient Enrolled in Phase 1b Clinical Trial in Brain Cancer Proof of Concept T-type Calcium Channel Drug Mibefradil to be Tested as Radiosensitizer  Exciting new trial. I love the concept of repurposing an approved drug for brain tumors, because IF it works, anyone can use it immediately off label and we do not need to wait years for FDA approval! I wish them luck.  

  387. [10/25/2014] Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 in First Stereotactic Implant for Inoperable Brain Cancer  This is another new option, but keep in mind it is 1 patient and only a very short follow up  

  388. [10/23/2014] Brain barrier opened for first time to treat cancer  Interesting new way to open the blood brain barrier.

  389. [10/22/2014] Neural stem cells: On the frontier of brain cancer therapy  This is a fascinating new clinical trial for recurrent high grade gliomas.  The neural stem cells migrate to the tumor cells, and carry an enzyme that converts a harmless oral anti-fungal drug into a toxic chemotherapy drug only in the local area where tumor cells are.  Hopefully this will result in the cancer cells getting killed and minimizing side effects to the noraml cells.  It is a phase 1 trial so there are no results to look at yet, but it is worth thinking about this trial. Click HERE for details on the trial

  390. [09/28/2014] Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma  This is an interesting trial design - hey tested every combination of temodar and 3 add on drugs... there probably wasn't enough patients to be sure but early result look like adding isotretinoin  (Accutane) actually did worse than temodar alone, and none of the combinations did much better than temodar alone. The best was all 3 drugs plus temodar, but not by much over temodar alone.  

  391. [09/15/2014] Challenging the notion of personalized medicine   This could be very important in the fight against brain cancer.  It makes a lot of sense.

  392. [09/04/2014] A one-two punch for brain tumors? New clinical trial opens at U-M  Sounds like an interesting approach

  393. [08/31/2014] Atlantic NeuroSurgical Specialists (ANS) Introduce Noninvasive Treatment for Brain Tumor Patients  There are a lot of new doctors who are certified in the use of this FDA approved treatment for recurrent GBMs.. go to and put in your zip code near the top right of the page to find one near you.

  394. [08/25/2014] Insys Therapeutics (INSY) Granted Orphan Drug Status for Cannabidiol for Brain Tumors  This is a big step forward for development of this line of treatment

  395. [08/23/2014] EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma  This is the treatment guidelines from the European Association for Neuro-Oncology Task Force on Malignant Glioma.  I completely disagree with them.    For young (up to 70 years old) newly diagnosed Glioblastoma patients, they say the treatment should be: Surgery (resection or biopsy), followed by radiotherapy with concurrent Temozolomide, followed by 6 months of Temozolomide.   For recurrent, they say more surgery, more radiation, more chemotherapy or Avastin. For older patients, they say radiation is optional based on MGMT and performance status.   Here in the USA, the standard treatment for newly diagnosed younger patients is a clinical trial. IF that is not possible, then the standard therapy is the same as the EANO guidelines.  The EANO guidelines doesn't suggest clinical trials.    I feel clinical trials are the best way to go, but if not, I would say to follow the standard surgery, radiation and temodar, AND  would also do a molecular testing such as the Foundation Medicine test.  If they find any mutations in your tumor that are targeted by available drugs then I would add those drugs also.   For Recurrent GBM, here in the USA, tumor treating fields (Novocure's TTF-100A device) are approved for recurrent GBM and is in trials for newly diagnosed.  Research  has shown that tumor treating fields may be the best treatment for recurrent GBMs.  The EANO guidelines do not mention it.     The scary part is that the European governments can use this document to justify excluding payments for treatments not recommended.  That makes this a political document - based more on a cost / benefit ratio than based on what is best for the patient.   The only advantage the EANO guidelines have over the USA guidelines is the use of Gliolan, which is a dye used during surgery which allows more of the tumor to be removed safely.  It is standard in Europe but not even FDA approved here in the USA yet.    

  396. [08/23/2014] Clinical trial offers promising results for brain cancer patients  There is a video about this procedure at  

  397. [08/17/2014] Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.  This researcher is saying that combining 3 immunotherapies resulted in dramatic survivals in mice and wants to try it in humans with GBM.   This is one of the most promising avenues of research. The drugs are available (in trials for other cancers).  These researchers have asked us to fund the trial, but we did not have enough money to do so.   The only thing holding up the trial is funding.  If anyone wants to help us fund this, contact us!

  398. [08/17/2014] Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy.  This shows that it is probably safe to the fetus to have radiation therapy to the brain while in the 3rd trimester.  

  399. [08/17/2014] Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.  This study on recurrent GBM patients is disappointing. 97% of the patients died. Clearly we need better treatments. However, given this information, it seems better to add CCNU than to use Avastin alone. 

  400. [08/17/2014] A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.  This is one of the most important articles of the year. One of the main problems that slows down drug development for GBMs is the inability to agree on tumor response or progression.  If this method is proven to work, it can drastically speed up the search for the cure.

  401. [08/17/2014] The Effect of Timing of Radiotherapy in Patients with Newly-Diagnosed Glioblastoma Multiforme Receiving Temozolomide: An Analysis Based on the University of California, San Francisco Experience.  This study suggests that starting radiation 30-34 days after surgery may be better than starting sooner - or later than 35 days..  However, they did not correlate it with WHY some patients waited 30-34 days, others waited over 34 days and yet others had radiation sooner.  That might account for the differences.  To test this correctly, patients should be randomized to start radiation at the standard time or at 32 days and see if there is a difference.

  402. [08/16/2014] Analyzing temozolomide medication errors: potentially fatal.    I have heard of a few cases where people took the wrong dosage of Temodar.  It is pretty complex compared to the medicines we are used to taking.  There are 3 main sources of errors:  Doctor prescribing wrong dose, pharmacy giving you wrong dose or instructions, and patient making a mistake in understanding the instructions.    First - do a reality check. Go to and figure out what the ideal dosage should be for you.  The doctor may have reasons for changing it but if it is not close to what this app says, ask him why it is different.     Next: Make sure the pharmacist has clearly marked how to take the capsules. There are different sizes that are used to add up to the correct dosage.  Make sure to double check before taking each dose: how many mg you are supposed to take and then how many you are about to take. IF you have any questions, call the doctor, nurse or pharmacy before taking them.  If your mind is not completely sharp, ask someone else for help to double check the medication before you take it.  Read the warning instructions before starting.

  403. [08/16/2014] Predicting the electric field distribution in the brain for the treatment of glioblastoma.  Good to see new teams of researchers working on Tumor Treating Fields, but I wonder why they didn't use Novocures' NovoTAL system which allows the doctor to optimize the field strength at the tumor.

  404. [08/12/2014] NW BIO PROVIDES UPDATE ABOUT PHASE III DCVAX®-L TRIAL FOR GBM AND "INFORMATION ARM" COMPASSIONATE USE PATIENTS  This is mostly good news about the DCVax trial.  This is one of my favorite trials. There are 2 major announcements: 1.  The patients on the compassionate use arm of the trial seem to have done much better than expected.  These patients had the vaccine made but were excluded from the trial because they had a recurrence before the trial could actually start.   These patients usually die quickly but the vaccine seemed to help those. 2. They have changed the number of patients in the trial, as well as the point in time when they evaluate the trial.  This may be good or bad - hard to tell. The good point is that will increase the chances that the trial shows positive results, however it is going to delay the results - maybe by a year.  As the ICT-107 trial showed, when you look at the results too early, you can't see the effect the treatment has on the "tail" - the number of people who do well for a long period of time. You just see the people who did not respond to the treatment.  

  405. [08/04/2014] Novocure Announces Commercial Launch of NovoTTF™ Therapy in Europe and Israel The Novocure system is now available in Europe and Israel!  

  406. [08/04/2014] MD Andesron Reviewed Study Reveals Bevacizumab/lomustine Combination Improved Recurrent Glioblastoma Outcomes  This study shows relatively good results for the combination of Avastin and lomustine. It also showed disappointing results for Avastin alone. However, the bottom line was almost all patients died, so we need more work to get better treatments.

  407. [07/23/2014] Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order  The Novocure system is now available in 8 other countries (beside the USA where it was FDA approved a few years ago)!

  408. [07/09/2014] A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.  hydroxychloroquine is an anti-malaria drug that many cancer patients take because in the lab it helps. This trial tested if it is practical and effective to add to the standard of care for GBM. They found that the dose needed to make it useful was too toxic.  All 3 patients at the highest dose had severe to life threatening side effects. The conslusion is that it is not proactical to use this drug but that it may be worth trying to create a new drug to target this pathway with less side effects

  409. [07/08/2014] Brain tumor invasion along blood vessels may lead to new cancer treatments  This reinforces the theory that Dr John Boockvar presented at one of our conferences (see : namely that the most aggressive  tumor cells migrate along the blood vessels and those are the ones we need to target. Dr Boockvar is using intra-arterial avastin to target this "tumor cell niche".

  410. [07/08/2014] A New Study Reveals Longer Survival Outcomes For Patients With Malignant Brain Tumors  This press release talks about a different way to aim the Gamma Knife. Instead of just hitting the tumor, they try to predict the most likely path for it to grow and treat that area also.  Sounds like a great idea.

  411. [07/07/2014] Driving glioblastoma growth by alternative polyadenylation  This may lead to a better way to treat brain tumors.

  412. [07/04/2014] Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis Good results.  I like the idea of adding the checkpoint inhibitor to increase the effect of the vaccine.

  413. [07/04/2014] NovoTTF Therapy for recurrent glioblastoma - PRiDe (Patient Registry Dataset) When the NovoTTF Therapy was approved by the FDA, they required  the company to track the patients who use the treatment. This is the report on the first 457 patients to use it commercially (outside of the trials). It gives a feel for how it works in the real world.     Keep in mind that it does not report on any other treatments patients did. Since it was outside of the trial, patients are allowed to do anything they want in addition to the NovoTTF therapy.  There also was no control group to directly compare it to and they did not show historical controls.   The results are remarkable. Usually reports of patients using a treatment in the real world are much worse than those in the trials. In this case the results in the real world are much better than in the trial.  I think it may have to do with compliance.  If you are paying for it,  you have more of a tendency to use it. In the trial, there were many patients who didn't even use it for a month.  Some highlights:   30% of patients survived over 2 years (after recurrence of GBM), and average survival was 9.6 months.  It is hard to compare patients directly, but in general most other studies report an average survival of  3-6 months. The large study used to get FDA approval for Avastin for recurrent GBM reported an average of 6 months survival and about a 15% survival at  90 weeks (almost 2 years.) They broke down the results by compliance - what % of the time the patient actually used the treatment.  If used less than 75% of the time, average survival was only 4 months. However, if used over 75% of the time, average survival was 13.5 months.        

  414. [06/25/2014] Retrospective study of using carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.  This reports that adding BCNU or CCNU to Avastin after Avastin alone fails, did not really help much.  Average survival was only 4.5 months

  415. [06/21/2014] NW BIO REAFFIRMS DCVAX(R)-DIRECT CLINICAL TRIAL INTERIM DATA ANNOUNCEMENTS  This has to be the most bizzarre situation I ever came across in the brain tumor world.  Northwest Bio has a few cancer vaccines in clinical trials, and apparently became the target of website that is trying to manipulate stock prices.  Every time this website publishs something negative about the vaccine, the stock dips and there is a lot of money to be made.  The stock price eventually rebounds, then they do it again.  This type of behavior should be investigated, but the bottom line is not to pay any attention to it.  It has nothing to do with the science. It is all about greedy people trying to make money without regard to what it may do to cancer patients.

  416. [06/21/2014] Low carb ketogenic diet can manage cancer, says Dr. Adrienne Scheck  When I first heard about using a ketogenic diet to treat brain tumors I thought it was crazy. However, I met this researcher and attended one of her presentations on it where she showed results in mice - comparing radiation alone against radiation plus the ketogenic diet and in the mice studies, there was a big improvement when the diet was added.  She is now testing it in people. Too early to tell but this is something that I would keep an eye on  

  417. [06/19/2014] Itraconazole suppresses the growth of glioblastoma through induction of autophagy: Involvement of abnormal cholesterol trafficking.  Itraconazole is an antifungal drug used to treat fungal toenails and other fungal infections.  It is very safe with minimal side effects.  It has been tested for use in other cancers. A recent study showed that it can reduce the size of skin cancers.     

  418. [06/19/2014] Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme.  Interesting study...  it says if your blood glucose goes too high during radiation, your survival may be cut in half. This may fit in perfectly with another article mentioned in this News Blast on Metformin, which can help control the blood glucose levels. Perhaps controlling blood glucose during radiation or when using steroids may help.

  419. [06/19/2014] Effect of metformin on the human T98G glioblastoma multiforme cell line.  Some people are using this now for brain tumors. 

  420. [06/19/2014] Progesterone could become tool versus brain cancer  Interesting, but I caution that we need to see the research before trying it. They say a low dose can make the tumor grow faster while a hig dose inhibits growth... so we need to see exactly what doses are needed... as well as the effect of p53 mutations

  421. [06/16/2014] ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting  Pretty impressive results. The most important number is that currently 21% of the treated patients are alive compared with only 7% of the control group.  This is for a simple series of shots in the arm with minimal or no side effects.

  422. [06/14/2014] MUSELLA FOUNDATION AWARDS 8 BRAIN TUMOR RESEARCH GRANTS   We had the most grant applications that we ever had this round of granting.  Many excellent projects are not going to  be done because funding is not available.  Most other sources of funding are drying up I have never heard so many researchers tell me that they spend more time looking for funding than doing actual research. 2 of the researchers told me that they are leaving brain tumor research because it is so hard to get funding.  If you would like to help us fund more research - either through donations or hosting a fundraiser for us, or setting up an memorial fund or in honor of fund, - contact me.   888-295-4740 or, or make a donation at We also have a  very large project that need funding - this project will speed up the process of finding the cure. We need to raise a few million dollars to run it. If you are in a position to help with it - contact us!

  423. [06/13/2014] Novocure Announces the Presentation of Subgroup Survival Data for Recurrent Glioblastoma Patients Treated with NovoTTF™ Therapy  Some more results on the Novocure Treatment.  They do not mention the historical results of other treatments, but a median overall survival of 20 months for GBM patients at first or second relapse is pretty impressive.

  424. [06/10/2014] Carbon ion beam is more effective to induce cell death in sphere-type A172 human glioblastoma cells compared with X-rays.  Carbon ion radiation is in use in Japan and Germany. It may have an advantage over standard radiation.  We funded research into carbon ion radiation, which looked good,  but it was way too expensive to build a treatment facility.

  425. [06/08/2014] The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTFTM-100A system. The last sentence may be the key to a major breakthrough. The Novocure system worked great in the lab - they were able to cure all mice with brain tumors. The initial human gbm trial also came out great. Then the large trial for patients with recurrent gbm didn't come out as good as we hoped for - it was as good or better than any other treatments used, with less side effects, but no major improvement in survival over chemotherapy and/or Avastin. However, the FDA required them to monitor all patients who use the device after it was approved. They reported initial results on all of the hundreds of patients who used the device and the results were better than in the trial. Details will hopefully be released next week.   I think the reason the results improved is experience. The doctors learned how to better aim the electrode placement and realized the importance of high compliance rates. This article brings up what might be the missing key. Theoretically, the device is tuned to kill a range of cell sizes centered on the average size of a gbm cell. This article says that perhaps the device does kill those cells where the field intensity is strong enough, but that if the electrodes are not placed correctly, the edges of the field is not strong enough, and if a gbm cell mutates into a "giant cell" they may be too large to be killed and those cells can repopulate the tumor.   We are hosting a conference in November for researchers working with the device. Hopefully we will see these issues addressed!

  426. [06/08/2014] U.S. to test immunotherapy drugs on newly diagnosed brain tumors  This is one of my favorite new trials.  It worked pretty good with melanomas. Let's hope it works with GBMs.

  427. [05/28/2014] EMA advisors reject Avastin for brain cancer  Unfortunately this will make it hard for Europeans with brain tumors to get access to Avastin.  

  428. [05/28/2014] UAB study identifies new way brain tumors become more malignant  New target found.. Hope they can find a way to use it as a treatment!

  429. [05/25/2014] The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study.  This was not a controlled trial, but the results look pretty good. They use a special laser to kill brain tumors that are not easily operable and the results are similiar to removing the entire tumor.

  430. [05/21/2014] Dr. Al Musella named as Adviser to the Glioblastoma Drug Discovery Group at Duke  I am honored to join the GBM Drug Discovery Group at Duke.

  431. [05/21/2014] Autologous T cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma.  Great project - but of course too early to say how effective it is.

  432. [05/21/2014] The Electric Anticancer Helmet Battles Brain Tumors   Popular mechanics picked up on the story of the Novocure system.  They made a mistake in how it works.. they say "NovoTTF blasts tumors with alternating electric currents "  when it should be alternating electric FIELDS. 

  433. [05/21/2014] Diffusion Pharmaceuticals Clinical Trial of TSC in Brain Cancer Reaches One Year Interim Endpoint They are reporting very early results in the trial for newly diagnosed glioblastomas.    For more details on the trial go to:

  434. [05/19/2014] Novocure Announces the Publication of New Survival Data for Recurrent Glioblastoma Patients Treated with NovoTTF™ Therapy  This is pretty impressive.  According to the press release, this is the best reported results of any "non-experimental" treatment for recurrent glioblastomas.  This reports on 457 patients, which is a very large number. The only experimental treatments that reported better results were in very small trials of about 10-20 patients and so far those results have never held up in larger trials.

  435. [05/15/2014] Autologous T cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastom  Very exciting work.

  436. [05/15/2014] A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.  This may be a new way to deliver treatments into the brain over long periods of time.

  437. [05/14/2014] NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data.  The first 457 patient with recurrent gbms who used the Novocure NovoTTF-100a therapy after it was FDA approved were analyzed to see how they did.   This is for people outside of the trials. Results were much better than the large trial that resulted in FDA approval.    There are 2 trials going on novocure device.  One for newly diagnosed gbm  and one for recurrent gbm. It is also available by prescription at over 100 major brain tumor centers  (The advantage of entering the trials are the costs.)

  438. [05/08/2014] Novocure "Tunes-In" During Brain Cancer Awareness Month This May to Support People Fighting Glioblastoma  I need everyone's help on this.  In addition to raising awareness, this is a fundraiser that doesn't cost you any money.  I need people to visit the website, and participate in the twitter and facebook campaign.  Participation is free and easy.   For Twitter: Go to Log in (register if you do not have a twitter account)  and search for the hashtag #tuneIn2GBM  pick 2 of the tweets and retweet them (Just click the retweet button).   Try to do that every day during May.  And ask your friends to do the same.   For Facebook: Log in (or register) with and go to: Just click the LIKE  or Follow button for the page and any articles from me, and also from the partners mentioned in the press release!   thanks    

  439. [05/05/2014] Aduro BioTech Announces Initation of a Clinical Trial of Its Novel Immunotherapy in Patients with Brain Cancer at Providence Cancer Center Sounds interesting

  440. [05/04/2014] Human fat can help treat brain cancer  Interesting - will be watching this as they apply it to people.

  441. [05/02/2014] Why is glioblastoma so deadly? DelMar discusses the need for new cancer research and treatments for Brain Tumor Awareness Month  This trial may be a good choice for GBM patients who have unmethylated MGMT

  442. [04/26/2014] Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma.  Exciting approach. Not done in people yet, but I will be watching this one.

  443. [04/23/2014] Glioblastoma Vaccine Hits Primary Endpoints in Phase 1 This phase 1 trial did better than expected (but that is only with the endpoint of safety and immune response, they did not mention survival in the article).  Sounds like a great concept. They have an approach similiar to ICT-107 but with different  targets. We will be keeping  an eye on this one!

  444. [04/23/2014] Glioblastoma stem cells: a new target for metformin and arsenic trioxide.  Sounds interesting in theory - but a clinical trial is needed to test it. Should be easy because both components are fda approved for other things. Keep in mind arsenic at the wrong dose can be fatal.

  445. [04/18/2014] A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC).  Unfortunately, this treatment - by itself - did not help much. The treatment sound interesting. Perhaps if combined with other treatments it would have a larger impact. Another take away from this study is the low bar - they were trying for 1 month progression free survival (for the group who failed Avastin) . I never heard of using that before. And only 20% of the pateints achieved 1 month progression free survival.  Points to the need for more research.      

  446. [04/18/2014] Stereotactic biopsy of brainstem lesions: Techniques, efficacy, safety, and disease variation between adults and children: A single institutional series and review.  This reinforces the idea that biopsy of brainstem tumors is not as dangerous as we used to think. It is becoming more common and  as this study reveals, can have a major impact in outcome. Almost 10% of the time, it turned out to be a TB infection instead of brain tumor(this is India - I would assume a much lower rate here in the USA).  On the other hand, it shows that studies of brainstem tumors done without a biopsy have to be interpreted carefully - as you are never quite sure that it was a tumor to begin with - and if it is a tumor, which grade

  447. [04/16/2014] Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna. This is a perfect example of how you can use statistics incorrectly to make anything look good.  The inclusion group was defined as patients who had at least 3 homeopathic consults in 4 years.  If you take any group of cancer patients and only count those that lived 4 years, of course they are going to show better results.  This doesn't capture those for whom the treatment did not work.

  448. [04/16/2014] ERGO: A pilot study of ketogenic diet in recurrent glioblastoma.    This is a small trial of the ketogenic diet with and without Avastin, and it didn't help at all, however, this is not the same low calorie ketogenic diet that has shown some promise.  

  449. [04/13/2014] Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF.  This trial did not show much benefit for using Avastin and Irinotecan for newly diagnosed unresectable GBMs.  There was no difference in overall survival, however, the patients in the control group were able to cross over when the progressed, and there was about a 2 month advantage in time to progression.

  450. [04/12/2014] Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy  This is only 1 patient, and at the time of the report was only 6 months from the start of the treatment, but shows proof of concept that a personalized approach may work. 

  451. [04/12/2014] Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

    This is one of the more important articles of the year, and for those of you who love reading highly technical medical literature, well worth reading the entire article (I can not post the full text on because of copyright restrictions). This explains how IL13Ra2 works and why it is so important. It also reviews the trials that targeted this and why they failed with hope for future trials.



     As I was reading about the problems of the prior trials, which involved not being able to deliver the drug to the right place using convection enhanced delivery, I thought to presentations from the Tocagen trial which appear to have perfected convection enhanced delivery. I wonder if  they repeated the trials today with the delivery technology from the Tocagen trial, perhaps we would have seen much better results.

  452. [04/12/2014] Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.  This says that the flu vaccine is not as effective in brain tumor patients as it is in the general population.  It doesn't mean that you shouldn't get the shot, just that it is more important than usual to make sure those around you get it!

  453. [04/12/2014] Interim Clinical Data for Tocagen`s Toca 511 & Toca FC in Patients with High Grade Glioma  Good news on the Tocagen Trial.   Safe, well tolerated and early results are better than historical controls. This is one of my favorites. Disclaimer:  Tocagen is a small sponsor of our organization, and we are a small sponsor of their clinical trials!

  454. [04/09/2014] Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study.  I am a fan of fractionated stereotactic radiosurgery for GBMs. My sister in law participated in an earlier trial using FSR and a different chemotherapy drug and did very well for about 8 years. She did better than most in that trial but perhaps temodar is a better drug to use along with FSR. 

  455. [04/09/2014] IBTA Newsletter

    From our friends at the IBTA.  Sad to see Denis is retiring as Chair of the IBTA.  Kathy Oliver will take his place. Good luck and congratulations to Kathy!

  456. [04/08/2014] Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion.  When I first heard about the drug Cilengitide, I thought it would be perfect to use with a treatment like Avastin.  I hope to see human trials of this soon.  My thoughts:  as shown in this article, Avastin cuts off the blood supply to the tumor, and stops a new blood supply from forming, so the only way the tumor can survive is to invade surrounding areas looking for a new blood supply.  It makes sense to combine it with a drug that stops that invasion.

  457. [04/03/2014] Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors.  This may be one of the most important articles of the year. It is only in mice, but 100% of the mice were long term survivors. I would love to see this tried in people.  

  458. [03/30/2014] Phase II Trial of 7days on/7 days off temozolmide for recurrent high-grade glioma. Looks like we need to find better treatments, although for recurrent anaplastic astrocytoma, it does look promising

  459. [03/27/2014] Inhibitory Effect of Disulfiram/Copper Complex on Non-small Cell Lung Cancer Cells.  Although this project was not done for brain tumor cells, it illustrates a very important concept.  I hear of some of our members trying Disulfiram off label to treat their tumors.   There was also a project a while back that tested a copper restriction as a treatment for brain tumors.  So some members combined both.  However this study points out that in lung cancer cells (we do not know if it is true for brain), copper is needed to make the Disulfiram work.   This points to the need to track people who try these combinations..  this is WHY we run the brain tumor virtual trial. Go to and click on Virtual trial for details and to join.  Everyone who has a brain tumor should participate.

  460. [03/21/2014] Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule  Interesting new approach. Too early - only in mice now, but it looks like something to keep an eye on.

  461. [03/19/2014] IBM’s Watson, New York Genome Center partner on brain cancer treatment  I love this.  It would be a perfect tool to use with our brain tumor virtual trial!

  462. [03/19/2014] Methods for the detection of cytomegalovirus in glioblastoma cells and tissues.  This is a controversial area. Some centers find cytomegalovirus in all GBM cells, other centers can't find it at all. This is an attempt to standardize the procedure for looking for the virus.  Hopefully, this will allow all labs to confirm that the virus is present in a very high number of gbm cells

  463. [03/18/2014] First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial  Sounds like an interesting trial.

  464. [03/13/2014] Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy We still do not know the best way to use Avastin. This articles seems to say that it doesn't matter when you start it - at the start, after first, second or third recurrence.  It still gives about the same effect.

  465. [03/13/2014] IBTA E-NEWS  Form our friends at the IBTA

  466. [03/13/2014] Small But Fierce: Four Funders Come Together for Brain Tumor Research  We are  one of the organizations mentioned!

  467. [03/12/2014]  It's nice to see these top researchers to get the recognition they deserve!  

  468. [03/11/2014] Tocagen Doses First Patient Intravenously in Clinical Trial of Selective Cancer Therapy, Toca 511 & Toca FC  The Toca 511 trial has been one of my favorites. It is a new type of gene therapy where a virus that only grows in tumor cells delivers a gene that can convert an oral  nontoxic antifungal drug into a powerful chemotherapy, only in the cancer cells that were infected by the virus.  There are now 3 separate clinical trials going on for the Tocagen treatment.  The original 2 used local delivery of the virus to the area of the tumor. This one adds an IV injection of the virus and also local delivery. The idea is that it may be better able to hit those tumor cells that are spread out in the brain, far from where the MRI says the tumor is. The Musella Foundation is one of the sponsors!

  469. [03/11/2014] Exclusive: Germany OKs Northwest Bio brain cancer drug, shares soar  Great news!  DC-Vax can now be sold in Germany.  I do not know yet if Americans can go get it and bring it back. If anyone tries, please let me know how it goes.

  470. [03/08/2014] Implications of bevacizumab (Avastin) discontinuation in adults with recurrent glioblastoma.  This article looked at GBM patients  who took Avastin for longer than 6 months and then discontinued it.  1/4 of the patients stopped for reasons other than tumor progression, and 3/4 stopped because of tumor progression. Then they analysed what happened, looking for a "theoretical" rebound effect. They didn't find it. Those who stopped because of other reasons did a lot better than those who stopped because of progression.

  471. [03/08/2014] Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.   It is too early to tell if it would help people with gbms, but the best thing is that the drugs are already approved, so if the trial looks good,  we can use these off label  quickly!

  472. [03/07/2014] NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board`s Safety Review  Great news! The DC-Vax trial passed it's  safety review and can continue without changes.  Of course, that is what we expected but it is great to hear!  Good luck to the trial! 

  473. [03/06/2014] Cellectar begins phase II imaging trial of I-124-CLR1404 in patients with glioblastoma    This trial is trying to find a better way to see the true extent of the tumor.  There is a great need for better imaging - a regular MRI is not really good enough - many times an MRI may say progression where there isn't progression or shrinkage when there really is progression. 

  474. [03/05/2014] Update posted for "Treatment Options for Glioblastoma and other Gliomas" by Ben Williams  Ben is an old friend of mine - he is an 18 year survivor of a gbm, and he wrote an excellent book about his thoughts on how to beat a GBM, called "Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About".  He writes a yearly update so that it is always fresh. This is the 2014 update, free for everyone.   You can read it without reading the book, but the book is also valuable for the concepts.

  475. [03/02/2014] Study questions anti-cancer mechanisms of drug tested in clinical trials  Metformin looks good, at least in the lab.  

  476. [03/01/2014] Neuro-Oncology Field Sets Action Plan to Advance Use of Imaging-Related Endpoints In Clinical Trials  I am proud to be a part of this Coalition.  The goal is to find ways to speed up the approval process for brain tumor treatments.  Currently, it is hard to determine when a brain tumor progresses because sometimes the MRI scan looks worse while the patients are actually doing better. This is called Pseudo-progression and happens frequently after radiation combined with chemotherapy, and also sometimes happens with immunotherapies. On the other hand, Pseudo-response is when the scan looks better and better while the tumor is actually getting worse. This sometimes happens with the anti-angiogenesis treatments.   Because it is hard to tell what is actually happening, the FDA is taking the stance that only overall survival is a valid endpoint for approval of brain tumor treatments. Obviously, that would be the best endpoint to use from a scientific point of view, but practically it brings up a lot of problems compared to using time to progression as an endpoint.  It costs a lot more money and takes a lot more time to use overall survival.  For patients, if they are randomized to a placebo in a trial using progression as an endpoint, they can sometimes then cross over and get the treatment after progression. If overall survival is the endpoint, it wouldn't make sense to allow this. Bottom line is that more treatments could be developed in much less time and with much less expense if progression is able to be used.      


  477. [02/26/2014] DNAtrix Wins $10.8 to Develop Brain Tumor-Attacking Virus  Exciting news.. a $10.8 million grant for brain tumor research!  I wish them luck - sounds very interesting

  478. [02/20/2014] Bevacizumab in Glioblastoma — Still Much to Learn  This is an editorial in the New England Journal of Medicine in response to the reports on the 2 large trials of Avastin for newly diagnosed glioblastoma.  These 2 trials both showed a small increase in progression free survival, but no increase in overall survival.   However, the had opposite results in quality of life outcomes. Confusing, but the author brings up some good points on how to proceed from here.

  479. [02/13/2014] IBTA Newsletter From our good friends at the IBTA 

  480. [01/28/2014] Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors.    Amazing results with such a seeminly easy procedure... but of course the standard warnings apply - it is a small group of patients and they only follow them for the first year. But interesting to watch

  481. [01/25/2014] Advocacy Alert: We still need your help to sign petition!  I am sending this out again as we need more people signing!  We have about 2,600 people who signed already - which is the most I ever had for any petition involving brain tumor advocacy!  However, we have another week to get more, and we can make this overwhelming!  This news blast goes out to 12,000 people.   IF you are reading this and didn't sign it, please do so now!  Even if you aren't a fan of this particular treatment, the concept that Medicare could deny a treatment that was approved by the FDA and listed as the standard of care by the NCCN guidelines should terrify you.

  482. [01/25/2014] Cedars-Sinai Clinical Trial Studies Vaccine Targeting Cancer Stem Cells in Brain Cancers  Here is another press release on the same vaccine trial I just mentioned...  but it gives more details about the vaccine.

  483. [01/25/2014] Launch of Cedars-Sinai Study on Cancer Stem Cells in Brain Cancer  This is an exciting new vaccine trial - just opened this week for recurrent glioblastomas.

  484. [01/17/2014] Advocacy Alert: We need your help to sign petition!  This is our most important issue today. Medicare doesn't want to pay for an FDA approved brain cancer treatment that is the standard of care.  Please forward the attached message to all of your friends!

  485. [12/31/2013] Brain Cancer and Brain Tumor Patient Advocacy Organization Announces Grand Opening of Patient Support Services Center in Redmond, Washington  Our friends at the Chris Elliott Fund opened a new patient support service center!  Good luck to them!  And please try it!

  486. [12/22/2013] Two-drug combination slows malignant brain tumors in mice  Interesting combination -  blocking both PI3K and Shh..  They  do not say which drugs  are  involved or the name  of the  trial.  There was an oral  SHH inhibitor approved recently - Erivedge.  And there is alot  of excitement over the drug BKM120 which is still experimental. Will let you know when I find out which trial this is.

  487. [12/18/2013] Positive Phase 2 Results from Agenus` Brain Cancer Vaccine Published in Neuro-Oncology  Pretty good news on a vaccine trial....  there was no control group but it beat historical controls. Survival (I assume after recurrence) was 11 months for the vaccine, compared to 3 to 9 months for historical controls.  

  488. [12/15/2013] Centers for Medicare and Medicaid Services (CMS) Has Established Permanent Billing Codes for the NovoTTF-100A System™  Medicare has created 2new billing codes for the Novocure system...  this  is  a major step towards getting this new brain tumor treatment  covered by more insurances.

  489. [12/04/2013] Mayo Clinic Researchers Find Shape-shifting Stops Migrating Cancer Cells Interesting new approach.

  490. [12/04/2013] Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas  Another tool in the toolbox in the fight against cancer.

  491. [12/04/2013] Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagen`s Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma  Aside from the exciting news about how the ongoing Tocagen trials are going, there was a poster presentation describing a new clinical trial that injects the virus intravenously.  The trial is actually a hybrid - they inject half of the dose IV, then 11 days later, do a surgery to remove whatever tumor is remaining, and inject the rest of the dose.  This is exciting because they do the surgery in part to make sure the virus got to all of the tumor cells.  IF that is true, then future trials may be completely IV, and may allow diffuse tumors on both sides of the brain. Henry Ford Health System in Detroit is currently enrolling patients for this study. Henry Ford Health System in Detroit is currently enrolling patients for this study. 

  492. [12/04/2013] Killer cocktail fights brain cancer This is another very interesting combination.  Of course we have seen many things in the past work on mice then not in people, but this is one of those combinations that make a lot of sense.  This one should get into human trials quickly, and if it does work we may have quick access to it.

  493. [12/03/2013] Musella Foundation awards brain tumor research grant  This grant was approved and paid within 24 hours of the application! That is the second time in a row that we were able to process an important grant so quickly.  Most organizations take about 6 months to do this.  Speed is of utmost importance because these projects build up the knowledge needed to ultimately find the cure.  Being able to cut 6 months off of the process can save many lives.  No corners were cut on the evaluation process.  The grant was approved by 6 of our reviewers.  We are able to do this through the generousity of our donors.  Thank you!

  494. [11/30/2013] Scientists trumpet preclinical success of combo immunotherapy against brain cancer  One of the most promising new approaches is mentioned... combining Yervoy with nivolumab.  GBM trials will hopefully be starting soon on htis combination.

  495. [11/25/2013] Update: 50 Percent of Patients in Cedars-Sinai Brain Cancer Study Alive After Five Years This was presented at the Society of Neuoroncology meeting last week.  Exciting news. Using a vaccine that had no significant side effects - and doesn't even require a tumor sample, 1/2 of the patients alive at the 5 year point, and 7 out of 16 still alive 5 to 7 years after treatment.  This was from the original phase 1 trial. They completed a phase 2/3 trial last year and are just waiting to see the outcome. Hopefully they will present the results of that trial soon.

  496. [11/15/2013] Novocure Announces FDA Approval of the NovoTAL™ (Transducer Array Layout) System  This is a new system to optimize the treatment of GBMs using tumor treating fields.  

  497. [11/15/2013] IBTA Newsletter  From our good friends at the IBTA.  A lot of interesting things in this issue.. The Musella Foundation will also have a table at SNO - if anyone is attending, stop by and say hi.  

  498. [11/13/2013] Study Results Show Dose-Intensified Temozolomide Chemotherapy in the Adjuvant Setting Does Not Improve Survival in Patients with GBM  Apparently. the standard schedule is better than the dose intensive schedule for GBM patients using Temodar.  However, what I would love to see is a trial comparing different lengths of treatment. This trial used up to 12 months of treatment.  Overall survivals were about 6 months after they stopped using the Temodar in either arm.  Doesn't make sense to me to stop at 1 year.

  499. [11/13/2013] Pharmaceutical Company Starts First Human Trials For Cannabis Treatment For Brain Cancer I like the way this is set up.  Although it is too small of a patient population to rely on (I hope they measure IDH1 mutations at the very least), it is a big step in the right direction. If it shows a benefit, then a larger study can be done.

  500. [11/10/2013] New Clinical Trial to Test Intra-arterial Infusion for Malignant Pediatric Brain Tumors  I liked this trial in adults, and am happy to see it in pediatric.  Hopefully it will allow Avastin to be used in kids without systemic side effects.  It may have a higher chance of complications for the actual infusion, but then there is less exposure to the rest of the body, and if it is done the same way they use it on adults, it is just 1 infusion ever 3 months. When I first heard about intra-arterial Avastin I thought it was a crazy concept, but then I talked to the researcher who does the procedure and he convinced me that it may work.  I got him to speak at a support group meeting and videotaped it.  Click HERE to see the video about the procedure in adults (I assume it is similar for kids)

  501. [11/09/2013] NW Bio`s DCVax Featured On Fox News And Fox Business News  This is one of my favorite treatments.   

  502. [11/08/2013] Incurable Brain Cancer Gene Silenced: Gene Regulation Technology Increases Survival Rates in Mice With Glioblastoma  Interesting new approach.. will keep an eye on this.

  503. [10/10/2013] Breast cancer and brain tumours not caused by viruses  I disagree with this study.. the virus might not directly cause the tumors but it is very possible and likely that they can influence the tumor to be more malignant..  and I feel that CMV is an important target for GBM treatments

  504. [10/02/2013] Long-term treatment with temozolomide in malignant glioma.   It never made sense to me to stop Temodar at 6 months. The reason they always give is that is the length of time used in the trial was 6 months so they use that. However, that 6 months was chosen to allow the trial to conclude quickly.  They never tested varying lengths of treatment against each other.   The other argument to end treatment early was increased chance of side effects. This article shows in a small group, that it is relatively safe to continue for an extended period of time.  There is also the risk of developing a secondary cancer - but that risk is smaller than the original tumor growing back and killing you.

  505. [09/23/2013] Agenus Reports Positive Phase 2 Results For Brain Cancer Vaccine  Very good news.

  506. [09/22/2013] Combo of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds  This is an exciting finding.. these researchers have shown that Avastin does make the GBM cells more invasive. (A recent article we posted here said that it doesn't), at least in the test tube.  They also show that adding dasatinib would stop that invasiveness.  They are now about to try it in human trials.  WIll watch this one closely. Best part is that both drugs are available now - Avastin is approved for GBMs and dasatinib is approved for leukemia but can be used off label for anything.

  507. [09/20/2013] Living with glioblastoma: How one patient is confronting cancer This article is about the Novocure system.  They now have over 100 centers in the USA that are certified to use it. 

  508. [09/17/2013] IBTA Newsletter  From our friends at the IBTA!  

  509. [09/14/2013] Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma. The Musella Foundation funded this experiment! The concept is excellent - the thinking was if Avastin cuts off the blood supply to the tumor, the tumor cells will try to find a new blood supply by migrating towards areas of higher oxygen content.  This makes the tumor resistant to Avastin. If you combine Avastin with a drug that stops the invasion, you may prevent the resistance and kill the entire tumor.  We funded a prior research project that showed BMP4 has an anti invasion effect so it seemed like a good candidate for this experiment.   Unfortunately, it didn't work out as expected.  The Avastin did not increase the invasiveness of the tumor!  Since there was no increased invasiveness, the BMP4 didn't have much effect.  Since other experiments we funded have shown that Avastin does increase invasiveness in a different mouse model, I think this experiment should be repeated in a few other models and perhaps try a few different anti-invasive drugs.  

  510. [09/14/2013] Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children`s Oncology Group.  Unfortunately, this trial didn't turn out well. They used cilengitide by itself and most children progressed quickly. This is an interesting drug. I think it will turn out that it is very useful - but in combination with other treatments as part of a comprehensive cocktail approach. I hope these negative results do not stop further research into combinations. This also points out an important point when looking at results. They had a 3 year survivor who is still doing well.  If that person happened to be in an online support group - the people in that group might tend to think - wow - this is a miracle drug - since they didn't see the other people in the trial doing poorly, they assume the trial worked. But what happens is that in some cases - particularly children, some people do well no matter what treatment you do to them.  You need to compare the results of the experimental group to what would be expected with standard treatments and show an improvement. You can not judge by 1 or a few individual cases.

  511. [09/14/2013] Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.  This article shows that - in the lab - a common food additive that has been deemed "safe" by the FDA may have anti tumor properties and in the test tube may help Temodar work better. Of course, this isn't in humans so we do not know yet if it would help people, but I love the idea of using a readily available, cheap, nontoxic to increase the chances that Temodar would help..  

  512. [09/13/2013] Musella Foundation awards research grant for promising new brain tumor therapy  This is an exciting new treatment. It is a next generation combination targeting 2 pathways: 1. an antiangiogenic drug - which blocks the formation of new blood vessels, which starves the tumor 2. Anti-invasion - so the tumor cells can't spread out looking for a new blood supply.  

  513. [09/10/2013] Musella Foundation Brain Tumor Co-payment Assistance Program Hits the $1 Million Mark!  I mentioned this last week but it just came out as a press release!

  514. [09/06/2013] Survival in Patients with Glioblastoma Receiving Valganciclovir  Very Important Article.  First the warnings:  1. this is a small study, funded in part by the company that makes the drug. 2. It was not randomized, and there was no control group - they compare to historical cotnrols..  3. We have seen other treatments do very well in small, selected patients then not do well in large controlled trials. Having said that, these results are outstanding, doubling the average survival time by using a simple, easily available  (but expensive)  anti-viral pill.   It is probably too soon to say we should try it but I would say it definately needs another trial, and I wouldn't hesitate to enter the trial if I had a gbm.  For more background, read the articles on on this concept: Click HERE and here and HERE

  515. [09/04/2013] Musella Foundation Brain Tumor Co-payment Assistance Program Hits the $1 Million Mark!  This is an amazing program. It makes an immediate impact on patient's lives. Many times we heard from patients who were going to foergo Temodar during radiation because of the expense. As you know, using Temodar at the time of radiation quadruples the chances of a GBM patient surviving at least 4 years. However, it is very expensive even if you only have to pay 20% some people think twice - especially if they were also just told they will never work again.  This removes some pressure at the time most families are under the biggest strain of thier lives. The program opens and closes as we have funding available. I know people prefer to donate toward research, but consider that this is also an important cause. I set up our donation system so people can designate where we use the donation - for copayments, for research or anywhere needed.  Please consider making a donation - or consider adding us to your will - or hosting a fundraiser for us!

  516. [09/03/2013] Testing of vaccine for brain cancer -Nassau County, NY  I mentioned this a few weeks ago but this article adds a short video about the vaccine.

  517. [09/03/2013] Analyst: Celldex aiming at accelerated approval with brain cancer drug  There are a few new ways to get treatments approved by the FDA - hopefully the results of the trial will be good enough to convince the FDA to let us get access to this vaccine much sooner than the standard process!   I will be at the meeting when they reveal the results - will let you know how it went!

  518. [08/26/2013] Lighting up brain tumors This is one of my pet peeves about the USA FDA.  This treatment can help surgeons remove more of the tumor safely, and it is approved in Europe, used on thousands of patients safely. The FDA refuses to allow it's use here because they admit it is effective in allowing more of the tumor to be removed safely, but they question if that is a benefit.    They want a large randomized trial to be done comparing overall survival with patients who use this vs those who use a placebo.  I know that is one trial I would not be referring patients to. It is unethical and unnecessary.      I love the FDA - they understood the need to approve Avastin and the Novocure system even when they only showed a small benefit.  Now that they are approved and being used in combinations - they are showing better progress.   It is just in cases like this where FDA policy goes against common sense.  


  519. [08/26/2013] Researchers start clinical trials on neutron beams to treat cancer  Boron neutron capture therapy is an old treatment consisting of giving the patient a boron containing drug which concentrates in the tumor, and then shooting neutron beams at it. The neutron beams do not hurt the cells that do not have boron - but in the cells that did take up boron, the neutrons split the boron releasing radioactive particles that kill the cell. This has been tried before but the problem was fiding a way to get the boron into all of the tumor cells.  Years ago we did not have that technology, but now we are much closer!  Worth trying again.  

  520. [08/26/2013] Brain Cancer Survival Improved Following FDA Approval of Bevacizumab  This study looked at a large group of patients and concludes that the approval of Avastin for GBMs has imporved survival!

  521. [08/17/2013] Analyst: Celldex aiming at accelerated approval with brain cancer drug  This is excellent news.  The combination of Celldex and Avastin seems perfect. Celldex is a vaccine against EGFRvIII - which is a marker found on the worst subtype of GBMs.  I have heard rumors (the trial is still ongoing) that even when Celldex patients have a recurrence, usually the recurrence is EGFRvIII negative which gives a much better prognosis and more of a chance for other treatments to work.    Avastin is an antibody against VEGF which is another growth factor.  It is possible that a tumor needs one of these 2 growth factors to grow. Blocking them both makes sense

  522. [08/11/2013] IBTA News A summary of brain tumor news from our friends at the IBTA!

  523. [08/10/2013] Cancer Treatment In Clinical Trials At UC San Diego  We mentioned this trial recently but this article has a nice video that explains it! Worth watching the video! It is about the Tocagen trial for Glioblastoma multiforme

  524. [08/05/2013] ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma  Interesting trial.. worth looking into for recurrent gbm

  525. [08/04/2013] Novocure Treats First Recurrent Glioblastoma Patient in Japan with NovoTTF™ Therapy  First use of the Novocure System in Japan.

  526. [08/02/2013] Brain Tumor Center to Study Vaccine
    North Shore center to study glioblastoma patients.

    Dr Schulder is on our medical advisory board and one of my favorite brain tumor neurosurgeons..   he is doing a trial of rindopepimut (which used to be known as cdx-110). This is a vaccine against the Epidermal Growth Factor Receptor version 3(EGFRvIII) , which is a mutation of the EGFR which is found on normal cells. (The article is wrong on that point).  If EGFRvIII is found on your tumor, it is a bad sign - the tumor is of the more aggressive variety because this receptor makes the tumor grow faster. This vaccine inactivates the EGFRvIII.  The hope is that it can stop the tumor from growing, or even if it fails, it might be able to convert the tumor into a slower growing tumor with a better prognosis.

    Best part is that it is relatively easy injections into the skin - not into the brain.

    (Disclosure:  the company that makes rindopepimut  is a sponsor of our foundation, and Dr Schulder is on our medical advisory board)

  527. [07/30/2013] Biomarker-based adaptive trials for patients with glioblastoma—lessons from I-SPY 2  One of the most important articles of the year.  I have been saying this for years but this is the first time I saw it in print. They propose a new method of clinical trials where many different treatments can be tested against each other in a rational way.  As they evaluate results, the trial adapts. If they see that certain biomarkers influence outcome, they can change the randomization based on that biomarker to increase the chances of good results.  For example, if a drug only seems to help people with a specific target, they stop using it on patients who do not have that target - they can still get randomized to the other treatments. If a treatment doesn't perform well, they drop it and rotate in the next one. If a treatment looks good, they drop it out of this trial and launch a traditional trial of it. This way they can test a large number of treatments, identify biomarkers that may be used to personalize treatments, and significantly reduce the amount of time (and money) needed to find the cure. It also improves the chances that the trial will help the participants - as once it is clear a treatment doesn't work - or if it doesn't work with that patient's markers, it is dropped.  

  528. [07/10/2013] Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma.  This is a new method of delivering higher dosages of drugs to the brain tumors. Looks promising - but too early to tell how it will work in people

  529. [07/10/2013] Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.  Another vaccine trial  with good results: about 3 times longer survivals compared to historical matched controls.

  530. [07/08/2013] New EU-Funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients  New concept in vaccine therapies.  The vaccine is custom made to each patient, based on a genetic profiling of your tumor.  The Musella Foundation and Voices Against Brain Cancer also have helped fund this!

  531. [07/03/2013] Phase 2 study of dose-intense temozolomide in recurrent glioblastoma This study showed that after GBM patients failed Temodar on the standard schedule, trying Temodar again in a dose-intense schedule of 21 days on and 7 days off did not help much. Only 13% had even a small response, and only 11% of patients were progression free 6 months later.   One interesting note on this paper is that they were incorrect on what the standard therapy of a glioblastoma is. Standard thereapy is defined by the National Comprehensive Cancer Network guidelines as well as the FDA approvals of treatments. Both say that the standard treatment of GBM now includes Gliadel Wafer implantation at both the initial surgery as well as subsequent surgeries, and the use of the Novocure Novo-TTF 100a system at recurrence.   NCCN Guidelines can be found at:

  532. [07/03/2013] Dr. Gregory Foltz, who founded brain-cancer clinic, dies at 50  We lost one of the best brain tumor researchers in his prime.  So sad. Very nice man - brilliant, compassionate and driven to find the cure of gbms for us.  He will not be forgotten. His work lives on - it would be fitting if his program leads to the cure.

  533. [07/02/2013] New search feature on  Should have done this a long time ago!  Feel free to make suggestions on improving

  534. [07/02/2013] National Cancer Institute Designated Cancer Center Featured Article: ‘Promising Target’ Found in Treating Deadly Brain Cancer at UVA  Interesting new target -  but it is a few years away from human trials.

  535. [06/30/2013] Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.  We always knew GBM patients had a higher chance of developing blood clots in the legs and lungs... but never knew why.  This article may have the answer.

  536. [06/29/2013] IBTA Newsletter  From our friends at the IBTA

  537. [06/18/2013] NW BIO HAS INITIATED ITS DCVAX® -DIRECT PHASE I/II TRIAL FOR ALL SOLID TUMOR CANCERS  This trial is for any type of cancer. Not sure yet if they include brain metastases. (They have another trial for GBM). 

  538. [06/14/2013] Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma.  This sounds like one of the most promising avenues of research... find out why Avastin stops working and how to turn that around.  I feel that the answer to this question may lead to a major breakthrough, hopefully using drugs that are already available so it can be used by all who need it quickly.

  539. [06/14/2013] Advancing Neuroscience: MRI Interventions, IMRIS and Tocagen Combine Technologies to Precisely Deliver Potential Cancer-Fighting Drug to Brain Tumors  This is one of my favorite experimental treatments... and it looks like they may have found a better way t deliver it to where it is needed.

  540. [06/11/2013] Disseminated progression of glioblastoma after treatment with bevacizumab.  Avastin has gotten a lot of bad press recently. Here is some good news about Avastin from UCSF - one of the best brain tumor centers in the world!   There have been reports that Avastin causes the tumor to become more invasive. The thinking is that it works by stopping the tumor from forming new blood vessels, which are needed for the tumor to grow. However, when you cut off the blood supply to the tumor, you would think it makes sense that the tumor cells migrate and look for a new blood supply. There have been some reports that Avastin makes the tumor more invasive.  This report says that is not true.

  541. [06/02/2013] Cyto-megalovirus might speed brain-cancer growth  We had known about a link between cyto-megalovirus (CMV)  and GBMs for a few years. This article gives an explanation of how the virus may activate a pathway that drives tumor growth.  There is a drug available against the CMV - and it is in trials now in Europe.  There is also a vaccine against this virus in trials. This opens the door not only for a treatment but the possibility of using a CMV vaccine to prevent the development of cancer (not only brain tumors)!

  542. [06/01/2013] Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer This trial looked at a large number of newly diagnosed GBM patients.  1/2 received the standard treatment of Surgery, Radiation and Temodar during radiation and for 6 months afterwards, or that same treatment + Avastin until recurrence.  Temodar was stopped after 6 cycles in both groups.  The results weren't as good as we were hoping for but they are a small step foward. They reported no difference in median overall survival, but there was a big increase in progression free survival in the Avastin group ( 8.4 months vs. 4.3 months), as well as the % of patients alive at the 1 and 2 year points.  "Seventy-two percent of people treated in the Avastin arm were alive at one year compared to 66 percent of people in the placebo arm (p=0.049). Thirty-four percent were alive at two years compared to 30 percent, respectively (p=0.235)."   In human terms this means that although on average both groups lived about the same length of time, the Avastin group was in better shape for most of that time.  This is very important. And more of the patients in the Avastin group went on to do much better than the ones in standard of care group.    So it looks like Avastin should play a role in the treatment of GBM but the question now become what is the best way to use it? For newly diagnosed or at recurrence? (It is already approved for recurrent GBM). Or perhaps in combination with other treatments. More research is needed.  We (The Musella Foundation) has been funding exciting research looking at ways to make Avastin work better. Hopefully we can figure out why it helps some patients and not others, then make it work for all.   (Disclosure: Genetech - the makers of Avastin - is one of our sponsors)  

  543. [05/26/2013] HAMLET: functional properties and therapeutic potential.  This is another completely new concept in brain tumor treatments.

  544. [05/26/2013] Cold plasma successful against brain cancer cells  Exciting research on a new way to treat brain tumors.  It is still only in the lab but this is a completely different treatment method. Cold Plasma is a gas that has been used to sterilize foods. It has now been found to have a strong effect on cancer cells.  It is too early to try it on people, but this is something to keep an eye on

  545. [05/26/2013] Restoration of Sensitivity in Chemo - Resistant Glioma Cells by Cold Atmospheric Plasma. [Full Text]  This is the full text of the technical article on Cold Atmospheric Plasma.  See previous article for layman's version!

  546. [05/18/2013] ?v-Integrin isoform expression in primary human tumors and brain metastases. Integrins are receptors on the cell membrane that help a cell communicate with it's enviorment.  This article shows that there are various subtypes found on primary and metastatic tumor cells which may open up a new target to use for treatments.  There is an Integrin blocking drug in trials for GBMs now (Cilengitide). Perhaps the trials should be extended to metastatic tumors.The early trials in GBM did not show significantly improved results but I wouldn't write this drug off yet - they need to find the best way to use it. I picture it as part of a cocktail approach.

  547. [05/18/2013] Irinotecan delivery by microbubble-assisted ultrasound: in-vitro validation and a pilot preclinical study.  Irinotecan (CPT-11) looked like a very promising drug in the test tube and with other cancers, so it was tried IV in clinical trials with Avastin.  It did slightly better but probably not worth the extra side effects.  This project looks at a different way to get the drug into the brain at a higher concentration  without hurting the rest of the body. I love concepts like this. IF they can get a high concentration in the brain, it may work much better.

  548. [05/18/2013] Isotretinoin maintenance therapy for glioblastoma: A retrospective review.  Isotretinoin (Accutane) is a drug approved for acne.  Some doctors have been using it as maintanance therapy for GBMs to try to slow down regrowth of the tumors. This article reports on a small number of patients who tried it.  There was an amazing increase in progression free survival, but no significant difference in the 2 and 3 year survival numbers.   By itself, an increase in progression free survival is meaningful to patients - this means a longer time of feeling relatively good.  It also brings up the opportunity to combine it with other treatments and give those other treatments more time to work.

  549. [05/18/2013] Defining pseudoprogression in glioblastoma multiforme. Pseudoprogression means that the MRI scan looks like there is progression when in reality it is not  progression. It was rare until we started using Temodar at the same time as radiation, now it occurs in about 12% of the people according to this article (I heard other numbers of about 50%). This article is the first time I saw mention that there is a major survival advantage when you see pseudoprogression - more than double the survival time compared to people who do not get pseudoprogression.  

  550. [05/08/2013] ?1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma.    This is a very exciting abstract.   They may have found why the tumor becomes resistant to Avastin, and possibly a way to stop it. 

  551. [05/08/2013] Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.  Interesting. Best part is the drug is available (off label).. may be worth starting a human trial of it.

  552. [05/04/2013] Agenus trial of brain cancer vaccine shows better survival rate  Exciting results from another brain tumor vaccine!

  553. [05/04/2013] "Tune-In" to Glioblastoma During Brain Cancer Awareness Month in May and Help Novocure Support Those Fighting the Disease  The Wall Street Journal picked up the press release about our twitter campaign!  Please help out with this.  Every time my message on twitter gets retweeted, Novocure will donate $5 to the Musella Foundation and $5 each to 2 other brain tumor organizations, up to $10,000 per organization.  This literally takes 2 seconds if you already have a twitter account.  Search for: @AlMusella and look for 1 of the tweets about the event. Hover over the message and a menu appears. Click RETWEET then Click OK.  You can do it every day and ask your friends to do it also!

  554. [05/04/2013] Monteris® Medical First-In-Humans Trial Published  This is a very small trial but shows that this new treatment may be worthwhile. It is a new type of minimally invasive laser surgery. It is already approved and in use in a few centers across the country. Go to for details.

  555. [05/04/2013] MRI Interventions` ClearPoint(R) System Helps Advance Brain Cancer Clinical Trial of Investigational Gene Therapy Drug Toca 511, Demonstrates Benefits of MRI-Guided Drug Delivery  This is one of my favorite experimental therapies.  It is a gene therapy delivered by a virus that only infects tumor cells.   They are now testing a new system of administration to try to cover the entire tumor.

  556. [05/04/2013] Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset.  This study shows that participating in a clinical trial - ANY trial - results in a better outcome than not participating in a trial. I have always said this but here is the proof.  It may have to do with being watched closer when in a trial - even if you are in a control group.  Your scans and pathology reports get second opinions and they spend a lot more time reading them knowing that you are in a trial. 

  557. [05/02/2013] "Tune-In" to Glioblastoma During Brain Cancer Awareness Month in May and Help Novocure Support Those Fighting the Disease  This is the easiest fundraiser we ever had!  Just retween one of our tweets with the hashtag #TuneIn2GBM and Novocure will donate $5 to the Musella Foundation and 2 other organizations (Up to $10,000 per organization)! Please ask all of your followers on twitter to do the same!

  558. [05/02/2013] Top Neurosurgeons from Long Island Brain Tumor Center Offer New Treatment for Recurrent Glioblastoma  Another new center that offers the Novocure system!

  559. [04/19/2013] NW Bio Announces That Another Brain Cancer Patient From Phase I/II DCVax(R)-L Trials Has Surpassed Ten-Year Cancer-Free Survival Amazing story... Having 1 ten year survivor could be a fluke.. but 2 ten year survivors is very impressive.

  560. [04/17/2013] The impact of improved treatment strategies on overall survival in glioblastoma patients.  This is one of the most important articles of the year. First, it shows that adding Temodar at the same time as radiation will double overall survival times compared to using radiation without Temodar.. We already knew that but it is nice to see it confirmed. The new part is that using a dye called 5-ALA at the time of surgery (that allows the surgeon to see where the tumor is)  adds another 3.5 months to the average survival time.. and in those cases where it allows for a complete resection, it adds another 11 months.    This dye is approved in Europe and used as a standard treatment for years.  Getting it approved here in the USA would be a big step foward.  3.5 months might not seem like much, but it can buy the time for other treatments to work.    

  561. [04/12/2013] Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma. Neuroblate is the new name for what was called the AutoLLT system.  It is an fda approved treatment for brain tumors which uses lasers to directly kill tumor cells.  This reports very good results on a small trial of patients with recurrent gbms. (Remember - small trials can give an indication that a treatment is effective, but the larger the trial, themore sure we can be that something actually works. There were many cases where success in small trials did not pan out in larger trials). Having said that, this is a new option for patients with recurrent GBMs. I went to a lecture on it recently where they showed some pretty amazing before and after MRIs as well as results for other tumor types.

  562. [04/12/2013] J Neurooncol. 2013 Apr 6. [Epub ahead of print] Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S. Clinica di Oncologia Medica, AOU "Ospedali Riuniti", Università Politecnica delle Marche, via Tronto 10/A, 60100, Ancona, Italy, Abstract Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients` progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile. PMID: 23564276 [PubMed - as supplied by publisher] Fotemustine is a chemo drug in the same class as BCNU and CCNU. It is available all over the world except the USA.   This wasn't a controlled trial so we don't know if it is better than the chemo drugs we have available, but it does show some activity in the elderly after failing with Temodar.

  563. [04/10/2013] Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. This tests the idea that using a different schedule for Temodar 21 days on and 7 off, after Temodar on the standard schedule of 5 days on and 23 off, may work.. In this study - it didn't. 

  564. [03/24/2013] Treatment outcome and prognostic factors of adult glioblastoma multiforme. This article talks about the outcomes for GBM patients treated with the standard treatments  in Iran. Average progression free survival was 6 months and average survival was 11 months. Only 7% of patients had a complete resection.  Here in the USA,  a much higher % of patients get complete resections, and the average survival with standard treatments is over 18 months.  There are some small trials that reported overall survivals of 38 months. This points out the need not only for us to find the best treatments but to make sure they get out to the rest of the world.  WIth the latest treatments being so expensive, that might not happen for a long time or ever.  Something has to be done about that. I have no idea how to approach it.  Any ideas?  

  565. [03/24/2013] Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.  This is the type of thinking I love to see.  I have always thought that the cure is going to be in a well thought out cocktail of drugs - such as an anti-angiogenesis drug which does work pretty well for a while, as well as targetted therapies that shut down all of the possible resistance pathways. Perhaps throw in other treatments such as vaccines and tumor treating fields and we may hit a home run someday soon.

  566. [03/24/2013] Diazepam (Valium)( Inhibits Proliferation of Human Glioblastoma Cells Through Triggering a G0/G1 Cell Cycle Arrest.  Valium may help slow down the tumor... very interesting.

  567. [03/20/2013] New Trial: Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme  This is one of my favorite neurosurgeons.. when I first heard about him  using Avastin in the way, I thought it was crazy, but after having him explain the thinking behind it, it makes a lot of sense. I videotaped his explanation - go to for the video. This might be a better way to use Avastin.  

  568. [03/13/2013] Body fat may help destroy brain cancer cells  This will make the work with mesenchymal stem cells (MSC) much easier for the patient - in the research being done in the past, they would have to remove bone marrow, which hurts a lot.  Now it would be something like liposuction (kill 2 birds with one stone - you get stem cells and also lose weight:).

  569. [03/08/2013] Bevacizumab (Avastin) treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.  Avastin has been used for treating radiation necrosis but this is the first time I heard of it being used to treat symptomatic pseudoprogression.  I guess it makes sense.  This article talks about using BNCT, which was tried decades ago and failed - but the technology has advanced to the point where it is promising again.  Combining BNCT with Avastin might make a big impact. It might allow higer doses of radiation with less harm. Very interesting.

  570. [03/02/2013] Dasatinib thwarts brain cancer metastasis after bevacizumab use  This is only in mice so far.. but very exciting. Will keep my eyes on this one..   The good news is this drug - also known as Sprycel - is approved for Leukemia, so it is readily avaialable off label.

  571. [02/25/2013] Merck KGaA Drug Fails in Late-Stage Brain Cancer Trial  I sent a similiar story out in the last news blast, but this article points out that they are still testing this drug on GBM patients  with an unmethylated MGMT gene promoter status. These tumors do not respond as well to the standard treatment, and adding a little something extra like this drug may help. Reading between the lines, now that they have the results of the big phase 3 trial, they probably analyzed the outcome in patients who have the methylated vs unmethylated status and must have seen it is worth continuing the trial on unmethylated patients.
     A little background on methylation status: there is a test that can determine what % of cells in the tumor have methylated or unmethylated MGMT promotor genes. If the gene is methylated, the gene becomes inactive and can not be used to produce the MGMT protien, which is a repair enzyme.  Chemotherapy, such as Temodar, work by damaging the DNA in cells so they can not reproduce. MGMT repairs the damage, which makes the tumor resistent to chemotherapy.  So a person who has a high % of methylated MGMT genes will have less repair enzyme and thus better response to chemotherapy than someone who has a low % of methylated MGMT genes. 
    This make a huge difference. Time to progression of the tumor is half as long in people who have the unmethylated MGMT gene compared to people who have the methylated status.

  572. [02/25/2013] Merck KGaA brain tumor drug fails clinical trial   There was a lot of hope for this drug. Failing the clinical trial does not mean that it is useless. It means that it didn't work in the manner that they used it, which is in combination with the standard treatments.  This drug has many effects on the tumor cells: it inhibits cell migration, differentiation,  angiogenesis, wound healing, immune and non-immune defense mechanisms, and oncogenic transformation.   It's place may be in combination with other targeted agents and/or vaccines in a well thought out cocktail approach. I hope research on this continues.

  573. [02/20/2013] The Chris Elliott Fund Announces Webinar for Brain Tumor Patients on Insurance and Financial Resources  From our friends at the Chris Elliott Fund.. Sounds worthwhile.

  574. [02/17/2013] IBTA E NEWS FEBRUARY 2013  From our friends at the IBTA!

  575. [02/16/2013] Reversing the Warburg Effect as a Treatment for Glioblastoma.  The "Warburg effect"  is an observation that cancer cells usually metabolize glucose differently than normal cells. These researchers are trying to change the process back to how it is in normal cells using a relatively simple chemical.  This is only in the test tube now and more research is needed before we can tell if it works in people.

  576. [02/16/2013] Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.  This project tested multiple samples from each tumor to see if there were variations within the same tumor, and found striking differences which may have a mahor effect on treatments.  If true (and this was a small study which needs to be repeated), then the concept of personalized medicine - targetting the tumor's specific mutations - might not work, as they found different parts of the tumor had different subtypes.

  577. [02/14/2013] Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomised, double-blind, hypothesis-generating study.  In the last news blast, I talked about using the anti-viral (anti CMV) Valcyte for GBMs.  Today I came across a report on a trial for Valcyte with standard therapy for GBMS.  This was a randomized trial - half get standard treatment and half get Valcyte for 6 months  in addition to standard treatment. The trial allowed patients to stay on Valcyte after the 6 months if they wanted to and they allowed the control group to switch to Valcyte - which complicates the interpretation.. as patients who were doing well probably stayed on the valcyte while those doing poorly probably stopped... so take this as an indication that it might help - not proof..  There was a small difference on scans but a big difference on overall survival: OS at 4 years was 27.3% in patients who used Valcyte for over 6 motnhs versus 5.9% in controls (P = 0.0466).  

  578. [02/11/2013] Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.  This is fascinating. There was a lot of talk at the recent Society of Neuro-oncology conference about cytomegalovirus and Glioblastomas. Various groups reported all or almost all gbm samples tested had this virus.  Now for the first time, this article shows that there is a very strong correlation between survival and how much virus is in the tumor. Low levels of the virus were associated with a higher survival. The group with the lowest infection level had 2 year survival rate of 63% compared to 17% in the high infection group, and the overall survivals was 20 months longer in the low infection group compared to the high infection group. This may  mean that CMV causes or at least helps make a gbm more resistent to treatment and more deadly. The good news is that there are relatively simple treatment available for CMV infections - such as Valcyte. There is a trial going on now to see if Valcyte can help treat GBMs. There is also a vaccine trial going on that targets CMV.

  579. [02/06/2013] Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-?B and HSP27/p38/AKT Pathways and by Inhibiting ABCB1.  I love this type of project. They are trying to find why the tumor becomes resistent to treatment and how to prevent that resistence.  They are using approved drugs - so if this can be shown to work in people, it can be used immediately by anyone and make a big impact.  

  580. [02/02/2013] Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma.  This article says that a gbm is not limited to the area of contrast enhancement.  I have been saying over and over that we need things like Gliagen - the dye that lets a surgeon see where the tumor is during the operation.  This article backs up the need.

  581. [02/01/2013] Long-term survival of patients with glioblastoma multiforme (GBM).  This article analysed survival patterns and found that once a gbm patient survives for 2.5 years after diagnosis, the chances of dying each quarter year go way down. 

  582. [02/01/2013] Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.  Interesting project.  I love the concept - combine treatments in a rational way to make them work better.  Of course, this is only in mice, which you can not rely on to say it will work in people, but I think it deserves a human trial.  This is the type of thing we can do with the the Virtual trial since both treatments are easily available.  We have 5 patients who tried that combination.  It is hard to say if it helped - we need more people..

  583. [02/01/2013] Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradiation. Carbon ion radiation is used in Europe and Asia, and may have better results than the standard photon ,gamma and proton radiation we use here.  The Musella Foundation has been funding a project to develop a new form of carbon ion radiation which may work even better.  We are trying to help speed up the process of getting it available here.

  584. [01/29/2013] New Research Project for recurrent glioblastoma patients on Avastin - Get a free genetic analysis!  Hi. We have just partnered with Genetech and 23andMe on an amazing project that I want you to participate in! This is ONLY for ADULT patients Living in the USA, with recurrent glioblastoma (and  breast, kidney, colon and lung cancer) who use or have used Avastin starting before 12/31/12. Participation is by mail and over the web.  Read attached article for details!

  585. [01/27/2013] Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies. This is way too early - not in humans yet - but very interesting.  Gliadel wafers - according to this article - release chemotherapy for 5 days after being implanted during a brain tumor surgery, and offers a small (but important) benefit.  They describe a new way to release chemo for 6 weeks - which may help much more.

  586. [01/27/2013] Surgery of high-grade gliomas guided by fluorescence: A retrospective study of 22 patients.  I know it seems obvious, but this study shows that removing more tumor helps people live longer.  The difference between a total resection and a sub total resection is 8 months in overall survival:  12 months vs 20 months.  This is with the simple addition of a dye that lets surgeons better visualize where the tumor is.   This dye (Gliolanis approved in Europe but the FDA in the USA is dragging it's feet in getting it approved for us. 

  587. [01/27/2013] Optimizing Glioblastoma Temozolomide Chemotherapy Employing Lentiviral-based Anti-MGMT shRNA Technology.   I love this type of thinking.  It is not in humans yet but I will watch this closely.  Basically, MGMT is a protien that can stop Temodar from working.  It actually repairs the damage to the DNA that Temodar causes. People with tumors that have low levels of MGMT do better than people with high levels. This project tries to block the MGMT from being created, so it should help people do better.

  588. [01/27/2013] Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab.  Obviously, the experiances of 1 patient does not prove anything, but this is an interesting combination.  There is a trial of cetuximab for Glioblastomas, using a super selective intra arterial delivery -which allows a much higher dose to the tumor.  Combining it with Avastim seems like a reasonable choice.

  589. [01/27/2013] Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature.  Interesting approach.  Might be applicable to other tumor types

  590. [01/23/2013] NCCN Guidelines® Recommend NovoTTF™ Therapy as a Standard Treatment Option for CNS Cancers  Important announcement:  the standard of care for GBMs has just been changed to include the use of the Novocure device at recurrence.  For more details on the Novocure device, first view the video on our home page at then from the menu at the top of the page, click LEARN ABOUT then NOVOCURE.  We have many of the research papers that were published about it, as well as a link to the list of doctors who are certified to prescribe it!

  591. [01/19/2013] NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.  Unfortunately, this reports that the combination of treatments mentioned did not work as well as hoped. 

  592. [01/06/2013] Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.  This abstract shows a much smaller overall survival benefit to adding Temodar at the same time as radiation than the "Stupp" report... only a 1.25 month advantage to adding Temodar to radiation.  It also points out that there are more side effects when adding Temodar to radiation. They conclude that we should question if the standard therapy is worth it. My thoughts: this is a smaller study and not randomized as the Stupp studt I tend to put more importance on the Stupp study - I wouldn't get rid of the standard therapy yet based on this study but it does show the need for more research.

  593. [12/30/2012] Musella Foundation For Brain Tumor Research & Information, Inc 2012 Highlights Highlights of our work over the year!  There is still time to make a tax deductible contribution for 2012!

  594. [12/30/2012] The Methodist Hospital and Remeditex LLC Work to Develop Brain Tumor Drug  Interesting new approach.. Too early - not in humans yet - but interesting idea!

  595. [12/27/2012] Electric field treatment takes aim at brain cancer Nice article about a man who is using the Novocure device. (Disclosure: The company that makes Novocure is one of our sponsors)

  596. [12/20/2012] Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.  This abstract shows that continuous low dose Temodar might be useful for recurrent GBMs and Anaplastic Astrocytomas, especially if the patient has not yet failed on Avastin.  An interesting side note is they found a smaller % of patients had mutation in EGFR than previously reported.  Perhaps that means people with these mutations in general do not do well enough to take part in a trial after having a few recurrences.  This has to be taken into consideration for the anti-EGFR trials.. 

  597. [12/20/2012] Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia.  I know it sounds obvious that the more tumor you take out the better the patient will do, but it was never really proven before. This is the most convincing evidence yet, and shows the importance of the 5-ALA dye and the brain tumor paint that I have been talking about recently.  Both of these allow the surgeon to see where the tumor is and result in a more complete resection.  Both are not yet approved in the USA.  5-ALA is approved and used routinely in Europe and in trials in the USA.Tumor paint is in early trials in the USA.

  598. [12/20/2012] Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin/Ran protein complex.  This is fascinating on 2 levels... first - they describe a protien complex Survivin-Ran  which may be responsible for making GBM cells resistent to Temodar, then they use a new method to create drugs using computer modeling - the start with the target  then engineer a drug on a computer that would attach to the protien complex - and then actually make the drug.  And in the test tube it actually works.  This is way too early to help us - but something to keep an eye on.

  599. [12/11/2012] IBTA E News December 2012  This is from our friends at the IBTA!

  600. [12/05/2012] Peregrine Shows Desperation in Dusting Off Ancient Brain Tumor Drug  This is an interesting treatment. Cotara is a monoclonal antibody against the parts of a cell that are exposed when they are dying - combined with a radioactive Iodine.  The hallmark of glioblastomas is necrosis - which seems to make this an ideal target for Cotara.  This article is scathingly against the company that i developing this treatment.  Don't worry about that nonsense.  The author has no knowledge of the science involved - he is just worried about money.  What he missed was that 10 years ago, the technology to deliver treatments like this using CED (Convection enhanced delivery) was just being developed. Typically less than half of the patients would get the drug to the right location.  And this was with the best surgeons in the USA.  In India - forget about it. I think that we are now at the point where CED can hit the target consistently - at least 90% of the time, and will get better with the experiance of the surgeon. That alone should greatly increase the chances of this treatments' success!  The trial should be open soon. I think it is worth considering.  

  601. [12/04/2012] Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study.  This article says that the every other week schedule of low dose Temodar did not work for recurrent glioblastomas who failed the standard schedule of Temodar.  

  602. [11/30/2012] Swedish Receives $2.5 Million Grant from the Ivy Foundation to Advance Brain Cancer Research  Major grant from the Ivy Foundation to one of my favorite brain tumor doctors.. Dr. Greg Foltz.   He was a speaker at one of our conferences.  You can see his lecture at:     He is working on finding drugs that are already FDA approved for other conditions that might also help brain tumors.  Great approach!

  603. [11/30/2012] Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.  This talks about the combination of Avastin and CPT-11 for recurrent glioblastoma.  They compared patients who took this combination with patients who did all other available treatments and this group did better by 7 months (70%).   Previous similiar studies showed a similiar benefit but when avastin alone was tested with avastin + CPT-11, the results were pretty close - the avastin + CPT-11 group did a little better but had more side effects. Not clear which is best yet.  

  604. [11/30/2012] RTK inhibition: looking for the right pathways toward a miracle.  This is theoretical but I love the thought process.. this researcher thinks he knows why Avastin sometimes fails - and thinks he may have a way to block the failure.  He did not try it yet - just thinking about it. We (the Musella Foundation) have funded 2 similiar projects - looking at drugs to add to Avastin to make it work better.  The first one failed to show a benefit, but the second one is still ongoing.  I think this concept is the way to a big breakthrough. We just need to find the right combination.

  605. [11/21/2012] Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial They are testing a new treatment for GBMs: trans sodium crocetinate . This drug increases the oxygenation of the tumor and is thought that it may sensitize the tumor to radiation and chemotherapy. It worked well in the lab. They tried it on a small group of GBM patients to test for safety and apparently it is safe enough to go ahead to a larger trial to see if it works.

  606. [11/19/2012] Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer with  This was the big news at the Society of Neuro-oncology conference this weekend.  There was about a 50% improvement in progression free survival by adding Avastin to the standard treatment, over using the standard treatment alone.  This means that patients feel better and can take care of themeselves longer with Avastin than without.    However, the question remains when is the best time to use Avastin, right at the start or wait for recurrence. That question is not yet answered.   There seems to be (but hasn't been tested yet) about the same time benefit for using at it the time of recurrence rather than at the start.  (Although using it at the start allowed patients to functional at the highest level for a longer period of time. )  My own thoughts (and I am not an MD - so take it for what it is worth):  My preference would be to enter a clinical trial for newly diagnosed GBM patients and hold off on the Avastin until the time of recurrence. IF you can not enter a trial, then it is a toss-up on when the best time to start Avastin would be. Either way can be argued.  There are more trials (such as the Tocagen trial) that now allow you to enter after having had Avastin, so that removes one of the barriers to using Avastin upfront.   Disclosure: Genetech is a sponsor of the Musella Foundation

  607. [11/13/2012] Multiple resections for patients with glioblastoma: prolonging survival.  This study shows that having multiple surgeries for glioblastomas does improve average survival.  Seems obvious - but in the past some doctors would advise that a 3rd or 4th surgery is a waste of time. This shows that each surgery does extend survival by months.. those moneths can be used to try another treatment.. increasing your chances of beating the tumor.

  608. [11/13/2012] A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).  Unfortunately - another negative study.. this time with thalidomide.  

  609. [11/13/2012] Continuous daily sunitinib for recurrent glioblastoma.  Unfortunately, another negative study.... using Sunitinib (Sutent) by itself.

  610. [11/13/2012] Avastin Reduces Brain Necrosis from Radiation  This is an exciting article.. it says that using Avastin in combination with stereotactic radiosurgery greatly reduces the chances of developing radiation necrosis from 50% to 3-6%, and almost doubles the average survival!   Disclaimer: Genetech - the makers of Avastin - are a sponsor of our organization! 

  611. [11/13/2012] Health News : Mayo Clinic in Arizona is the First in the Southwest to Offer New Treatment for Recurrent Glioblastoma Brain Tumors Although the Novocure NovoTTf-100a device is FDA approved for recurrent glibolastoma, it is not yet available everywhere.  Doctors have to become certified in it's use and the company needs to set up tech support centers in each area served.  For a list of centers that offer it now, go to:   Disclaimer: Novocure is one of our sponsors!

  612. [11/13/2012] A phase I/II trial of vandetanib for patients with recurrent malignant glioma.  This article reports the results of clinical trial of the drug Vandetanib (Caprelsa).  This drug is FDA approved for thyroid cancer and readily avaialble.  It is not approved for brain tumors. On brain tumors, it did not show good results when used alone.  My thoughts are that this type of treatment needs to either be individualized - used only when you know the patient's tumor overexpressed the targets, or as part of a cocktail where it is combined with other treatments to block multiple pathways at once so the tumor can not evade it.

  613. [11/13/2012] Long-term survival of patients suffering from glioblastoma multiforme treated with tumortreating fields.  This article reports long term results of the first Novocure TTF device trial:  4 out of 20 patients GBM (20%) alive, in good health and no longer receiving any treatment with no clinical or radiological signs of recurrence more than 7 YEARS after starting the trial! (2 were newly diagnosed, 2 were recurrent when they started the trial). This is amazing. The expected 7 year survival rate is about 4%, so you would expect less than 1 of the original 20 patients to survie. This is 500% better.     Disclaimer: The company that makes the Novocure TTF device is a sponsor of our organization.

  614. [11/09/2012] Houston’s Dr. Marnie Rose Foundation Exceeds $3 Million in Total Donations to MD Anderson’s Brain Cancer Research, Children’s Memorial Hermann Hospital  This is from our friends at the Dr. Marnie Rose Foundation. They raised over $3 million to fund brain tumor research!  Excellent job!  For our members in Texas - consider participating in thier Annual Run for the Rose on Sunday, April 14, 2013

  615. [11/08/2012] Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.  This article identifies an interesting link between the development of high blood pressure as a side effect from Avastin or Nexavar and how well it works for Glioblastomas.  Those who developed severe high blood pressure did twice as good as those who did not. Interesting..  too early to depend on it yet - it needs to be confirmed in other studies, but opens the door to new research to figure out WHY this may happen.

  616. [11/07/2012] Polifeprosan 20, 3.85% carmustine slow-release wafer (Gliadel) in malignant glioma: evidence for role in era of standard adjuvant temozolomide.  Gliadel wafer is a biodegradeable impant that can be inserted into the resection cavity after removing a brain tumor. It slowly releases chemotherapy directly to the area most likely to have a recurrence.   It was FDA approved about 10 years ago, based on trials run before Temodar was available.   This study updates the results to include people using Temodar and shows about the same results.. a small  improvement in survival time but it had a major  - about 30% -  reduced chance of dying for people who used the Gliadel vs the placebo wafer in the trial. There were minimal increases in side effects.  Worth considering if you are having a brain tumor surgery - but with one big warning - there are some clinical trials that do not allow people who have used Gliadel.  So it is very important to plan out what you want to do after the surgery. It is a very hard decision if your preferred clinical trial doesn't allow for the use of Gliadel..  you trade an approved treatment with a good chance of helping most patients a little and a few patients a lot (gliadel) for an unproven treatment in the trial that has the chance for a bigger improvement - but has not been shown to be safe or effective yet.

  617. [11/07/2012] Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial.  This study shows that for elderly GBM patients (65-87 years old), it may be possible to cut the number of radiation treatments in half - to 15 visitis in 3 weeks from 30 visits in 6 weeks, and get about the same results.  Of course, the results either way aren't good enough and it might be best to try a clinical trial of just about anything. However, if you are going to use the standard treatment, saving 15 sessions will make a big difference in quality of life for those 3 weeks.

  618. [10/29/2012] Anti-Alcoholism Drug Helps Fight Deadly Brain Tumor   This sounds interesting but it is way too early to get excited about

  619. [10/11/2012] UC Irvine opens clinical trial of novel treatment for brain cancer   This is one of my favorite clincial trials (it is being done all over the USA) ... however, the problem is that you need to enter the trial BEFORE your first brain tumor surgery.  Most people do not hear about this until after it is too late  We need to spread word of options such as these.  My pet peeve is that most neurosurgeons will not discuss the fact that by doing the surgery you will be forever excluded from clinical trials that require you to join before the first surgery.   Something to think about if you are about to have that first surgery.

  620. [10/11/2012] IBTA E NEWS OCTOBER 2012  This is the monthly newsletter from our friends at the International Brain Tumor Association.

  621. [10/10/2012] The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.  Interesting article.  It says that the addition of Temodar at the same time (and after) as radiation (which is now the standard of care) does NOT change the pattern of recurrence.  Most (91%) had recurrence in the same area as the original tumor which is about the same as when they used Temodar only after radiation.  The significance is this may mean widening the area radiated won't make much difference.

  622. [10/10/2012] Impact of extent of resection for recurrent glioblastoma on overall survival.  This articles says that at the second surgery for a GBM, getting a complete resection adds a few months to survival.  We already knew that was true for the initial surgery. This might not sound like much, but it may be enough added time for something else to work.

  623. [10/10/2012] Bevacizumab (Avastin) continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.  Although better than the alternatives tested,  still not good enough and shows the huge need for more research.  They didn't include the Novocure NovoTTF-100A which is the only other approved treatment for recurrent GBMs and they did not include any of the exciting clinical trials.

  624. [10/03/2012] Cell Therapeutics` brain cancer drug gets orphan status   It's a very good sign that the FDA gave orphan drug status!  Keep an eye on this one.

  625. [10/03/2012] ImmunoCellular Therapeutics to Present at 3 rd Annual Cancer Immunotherapy Conference and 2012 BIO Investor Forum  Live webcast tommorrow about this brain tumor vaccine.

  626. [09/29/2012] Model T muscle CARs can treat brain tumors. As I mentioned a few issues ago, the IL13Ra2 antigen is one of my favorite targets. I will be watching this.

  627. [09/22/2012] The impact of enrollment in clinical trials on survival of patients with glioblastoma.  Very important article.. I have been saying this for years:  Patients do significantly (live 30% longer) better in clinical trials even if they are assigned to the control group. They are taken care of better.

  628. [09/22/2012] Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.

    This article shows that when the surgeon thinks he/she "removed the entire tumor", he is wrong about 70% of the time.   This shows the need for the approval of the dye that lets the surgeon tell where the tumor is when operating, and also for more hospitals to get intra-operative imaging tools like MRI or ultrasound that can help them tell where the tumor is.

    Note that in many cases it is not possible to remove all of the tumor – the risk of neurological damage is too high, but the surgeon should know exactly how much of the tumor is being left behind. These tools can help.

  629. [09/19/2012] IBTA Newsletter  This newsletter is from our friends at the International Brain Tumor Association

  630. [09/16/2012] The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma.  This study shows that surgery alone for a recurrence of a GBM is not that useful: it adds on average 1 month to survival (compared to the group that had no treatments), and almost half of the patients had major complications from the surgery. However, combining surgery with chemotherapy gave the best outcome, adding 9 months on average - while chemo alone added only  3 months.   This is a small study and apparently wasn't randomized - so we don't know if perhaps people who were in better shape got to get both surgery and chemotherapy, and the patients who were in worse shape got no treatment - which would completely invalidate the results. However, it makes sense that combining the treatments would give the best outcome.  Perhaps adding more of the available treatments, like immunotherapy and tumor treating fields would yield even better results.

  631. [09/16/2012] A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R?2 tumor-restricted biomarker.  This is one of my favorite targets for brain tumor treatments.  The Musella Foundation has awarded 3 grants to the development of this system.  IL-13 is found on most brain tumor cells. Previous attempts to target this receptor had only limited success, because it is also found on normal brain as well as other organs. This researcher found a way to create a protien that binds only to the tumor associatd form of the receptor and not the naturally occuring one. Net result is it only attaches to tumors and not normal brain.  They are trying various ways of using thie targetting system. In this article, they discuss using it as an imaging agent - so we can see WHERE the tumor is - especially in cases where a regular MRI isn't helpfull as well as attaching a radioactive molecule to it to bring the radiation to the tumor cells.    <br><br> Not only can it target brain cancer, but it may also be useful for:  Prostate, Melanoma, Lung, Colon Cancer, Ovarian Cancer and some Breast cancers.  We have been trying to raise money for a human trial of this targeting system attached to a toxin.  

  632. [09/16/2012] Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.  Unfortunately, this trial shows that oral erlotinib (Tarceva) - an EGFR inhibitor - used by itself for recurrent gbms and anaplastic astrocytomas doesn't work well. Progression free survival was only 1.9 months.  Keep in mind that this only applies to oral use - which may mean not enough of the drug is getting to the tumor, and using it by itself.. it is possible that using it in other ways with other treatments may help.

  633. [09/16/2012] Gross Total Resection Rates in Contemporary Glioblastoma Surgery: Results of an Institutional Protocol Combining 5-ALA Intraoperative Fluorescence Imaging and Brain Mapping.  5-ALA is a dye used during brain tumor surgery to let the surgeon know where the tumor is.  This article shows that it helps increase the chances of a total resection for a Glioblastoma, without increasing the complication rate.  This dye is approved for use in Europe, but the USA FDA has not yet approved it here.  It is in clinical trials here and hopefully will be approved soon.

  634. [09/04/2012] Bevacizumab (Avastin) as first-line therapy for glioblastoma.  This article is based on smaller and earlier trials of adding Avastin to the standard of care for glioblastomas.  They report an improvment in progression free survival, but only a small improvement in overall survival.    We are eagerly awaiting the results of a much larger study - hopefully in 2-3 months - to clarify how best to use Avastin - either right at the start after radiation or wait until recurrence.  Right now we really do not know which way is best. Having said that, an improvement in progression free survival is still very important. It means that you can function and enjoy life for a longer time, and that is priceless.

  635. [09/04/2012] Gross Total Resection Rates in Contemporary Glioblastoma Surgery: Results of an Institutional Protocol Combining 5-ALA Intraoperative Fluorescence Imaging and Brain Mapping.  5-ALA is approved in Europe and is in clinical trials in the USA.  It helps the doctors to tell what is tumor and what is normal brain when doing a surgery.  This should be approved soon here in the USA and should be used in most brain tumor surgeries. I do not understand what is holding it up.

  636. [09/04/2012] A*STAR Scientists Discover Potential Drug for Deadly Brain Cance  This is early work but sounds exciting. I wish them luck.

  637. [09/03/2012] IBTA E News August 2012  This is the International Brain Tumor Association E-news letter. The Musella Foundation is not related to this organization - we are just passing it along (with thier permission) because it should be of interest to you!

  638. [08/29/2012] Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma This is one of the most important articles of the year.  It discusses the results of the first small ICT-107 vaccine trial.  The key outcome:  "At a median follow-up of 40.1 months, six of 16 newly diagnosed GBM patients showed no evidence of tumor recurrence. " Notice the Acknowledgments section:  This study was supported by funding from Musella Foundation For Brain Tumor Research & Information, Inc. and ImmunoCellular Therapeutics Ltd. This confirms that we (The Musella Foundation) seek out and fund the best research. Not only did we fund this project, but we also funded the early development on one of the targets of the vaccine.  This is a perfect example of how important YOUR donations are.  People always ask me if making donations can make a difference. This proves it.

  639. [08/15/2012] Suicide Gene killing deadly brain cancer: Nappanee woman in national study  This is one of the more promising new treatments out there... I am keeping an eye on it.

  640. [08/14/2012] Electric Helmet Treats Brain Tumors Describes this new, FDA approved treatment for brain tumors:  Includes a nice video of a patient using the Novocure NOVO TTF100A device.  For more details on the Novocure device, visit:

  641. [08/10/2012] The NovoTTF™-100A System selected as an award finalist based on its innovative design and 1st FDA approved indication for use against recurrent glioblastoma

  642. [08/09/2012] Implementation of a Multi-Institutional Diffuse Intrinsic Pontine Glioma Autopsy Protocol and Characterization of a Primary Cell Culture.

  643. [08/09/2012] Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.

  644. [08/09/2012] Impact of radiotherapy delay on survival in glioblastoma.

  645. [08/06/2012] Flo’s 3rd Annual Chili Cook-Off: A fundraiser to benefit the JFK Brain Tumor Center`s programs & services

  646. [07/30/2012] IBTA magazine

  647. [07/04/2012] New concept in treating brain tumors: Interlaced Therapy

  648. [06/26/2012] Crowdfunding brain tumor research project!

  649. [06/22/2012] Resistance of glioblastoma initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-ß (TGFß).

  650. [06/22/2012] Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First-Line Treatment for Patients With Glioblastoma.

  651. [06/22/2012] The effects of the NICE Technology Appraisal 121 (Gliadel and Temozolomide) on survival in high-grade glioma.

  652. [06/22/2012] Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.

  653. [06/13/2012] Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.

  654. [06/03/2012] Musella Foundation Co-Pay Assistance program is now closed!

  655. [06/03/2012] Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients.

  656. [06/03/2012] Noninvasive Application of Alternating Electric Fields in Glioblastoma : A Fourth Cancer Treatment Modality. Overview of how the Novocure TTF100-a Device works!

  657. [05/24/2012] Novocure(TM) Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy

  658. [05/23/2012] IBTA Newsletter

  659. [05/21/2012] Further Progress Made For DCVax-L Brain Cancer Clinical Trial

  660. [05/21/2012] Study Results of Novocure’s Pivotal Phase 3 Trial Published in European Journal of Cancer Show that NovoTTF™ Therapy was Comparable to Physicians’ First Chemotherapy Choice in Clinical Efficacy with Better Quality of Life Outcomes in Patients with Recurrent Glioblastoma

  661. [05/20/2012] Revised glioblastoma classification should improve patient care

  662. [05/18/2012] Northwest Bio Provides Update On DCVax®-L Brain Cancer Trial [Upgraded to phase 3!]

  663. [05/16/2012] Why dapsone stops seizures and may stop neutrophils` delivery of VEGF to glioblastoma.

  664. [05/16/2012] Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton Magnetic Resonance Spectroscopic Imaging Study.

  665. [05/14/2012] Novocure Announces Launch of Recurrent Glioblastoma Product Website

  666. [05/03/2012] A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

  667. [05/01/2012] The Legacy Brain Foundation is hosting the 7th Annual Celebration of Life event, honoring all brain tumor patients and their families,featurung internationally known brain tumor survivor, Dr. Ben Williams.

  668. [05/01/2012] A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.

  669. [05/01/2012] Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.

  670. [04/25/2012] MR-guided LITT for recurrent glioblastomas.

  671. [04/25/2012] Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.

  672. [04/25/2012] Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

  673. [04/20/2012] Test can reliably diagnose and monitor brain tumor without the need for surgery

  674. [04/20/2012] IBTA 2012 April E News

  675. [04/19/2012] Edison brain tumor specialist takes a human approach to one of medicine`s toughest jobs

  676. [04/17/2012] Cranium Crusaders Hosts 6th Annual Event Benefiting Brain Cancer Research

  677. [04/06/2012] Phase II Trial of Radiosurgery to Magnetic Resonance Spectroscopy-Defined High-Risk Tumor Volumes in Patients with Glioblastoma Multiforme.

  678. [04/06/2012] Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery.

  679. [04/03/2012] Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity.

  680. [04/03/2012] Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.

  681. [04/01/2012] Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.

  682. [04/01/2012] IBTA March 2012 E News

  683. [03/26/2012] Noninvasive imaging can detect mutations within a brain tumor

  684. [03/14/2012] Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

  685. [03/14/2012] Stem-like tumor initiating cells isolated from IL13Ra2-expressing gliomas are targeted and killed by IL13-zetakine redirected T cells.

  686. [03/14/2012] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.

  687. [03/14/2012] Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas.

  688. [02/25/2012] NW Bio Teams With the American Red Cross in DCVax® Program Initial Focus On Current 240-Patient GBM Clinical Trial

  689. [02/20/2012] IBTA E NEWS FEBRUARY 2012

  690. [02/13/2012] Diffusion Pharmaceuticals Begins Clinical Trial of TSC, a New Drug for Treatment of Primary Brain Cancer

  691. [02/09/2012] JFK (Edison, NJ )Becomes First East Coast Site to Open Clinical Trial of New Treatment Under Investigation for Aggressive Brain Tumors

  692. [02/09/2012] Consensus on the role of human cytomegalovirus in glioblastoma

  693. [02/09/2012] Bevacizumab (Avastin) improves quality of life in patients with recurrent glioblastoma.

  694. [01/30/2012] Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach

  695. [01/12/2012] Seeing what’s inside a tumor

  696. [01/09/2012] New trial sites for DCVax and Novocure added to our Clinical Trials and Noteworthy Treatments For Brain Tumors website!

  697. [01/09/2012] NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011 (For DCVax Brain Tumor Vaccine)

  698. [01/05/2012] Novel Brain Tumor Vaccine Acts Like Bloodhound to Locate Cancer Cells

  699. [12/24/2011] New feature added to Novocure!

  700. [12/22/2011] Improved Treatments for Brain Cancers Highlighted at Annual Society of Neuro-Oncology (SNO) Meeting

  701. [12/19/2011] IBTA E News November-December 2011

  702. [12/19/2011] New Treatment Protocol at Westchester Brain Tumor Program Offers a Ray Of Hope When a Deadly Brain Cancer Recurs

  703. [12/03/2011] Patient Receives First Prescription for FDA-Approved Brain Tumor Treatment

  704. [12/02/2011] Novocure™ Establishes Initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields (TTFields)™ Therapy

  705. [12/01/2011] EGFR activates mTORC2 in glioblastoma – a potential role for new therapies

  706. [12/01/2011] New Evidence Links Virus to Brain Cancer

  707. [11/29/2011] Device with AC current is comparable to chemo for recurrent glioblastoma

  708. [11/20/2011] Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology

  709. [11/10/2011] Glioblastoma survival in the United States before and during the temozolomide era.

  710. [11/10/2011] Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.

  711. [11/08/2011] IBTA E News October 2011

  712. [11/07/2011] Cleveland Clinic, UH testing therapies on deadly brain tumors

  713. [10/30/2011] Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial

  714. [10/22/2011] A simple guide screw method for intracranial xenograft studies in mice.

  715. [10/22/2011] The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and qu ality of care.

  716. [10/22/2011] Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

  717. [10/22/2011] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.


  719. [09/29/2011] Winthrop Study For Patients With Brain Tumors

  720. [09/25/2011] Release of Glutamate From Gliomas Sparks Seizures

  721. [09/25/2011] Swedish`s Ivy Brain Tumor Center Launches Two New Clinical Trials to Treat Brain Cancer

  722. [09/24/2011] Noscapine inhibits tumor growth in TMZ-resistant gliomas.

  723. [09/24/2011] Isolation of a new cell population in the glioblastoma microenvironment.

  724. [09/21/2011] Emerging Technologies In Brain Cancer Therapy

  725. [09/17/2011] Clinical Trial Tests Investigational New Drug for Malignant Brain Tumors

  726. [09/16/2011] Blocking Cholesterol in Brain Cancer Cells Offer a New Strategy to Fight Deadly Glioblastomas

  727. [09/16/2011] Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bev acizumab-induced Invasion in U87 Glioma.

  728. [09/12/2011] ImmunoCellular Therapeutics Announces 55% Overall Survival at Three years from Phase I Study in Glioblastoma

    38% of patients disease free at 3 years

  729. [09/12/2011] FDA Clears IsoRay`s GliaSite(R) Treatment for Brain Cancer

  730. [09/10/2011] Human Cytomegaloviru s US28 Found in Glioblastoma Promotes an Invasive and Angiogenic Phenotype.

  731. [09/09/2011] IBTA E NEWS AUGUST-SEPTEMBER 2011

  732. [09/09/2011] Flo`s 2nd Annual Chili Cook-Off - NJ

  733. [08/19/2011] Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma.

  734. [08/19/2011] Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection.

  735. [08/19/2011] Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment.

  736. [08/07/2011] NWBT Announces Further Expansion of Clincal Sites in Ongoing Brain Cancer Trial

  737. [07/31/2011] IBTA E NEWS JULY 2011

  738. [07/28/2011] Bevacizumab (Avastin)and daily temozolomide (Temodar)for recurrent glioblastoma.

  739. [07/26/2011] Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer

  740. [07/25/2011] Threshold Pharmaceuticals Announces Initiation of Clinical Trial Evaluating TH-302 in Combination with Bevacizumab at University of Texas at San Antonio

  741. [07/22/2011] The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma.

  742. [07/19/2011] Antiparasitic Mebendazole Shows Survival Benefit in 2 Preclinical Models of Glioblastoma Multiforme.

  743. [07/19/2011] Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.

  744. [07/17/2011] MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?

  745. [07/17/2011] The efficacy of carmustine wafers (Gliadel) for older patients with glioblastoma multiforme: prolonging survival.

  746. [07/14/2011] Immunosuppression in Patients with High Grade Gliomas Treated with Radiation and Temozolomide.

  747. [07/14/2011] Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study.

  748. [07/12/2011] Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

  749. [07/09/2011] Just Add Water and … Treat Brain Cancer

  750. [07/09/2011] Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

  751. [07/09/2011] MicroRNAs in Brain Tumors : A New Diagnostic and Therapeutic Perspective?

  752. [07/05/2011] IBTA E NEWS JUNE 2011

  753. [06/29/2011] Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial.

  754. [06/29/2011] Potential Role for Valproate in the Treatment of High-Risk Brain Tumors of Childhood-Results from a Retrospective Observational Cohort Study. *****Editor`s note: everyone should read this.*****

  755. [06/29/2011] Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.

  756. [06/16/2011] Tumor treating fields: concept, evidence and future.

  757. [06/16/2011] Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.

  758. [06/16/2011] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

  759. [06/16/2011] Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study .

  760. [06/16/2011] Engineering the brain tumor microenvironment enhances the efficacy of dendritic cells` vaccination: implications for clinical trials design.

  761. [06/16/2011] Specialised Therapeutics to License Brain Tumour Visualisation Drug Gliolan in Australia & NZ

  762. [06/16/2011] Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme.

  763. [06/13/2011] Stemline Therapeutics Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at ASCO

  764. [06/07/2011] Treatment with OPAXIO® (Paclitaxel Poliglumex),Temozolomide and Radiotherapy Results in Encouraging Progression Free Survival in Patients With High Grade Malignant Brain Tumor

  765. [06/07/2011] Tocagen`s First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma

  766. [06/06/2011] New Data From Phase 2 Brain Cancer Study With Prophage Series G-200 (HSPPC-96) Shows Improved Overall Survival

  767. [06/04/2011] Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times

  768. [06/02/2011] Bevacizumab (Avastin)-induced hypertension: pathogenesis and management.

  769. [05/31/2011] IBTA E NEWS MAY 2011

  770. [05/28/2011] Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

  771. [05/19/2011] Actress Jean Smart to Headline Local Events for Brain Cancer

  772. [05/19/2011] Injected patients with a virus to help kill brain tumors

  773. [05/19/2011] Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe

  774. [05/07/2011] The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma.

  775. [05/03/2011] Northwest Biotherapeutics` Ongoing Brain Cancer Trial Recruiting Additional Patients at Four Medical Centers Across US

  776. [04/29/2011] IBTA E News April 2011

  777. [04/27/2011] Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.

  778. [04/27/2011] Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.

  779. [04/27/2011] Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

  780. [04/27/2011] Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy.

  781. [04/27/2011] Valproic Acid and Warfarin: An Underrecognized Drug Interaction.

  782. [04/27/2011] The natural history of extracranial metastasis from glioblastoma multiforme.

  783. [04/15/2011] FDA clears first-of-a-kind device for brain cancer (Mentions Musella Foundation!)

  784. [04/15/2011] FDA Approves the NovoTTF-100A System for the Treatment of Patients with Recurrent Glioblastoma Multiforme (GBM) Brain Tumors

  785. [04/08/2011] Benefits of interferon-ß and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

  786. [04/08/2011] Bevacizumab (Avastin) for recurrent glioblastoma multiforme: a meta-ana lysis.

  787. [04/05/2011] A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.

  788. [04/03/2011] Scientists Find New Mechanism of Glioma Invasion

  789. [03/21/2011] FDA Advisory Panel Endorses New GBM Treatment

  790. [03/20/2011] IBTA E News March 2011

  791. [03/20/2011] FDA panel: Benefits outweigh risks of non-invasive therapy for glioblastoma

  792. [03/20/2011] Dendritic Cell Vaccine Increases Median Survival in Patients with Deadly Brain Cancer

  793. [03/17/2011] FDA votes to approve Novocure Device

  794. [03/12/2011] Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

  795. [03/09/2011] A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

  796. [03/02/2011] Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence.

  797. [02/23/2011] Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh

  798. [02/23/2011] Temozolomide in the treatment of high-grade gliomas in children: a report from the Children`s Oncology Group.

  799. [02/22/2011] Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.

  800. [02/22/2011] A multicenter phase I trial of combination therapy with interferon-ß and temozolomide for high-grade gliomas (INTEGRA study): the final report.

  801. [02/21/2011] Controversies in the Adjuvant Therapy of High-Grade Gliomas

  802. [02/18/2011] Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions

  803. [02/17/2011] Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.

  804. [02/16/2011] IBTA E News February 2011

  805. [02/12/2011] Activism Alert Update: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!

  806. [02/12/2011] Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas.

  807. [02/09/2011] Brain Tumor Vaccine Trial-Phase II Trial of ICT-107- opens in NJ!

  808. [02/08/2011] A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

  809. [02/08/2011] Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

  810. [02/03/2011] ImmunoCellular Therapeutics Ltd. (IMUC.OB) Enrolls First Patient for Phase II Study for Brain Tumor Candidate

  811. [02/03/2011] UT`s targeted particle fools brain`s guardian to reach tumors

  812. [02/02/2011] Activism Alert: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!

  813. [02/01/2011] Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence.

  814. [01/24/2011] Conversion of brain tumor cells into blood vessels thwarts treatment efforts

  815. [01/21/2011] New Phase 2 ICT-107 Vaccine trial opens in NJ!

  816. [01/13/2011] NEROFE--a novel human hormone-peptide with anti-cancer activity.

  817. [01/12/2011] A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma.

  818. [01/11/2011] A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors.

  819. [01/11/2011] Blocking Multiple Cell Signaling Pathways at Once: a Better Way to Treat Deadly Brain Tumors?

  820. [01/08/2011] Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.

  821. [01/03/2011] Pharma Strategy Blog: Glioblastoma recurrence after VEGF therapy: lack of rebound vascularisation as a mode of escape

  822. [12/29/2010] Rindopepimut,[CDX-110 vaccine] a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.

  823. [12/29/2010] Functional Drug Screening Assay Reveals Potential Glioma Therapeutics.

  824. [12/28/2010] Epicept announces start of phase IIb trial with brain tumour treatment

  825. [12/23/2010] ImmunoCellular Therapeutics (IMUC): At the Forefront of Brain Tumor Treatment

  826. [12/23/2010] Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial

  827. [12/23/2010] Electrical Device for Cancer Treatment Polarizes Audiences

  828. [12/16/2010] IBTA December 2010 E-News

  829. [12/07/2010] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

  830. [12/02/2010] Device for Glioblastoma May Offer Advantage Over Chemo

  831. [12/01/2010] Bevacizumab Combinations Effective in Phase II Glioblastoma Trials

  832. [11/28/2010] Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles

  833. [11/22/2010] Paclitaxel Poliglumex (OPAXIO®) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer

  834. [11/21/2010] Brain Tumors Grow Their Own Blood Supply

  835. [11/20/2010] Professor Zvi Ram Presents Phase III Recurrent Glioblastoma Survival and Quality of Life Data from the First Pivotal Study of the NovoTTF-100A at the 15th Annual Society for Neuro-Oncology (SNO) Scientific Meeting

  836. [11/15/2010] Cancer treatment shows promise

  837. [11/13/2010] Biocomputing: Numerical simulation of glioblastoma growth and comparison with conventional irradiation margins.

  838. [11/10/2010] Benefits of interferon-ß and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study.

  839. [11/09/2010] Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.

  840. [11/09/2010] Celecoxib and radioresistant glioblastoma-derived CD133(+) cells: improvement in radiotherapeutic effects.

  841. [11/05/2010] Cedars-Sinai "Nano-Drug" Hits Brain-Tumor Target Found In 2001

  842. [10/30/2010] IBTA E News October 2010

  843. [10/30/2010] Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

  844. [10/30/2010] Combined use of neuroradiology and (1)H-MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme.

  845. [10/29/2010] Targeted therapy for high-grade glioma with the TGF-{beta}2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.

  846. [10/24/2010] Oncomodulation by human cytomegalovirus: novel clinical findings open new roads.

  847. [10/22/2010] New Clinical Study for Recurrent Glioblastoma Being Conducted at City of Hope: Neural Stem Cell Platform: First-In-Human Trials




  851. [10/19/2010] Brain tumour vaccine set for trial

  852. [10/18/2010] Peregrine: brain cancer trial results show promise

  853. [10/14/2010] Selective cell death mediated by small conditional RNAs

  854. [10/13/2010] ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method

  855. [10/12/2010] Single-Arm Phase II Study of Conformal Radiation Therapy and Temozolomide plus Fractionated Stereotactic Conformal Boost in High-Grade Gliomas : Final Report.

  856. [10/11/2010] NOVOCURE REPORTS DATA SHOWING TTF THERAPY IN COMBINATION WITH CHEMOTHERAPY HAS THE POTENTIAL TO INCREASE OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (Editor`s Note: Although not related to brain tumors, this shows that the Novo TTF device has a strong effect on cancer.

  857. [10/06/2010] Celldex Reports Strong Clinical Results for Cancer Vaccine

  858. [10/04/2010] David M. Bailey 2/26/1966 - 10/2/2010

  859. [09/23/2010] Selective Serotonin Reuptake Inhibitors, Glioblastoma Multiforme, and Impact on Toxicities and Overall Survival: The Mayo Clinic Experience.

  860. [09/16/2010] The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas.

  861. [09/04/2010] ImmunoCellular Therapeutics Issues Letter to Shareholders

  862. [09/03/2010] Celldex, Pfizer Split Over Brain Tumor Drug

  863. [08/29/2010] A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

  864. [08/29/2010] Accumulation o f CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.

  865. [08/17/2010] ImmunoCellular Therapeutics Announces 2010 Second Quarter Results (And reports 100% 1 year survival!)

  866. [08/15/2010] First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a mu lticenter experience.

  867. [08/15/2010] Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

  868. [08/15/2010] A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

  869. [08/13/2010] IBTA E News

  870. [08/12/2010] Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.

  871. [08/03/2010] Scientists Develop “Designer Protein,” Opening New Door in Cancer Research

  872. [08/03/2010] Long-Term Follow-Up of DCVax®-Treated Brain Cancer Patients Shows 33% of Patients Reached 4-Year Survival and 27% Have Reached or Exceeded 6-Year Survival

  873. [07/28/2010] ImmunoCellular Therapeutics Announces Licensing Agreement with Targepeutics for Worldwide Intellectual Property Rights to Validated Immunotherapy Target

  874. [07/12/2010] Electrifying new brain cancer weapon

  875. [07/10/2010] A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

  876. [07/03/2010] The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma.

  877. [06/29/2010] A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro.

  878. [06/18/2010] Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

  879. [06/16/2010] Is Northwest Biotherapeutics (OTC:NWBO) Ready To Mount A Comeback?

  880. [06/08/2010] Reradiating Recurrent Gliomas Is Effective, Well-Tolerated

  881. [06/08/2010] FDA approves first human neural stem cell clinical trial to treat brain tumors

  882. [06/08/2010] BRAIN: 16% of patients with relapsed glioblastoma alive at 30 months (Avastin)

  883. [06/08/2010] Exceptional Survival Data, Lower Costs Key to the Competitive Advantage of DCVax(R) - Northwest Biotherapeutics` Vaccine for Multiple Cancers

  884. [06/08/2010] Brain cancer vaccine shows promise

  885. [06/08/2010] NovoTTF-100A improved response, time to treatment failure in recurrent glioblastoma

  886. [06/07/2010] Initial Experience Involving Treatment and Retreatment With Carmustine Wafers in Combination With Oral Temozolomide: Long-term Survival in a Child With Re lapsed Glioblastoma Multiforme.

  887. [06/07/2010] Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

  888. [06/05/2010] The Mike Overall Golf Classic to be held June 21, 2010 - Beaumont, Texas

  889. [06/05/2010] Cilengitide Study Provides Long-Term Follow-up Data in Glioblastoma Patients Receiving Investigational Drug for More Than 4 Years

  890. [06/05/2010] Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual ASCO Meeting

  891. [06/05/2010] Novel Electric Helmet Slows Brain Tumors Without Chemotherapy Side Effects


  893. [06/04/2010] ImmunoCellular Therapeutics` ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients

  894. [05/25/2010] Treatment disparities following the diagnosis of an astrocytoma.

  895. [05/22/2010] Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.

  896. [05/18/2010] IBTA E-News May 2010

  897. [05/13/2010] AACR: Targeted Agent Boosts Survival in Brain Cancer

  898. [05/13/2010] Generic drug shows promise for brain tumour treatment, study shows


  900. [05/08/2010] Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

  901. [05/08/2010] Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. /h3>

  902. [05/06/2010] Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma.

  903. [05/06/2010] Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma.

  904. [04/28/2010] Patient Trial of Personalized Two-Drug Therapy for Brain Tumors Launched

  905. [04/23/2010] Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent.

  906. [04/23/2010] Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

  907. [04/16/2010] Targeted Agent Blocked Growth of Deadly Brain Cancer in Preclinical Studies

  908. [04/15/2010] IBTA April 2010 E-News

  909. [04/01/2010] Teva UK Limited Launches Temozolomide Capsules

  910. [03/29/2010] Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study.

  911. [03/26/2010] AVASTIN now approved (In Canada) to treat colorectal, breast, lung and brain cancer

  912. [03/24/2010] Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study.

  913. [03/24/2010] A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study.

  914. [03/23/2010] Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.

  915. [03/17/2010] Lycopene in treatment of high-grade gliomas: A pilot study.

  916. [03/13/2010] Swedish Neuroscience Institute (in Seattle, Wash.) Brain Cancer Surgeon Publishes Major Feature Article in Scientific American MIND

  917. [03/10/2010] ImmunoCellular Therapeutics` Dendritic Cell-Based Vaccine Demonstrates Statistically Significant Increase in Survival in an Animal Model of Glioblastoma

  918. [03/09/2010] Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma.

  919. [03/05/2010] Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

  920. [02/28/2010] Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.

  921. [02/25/2010] Targeted Therapy Disappoints in Recurrent Brain Tumors

  922. [02/25/2010] Pfizer to Develop Brain Tumor Treatment with Companion Test from Qiagen`s DxS Unit

  923. [02/25/2010] MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

  924. [02/25/2010] Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

  925. [02/22/2010] Researchers identify a potential therapeutic target for brain cancer

  926. [02/20/2010] O6-methy lguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications./h3>

  927. [02/20/2010] Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

  928. [02/20/2010] Automated network analysis identifies core pathways in glioblastoma.

  929. [02/16/2010] Cancer Research UK and immatics Biotechnologies to trial vaccine for brain cancer

  930. [02/11/2010] New Scientific Publication Highlights Long-Term Survival of Brain Cancer Patients Treated With Peregrine Pharmaceuticals` Cotara(R)

  931. [01/30/2010] Lisa Kaminsky Millar

  932. [01/30/2010] Scientists Decode Brain Cancer Cell Line

  933. [01/28/2010] New therapies improving survival in patients with glioblastoma

  934. [01/28/2010] Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

  935. [01/26/2010] Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

  936. [01/25/2010] New Study Shows ImmunoCellular Therapeutics` Lead Investigational Cancer Vaccine ICT-107 Targets Cancer Stem Cells

  937. [01/23/2010] Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f.

  938. [01/23/2010] Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

  939. [01/23/2010] A Cookbook For Kristine

  940. [01/17/2010] IBTA E-News January 2010

  941. [01/12/2010] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

  942. [01/12/2010] Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.


  944. [12/06/2009] IBTA Newsletter

  945. [12/02/2009] Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial

  946. [11/30/2009] Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis

  947. [11/30/2009] Sagopilone, a microtubule stabilizer for the potential treatment of cancer.

  948. [11/30/2009] Human cytomegalovirus UL76 induces chromosome aberrations.

  949. [11/30/2009] Cytotoxic Effects of Temozolomide and Radiation are Additive- and Schedule-Dependent.

  950. [11/30/2009] Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer

  951. [11/21/2009] Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

  952. [11/21/2009] European advisory committee declines to recommend Avastin approval for deadly brain cancer

  953. [11/13/2009] Neurosurgery Resident`s Book Helps Ease Youths` Fears About Brain Surgery

  954. [11/12/2009] Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.

  955. [11/12/2009] Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

  956. [11/10/2009] New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine`s Bavituximab With Radiation in a Lethal Brain Cancer Model

  957. [11/05/2009] Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.

  958. [11/03/2009] MagForce Successfully Completes Final Clinical Trials for Nano-Cancer Therapy

  959. [11/03/2009] Gamma knife treatment for glioblastomas shows promising results - Survival rate increased by almost 4 months

  960. [11/01/2009] Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma.

  961. [11/01/2009] Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults.

  962. [10/29/2009] ImmunoCellular`s Promising Brain Cancer Vaccine

  963. [10/29/2009] Myriad Pharmaceuticals` Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)

  964. [10/22/2009] Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

  965. [10/18/2009] Cancer drug crosses key hurdle in brain: study

  966. [10/18/2009] IBTA October 2009 E-News

  967. [10/17/2009] Population-based study of pseudoprogression after chemoradiotherapy in GBM.

  968. [10/10/2009] Charlottesville firm’s drug could be a brain cancer breakthrough

  969. [09/28/2009] NovoCure, Ltd., Announces the Closing of a Financing Round Including New Investors Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures

  970. [09/24/2009] Bevacizumab (Avastin) Could Play An Important Role In Improving The Neurocognitive Function Of Patients With The Most Aggressive Form Of Brain Cancer

  971. [09/22/2009] Invasive Brain Cancer Studied

  972. [09/22/2009] Experts express hope for fight against brain tumors

  973. [09/07/2009] Small Cap Stocks Battling Brain Cancer

  974. [09/07/2009] *** Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

  975. [09/03/2009]

  976. [08/18/2009] M. D. Anderson - Orlando patient enrolls in groundbreaking clinical trial to fight Glioblastoma

  977. [07/16/2009] Castle Biosciences announces availability of DecisionDx-GBM biomarker test for brain cancer (glioblastoma multiforme) patients that predicts overall survival to first-line standard of care treatment

  978. [07/03/2009] Study identifies biomarker that safely monitors tumor response to new brain cancer treatment

  979. [06/30/2009] Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

  980. [06/30/2009] Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

  981. [06/30/2009] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.

  982. [06/20/2009] Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma.

  983. [06/20/2009] A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

  984. [06/20/2009] Very late relapses in glioblastoma long-term survivors.

  985. [06/20/2009] Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q.

  986. [06/20/2009] Bevacizumab (Avastin) and chemotherapy for recurrent glioblastoma: a single-institution experience.

  987. [06/20/2009] Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas

  988. [06/20/2009] Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study.

  989. [06/12/2009] Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

  990. [06/12/2009] Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

  991. [06/10/2009] Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: An Hypothesis.

  992. [06/02/2009] David Bailey will perform at 7pm on Saturday, June 6th in Hercules, CA (which is near Berkeley, CA)

  993. [06/01/2009] Pfizer and Celldex Therapeutics Present Update on CDX-110 (PF-04948568) Phase 2 Brain Cancer Studies at 45th Annual ASCO Meeting

  994. [06/01/2009] Most common brain cancer may originate in neural stem cells

  995. [06/01/2009] Drug Made From Cottonseed May Slow Brain Cancer, Researchers Say

  996. [06/01/2009] TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting

  997. [05/28/2009] Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

  998. [05/14/2009] Very late relapses in glioblastoma long-term survivors.

  999. [05/14/2009]

  1000. [05/14/2009] A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects.

  1001. [05/14/2009] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.

  1002. [05/14/2009] A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma.

  1003. [05/14/2009] Targeting brain tumor stem cells using a bispecific antibody directed against CD133+ and EGFRvIII+.

  1004. [05/14/2009] Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity.

  1005. [05/14/2009] A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18-month survival data (NABTT 0501).

  1006. [05/07/2009] The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

  1007. [05/07/2009] Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.

  1008. [05/07/2009] The survival impact of postoperative infection in patients with glioblastoma multiforme.


  1010. [04/29/2009] IBTA E-Newsletter

  1011. [04/09/2009] Stereotactic radiosurgery for glioblastoma: retrospective analysis.

  1012. [04/09/2009] Boron neutron capture therapy for newly diagnosed glioblastoma.

  1013. [04/09/2009] Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: Results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy.

  1014. [04/09/2009] Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.

  1015. [04/08/2009] Nanobiotix Reports ‘Proof of Concept’ for Its Nanoparticles in Treating Glioblastoma Multiforme (Brain Cancer)

  1016. [04/01/2009] FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)

  1017. [03/28/2009] Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study.

  1018. [03/23/2009] Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.

  1019. [03/16/2009] FDA to consider approval of Avastin for brain tumors - ACTION NEEDED!

  1020. [03/16/2009] New vaccine trial opens for pediatric (ages 3 to 20) high grade, low grade and brainstem glioma

  1021. [03/10/2009] Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  1022. [03/09/2009] FDA Panel To Review Genentech`s Avastin In Brain Cancer

  1023. [03/09/2009] European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

  1024. [03/08/2009] Human Cytomegalovirus Infection Downregulates the Expression of Glial Fibrillary Acidic Protein in Human Glioblastoma Cells, U373MG:Identification of Viral Genes and Protein Domains Involved.

  1025. [03/08/2009] Rechallenge with temozolomide in patients with recurrent gliomas.

  1026. [03/08/2009] Completely endoscopic resection of intraparenchymal brain tumors.

  1027. [03/08/2009] Occupational exposure to magnetic fields and the risk of brain tumors.

  1028. [03/08/2009] Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

  1029. [03/08/2009] Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.

  1030. [03/08/2009] Localized BCNU chemotherapy and the multimodal management of malignant glioma.

  1031. [03/08/2009] Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

  1032. [03/08/2009] Reduction of Protein kinase C zeta inhibits migration and invasion of human glioblastoma cells.

  1033. [03/07/2009] Northwest Biotherapeutics reported encouraging results for DCVax Brain Tumor Vaccine

  1034. [03/07/2009] Bradmer provides clinical trial update and announces evaluation of strategic alternatives

  1035. [03/07/2009] Study points to limitations of angiogenesis blockers

  1036. [03/05/2009] Brain tumor treatment may increase number of cancer stem-like cells

  1037. [03/04/2009] Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide.

  1038. [03/04/2009] Bevacizumab (Avastin) for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  1039. [03/04/2009] Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

  1040. [02/19/2009] Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival

  1041. [02/11/2009] Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034.

  1042. [02/11/2009] Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma.

  1043. [02/06/2009] Temozolomide Sales Reach $1 Billion

  1044. [02/03/2009] Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.

  1045. [02/03/2009] High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.

  1046. [02/02/2009] Safety and Efficacy of Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas.

  1047. [02/02/2009] State-of-the-Art Therapy for Glioblastoma Multiforme


  1049. [01/17/2009] Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma.

  1050. [01/12/2009] Gene therapy eliminates brain tumors through selective recruitment of immune cells

  1051. [01/07/2009] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma.

  1052. [01/05/2009] Salk researchers create brain cancer mouse model

  1053. [12/31/2008] The story of human cytomegalovirus and cancer: increasing evidence and open questions.

  1054. [12/31/2008] Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database.

  1055. [12/31/2008] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma.

  1056. [12/31/2008] Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma.

  1057. [12/31/2008] Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival.

  1058. [12/25/2008] ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial

  1059. [12/22/2008] Brain Tumor News Blast - fundraising appeal

  1060. [12/19/2008] M. D. Anderson neurosurgeon, Amy Heimberger, M.D., receives presidential award

  1061. [12/10/2008] Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

  1062. [12/05/2008] Drug slows brain cancer, Calgary researchers say

  1063. [12/04/2008] Ranbaxy in pact to market BioPro`s brain tumour drug (Gliadel) in India news

  1064. [11/25/2008] Brain-cancer center at Swedish maps tumors to design treatment


  1066. [11/23/2008] A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.

  1067. [11/19/2008] Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.

  1068. [11/19/2008] Pediatric glioblastomas: A histopathological and molecular genetic study.

  1069. [11/19/2008] Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme.

  1070. [11/19/2008] Phase I/II Trial Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177.

  1071. [11/19/2008] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab (Avastin) plus irinotecan (CPT-11).

  1072. [11/17/2008] Celprogen Introduces an in vivo Model for Human Brain Cancer (Human Glioblastoma GBM) for Drug Discovery Applications

  1073. [11/17/2008] The relative risk of brain cancer

  1074. [11/17/2008] A better way to find brain tumors

  1075. [11/06/2008] New Treatment Guidelines for Newly Diagnosed Glioblastoma Issued by American Association of Neurological Surgeons/Congress of Neurological Surgeons

  1076. [11/05/2008] Bradmer sponsors physician panel to raise awareness of brain cancer treatments (Live Webcast!)

  1077. [11/05/2008] Genentech Seeks FDA Nod for Avastin for Brain Cancer

  1078. [10/28/2008] Mechanism in cells that generate malignant brain tumors may offer target for gene therapy

  1079. [10/19/2008] High-grade glioma before and after treatment with radiation and Avastin: Initial observations

  1080. [10/19/2008] Temozolomide for high grade glioma.

  1081. [10/17/2008] Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases

  1082. [10/17/2008] Experience with irinotecan for the treatment of malignant glioma

  1083. [10/08/2008] Target Acquired: It may become possible to vaccinate against brain tumours

  1084. [10/04/2008] Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM).

  1085. [10/04/2008] A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma.

  1086. [10/04/2008] Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.

  1087. [10/04/2008] Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM).

  1088. [10/04/2008] A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

  1089. [10/04/2008] Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen.

  1090. [10/04/2008] Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)

  1091. [10/04/2008] A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide.

  1092. [10/04/2008] Prospective phase II trial for recurrent high-grade gliomas with capacitive coupled low radiofrequency (LRF) hyperthermia.

  1093. [10/03/2008] Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.

  1094. [10/03/2008] Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

  1095. [10/03/2008] Radiosurgery and carcinogenesis risk.

  1096. [10/03/2008] Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: Outcome compared with conventional chemotherapy: A report from the Children`s Oncology Group.

  1097. [10/03/2008] Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas.

  1098. [10/03/2008] TMZ-BioShuttle - a reformulated Temozolomide.

  1099. [10/03/2008] A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

  1100. [09/29/2008] Dosing Initiated in TransMolecular’s Phase 1/2 Clinical Trial for Intravenous Administration of 131Iodine-TM601 in Patients with Recurrent Malignant Glioma

  1101. [09/28/2008] Median Brain Cancer Survival Doubles in Vaccine Trials

  1102. [09/20/2008] Treatment Options for Glioblastoma and other Gliomas - By Ben Williams, Phd - new version posted!

  1103. [09/14/2008] Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain

  1104. [09/13/2008] Experience with irinotecan (CPT-11) for the treatment of malignant glioma

  1105. [09/10/2008] Cytopia Commences Phase II Study for Brain Cancer Drug

  1106. [09/10/2008] IBTA E-NEWSLETTER 10 September 2008

  1107. [09/07/2008] Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.

  1108. [09/05/2008] Researchers Detect Genetic Defects Guilty Of Deadliest Cancers

  1109. [09/05/2008] New clues found to treat brain cancer

  1110. [09/03/2008] Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.

  1111. [09/03/2008] Phase II Study of Metronomic Chemotherapy with Thalidomide, Carboplatin-Vincristine-Fluvastatin in the Treatment of Brain Stem Tumors in Children.

  1112. [08/30/2008] Phase II Pre-radiation R115777 (Zarnestra) in newly diagnosed GBM with residual enhancing disease.

  1113. [08/30/2008] Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.

  1114. [08/30/2008] Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.



  1117. [08/26/2008] High-grade glioma before and after treatment with radiation and Avastin: Initial observations

  1118. [08/10/2008] Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.

  1119. [08/10/2008] Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.

  1120. [08/10/2008] Temozolomide preferentially depletes cancer stem cells in glioblastoma.

  1121. [08/10/2008] Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.

  1122. [07/31/2008] Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme

  1123. [07/29/2008] A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

  1124. [07/26/2008] Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism.

  1125. [07/26/2008] Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience.

  1126. [07/17/2008] Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

  1127. [07/16/2008] When temozolomide alone fails: adding procarbazine in salvage therapy of glioma

  1128. [07/16/2008] Glioblastoma multiforme.

  1129. [07/16/2008] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

  1130. [07/16/2008] Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.

  1131. [07/16/2008] Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes

  1132. [07/03/2008] Does Herpes Cause Brain Cancer?

  1133. [07/03/2008] A New Method for Screening of Anti-tumor Agents

  1134. [06/26/2008] The Lori Arquilla Andersen Foundation Holds Fourth Annual Gray Tie Ball to Raise Funds for Awareness, Advocacy and Research to Find the Cure for Brain Cancer

  1135. [06/23/2008] Use of nanoparticles for cerebral cancer.

  1136. [06/23/2008] Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

  1137. [06/23/2008] Stereotactic Radiosurgery Can Extend Survival in Small Recurrent Glioblastomas

  1138. [06/23/2008] With an inoperable brain tumor, Bob Tisch wound up at Duke

  1139. [06/17/2008] Oncolytic Viruses Found to Stimulate Tumor Blood-Vessel Growth

  1140. [06/17/2008] Protox granted orphan status in Europe for brain cancer treatment

  1141. [06/17/2008] Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.

  1142. [06/17/2008] Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma.

  1143. [06/17/2008] Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.

  1144. [06/04/2008] Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients.

  1145. [06/04/2008] Survival Following CyberKnife Radiosurgery and Hypofractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme.

  1146. [06/04/2008] Rehabilitation in primary and metastatic brain tumours : Impact of functional outcomes on survival.

  1147. [06/04/2008] A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.

  1148. [06/04/2008] Cintredekin besudotox in treatment of malignant glioma.

  1149. [06/04/2008] Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide.

  1150. [06/02/2008] “Heroes of Hope” Grey Ribbon Crusade ™ Promotes National Unification in the Fight Against Brain Tumors

  1151. [05/31/2008] Golf Tournament to benefit Brain Tumor Research - June 23, 2008 - Sacramento, CA

  1152. [05/28/2008] Surgeon`s trial study on cancer is hailed

  1153. [05/28/2008] Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

  1154. [05/24/2008] Hints of Progress in Drugs Treating Brain Cancer

  1155. [05/20/2008] Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment

  1156. [05/20/2008] APNewsBreak: Sen. Kennedy has malignant brain tumor

  1157. [05/19/2008] Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.

  1158. [05/19/2008] Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience.

  1159. [05/16/2008] Avastin improves brain cancer survival

  1160. [05/15/2008] Treatment Outcomes of Glioblastoma Multiforme at Community Based Teaching Hospital

  1161. [05/05/2008] Modulatory effects of acetazolomide and dexamethasone on temozolomide mediated apoptosis in human glioblastoma T98G and U87MG cells.

  1162. [05/05/2008] Oncothyreon files investigational new drug application for PX-866 oncology compound

  1163. [05/04/2008] Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival.

  1164. [05/04/2008] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

  1165. [05/03/2008] Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.

  1166. [04/27/2008] Dichloroacetate (DCA) induces apoptosis in endometrial cancer cells.

  1167. [04/27/2008] Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

  1168. [04/27/2008] Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker.

  1169. [04/27/2008] New Therapies Could Change Cancer Treatment Strategies

  1170. [04/27/2008] Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research

  1171. [04/27/2008] Experimental vaccine offers hope against brain cancer

  1172. [04/27/2008] Cancer researchers receive NIH grant to advance brain tumor therapies from lab to clinical trials

  1173. [04/21/2008] Ashburn Foundation Announces 7th Annual “Heroes of Hope” Charity Event to Benefit Brain Tumor Research and Local Heroes

  1174. [04/20/2008] Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

  1175. [04/20/2008] Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

  1176. [04/20/2008] Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

  1177. [04/17/2008] Drugs in the pipeline: new therapies that could change treatment strategies

  1178. [04/17/2008] TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting -Data also reveal peptide’s synergistic interactions with anti-VEGF therapeutics-


  1180. [04/06/2008] A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.

  1181. [04/06/2008] Time course of imaging changes of GBM during extended bevacizumab treatment.

  1182. [04/01/2008] Golf Tournament for brain tumor research - June 23, 2008 - Sacramento, CA

  1183. [03/30/2008] The harm-benefit tradeoff in "bad deal" trials.

  1184. [03/30/2008] Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.

  1185. [03/30/2008] Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma.

  1186. [03/30/2008] Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma.

  1187. [03/30/2008] Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

  1188. [03/30/2008] Reduced Glioma Growth Following Dexamethasone or Anti-Angiopoietin 2 Treatment.

  1189. [03/30/2008] Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability.

  1190. [03/27/2008] Your $1 in a Million and Our Hero of Hope

  1191. [03/22/2008] Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer

  1192. [03/22/2008] Dan`s Fund Created at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute to support Brain Cancer Research

  1193. [03/18/2008] Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).

  1194. [03/18/2008] A fatal outcome in a patient with glioblastoma multiforme after receiving high-dose methotrexate.

  1195. [03/18/2008] Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  1196. [03/18/2008] Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.

  1197. [03/18/2008] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

  1198. [03/18/2008] Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.

  1199. [03/18/2008] Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.

  1200. [03/18/2008] Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials

  1201. [03/18/2008] Dan`s Fund created at Ohio State University

  1202. [03/18/2008] Genentech signals strong Avastin sales

  1203. [03/10/2008] Bevacizumab (Avastin) for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  1204. [03/09/2008] Gene Therapy `Trains` Immune System to Destroy Brain Cancer Cells and Reverse Behavioral Deficits

  1205. [02/27/2008] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

  1206. [02/27/2008] Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

  1207. [02/25/2008] A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

  1208. [02/25/2008] Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

  1209. [02/25/2008] Natural history and management of brainstem gliomas in adults : A retrospective Italian study.

  1210. [02/25/2008] Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients

  1211. [02/15/2008] Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

  1212. [02/15/2008] Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

  1213. [02/15/2008] Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.

  1214. [02/15/2008] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

  1215. [02/15/2008] Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.

  1216. [02/15/2008] Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.

  1217. [02/04/2008] The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

  1218. [02/04/2008] High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors.

  1219. [01/26/2008] Calibrant Announces Brain Cancer Drug Discovery Program with Cleveland Clinic

  1220. [01/26/2008] Localized Combo Treatment Promising Against Stubborn Deadly Brain Cancer

  1221. [01/26/2008] Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme : a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.

  1222. [01/26/2008] Boron Neutron Capture Therapy for Glioblastoma: Is it Worth Pursuing?

  1223. [01/18/2008] MGI Pharma Reveals Results From Study Involving Dual Implantation Of Gliadel Wafer And Radioactive Seeds - Quick Facts [MOGN]

  1224. [01/18/2008] Oncolytic measles virus strains in the treatment of gliomas.

  1225. [01/13/2008] Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

  1226. [01/13/2008] A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

  1227. [01/07/2008] Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma

  1228. [01/07/2008] TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma

  1229. [01/05/2008] Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.

  1230. [01/05/2008] Duke, UNC Researchers Target ‘Achilles Heel’ in Brain Tumors

  1231. [01/05/2008] Drug cocktail may help treat brain tumor


  1233. [12/21/2007] MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma.

  1234. [12/21/2007] Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.

  1235. [12/19/2007] Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study.

  1236. [12/19/2007] Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.

  1237. [12/19/2007] Brain Cancer Drug Looks Very Promising

  1238. [12/19/2007] ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model

  1239. [12/09/2007] Adjuvant chemotherapy for adults with malignant glioma: a systematic review.

  1240. [12/08/2007] A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle.

  1241. [12/08/2007] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.

  1242. [12/08/2007] A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

  1243. [12/08/2007] Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme.

  1244. [12/07/2007] Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII...

  1245. [12/05/2007] New additions to

  1246. [12/04/2007] Celtic Pharma - Update on XERECEPT

  1247. [12/02/2007] Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

  1248. [12/02/2007] Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology

  1249. [12/02/2007] Scientists say new vaccine shows promise in treatment of brain cancer

  1250. [12/02/2007] In Vivo Vaccination With Tumor Cell Lysate Plus CpG Oligodeoxynucleotides Eradicates Murine Glioblastoma.

  1251. [11/30/2007] Antiangiogenic agents for the treatment of glioblastoma.

  1252. [11/28/2007] Management of glioblastoma.

  1253. [11/25/2007] Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.

  1254. [11/19/2007] Genentech Reveals Encouraging Avastin Data; Bayer`s Nexavar Gets FDA Approval For Liver Cancer - Update [DNA]

  1255. [11/17/2007] Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.

  1256. [11/16/2007] Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

  1257. [11/16/2007] Bevacizumab (Avastin) plus irinotecan (CPT-11) in recurrent glioblastoma multiforme.

  1258. [11/09/2007] Brain Cancer Patient Benefits From New Treatment

  1259. [10/31/2007] Bevacizumab (Avastin) plus irinotecan (CPT-11) in recurrent glioblastoma multiforme.

  1260. [10/29/2007] Radiation plus chemo quadruples survival time for fatal brain cancer

  1261. [10/23/2007] Novel Vaccine For Aggressive Brain Tumors Tested By Mayo Clinic

  1262. [10/23/2007] Researchers Develop Vaccine for Brain Cancer

  1263. [10/22/2007] Drug may stave off brain tumor deaths


  1265. [10/19/2007] Avastin seen as helpful against deadly brain tumor

  1266. [10/19/2007] Clinical trial evaluating brain cancer vaccine is underway at NYU

  1267. [10/17/2007] Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis.

  1268. [10/17/2007] Bradmer provides Phase III Neuradiab trial update and guidance

  1269. [10/12/2007] ALA and Photofrin(R) Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.

  1270. [10/08/2007] Walk Around the World for Brain Tumo(u)rs and the Inaugural International Brain Tumo(u)r Awareness Week – News Update 8 October 2007.

  1271. [10/01/2007] Walk Around the World for Brain Tumo(u)rs and the Inaugural International Brain Tumo(u)r Awareness Week – News Update 1 October 2007.

  1272. [09/28/2007] InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors

  1273. [09/28/2007] Promising brain cancer drug moves to human trials

  1274. [09/20/2007] Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

  1275. [09/20/2007] Walk Around the World for Brain Tumo(u)rs and the Inaugural International Brain Tumo(u)r Awareness Week – News Update 19 September 2007.

  1276. [09/15/2007] Nichole`s Cord Foundation Launches Local Chapter with it`s First Ever Benefit

  1277. [09/15/2007] Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death.

  1278. [09/15/2007] Targeted drug combos could outsmart cancer

  1279. [09/09/2007] Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.

  1280. [09/09/2007] Coincidence vs cause: cure in three glioblastoma patients treated with brachytherapy.

  1281. [09/09/2007] Expression of Interleukin-13 Receptor {alpha}2 in Glioblastoma Multiforme: Implications for Targeted Therapies.

  1282. [09/09/2007] Long-term survival with glioblastoma multiforme.

  1283. [09/09/2007] Targeted therapies promise new hope for brain cancer patients

  1284. [09/01/2007] Methylguanine Methyltransferase Testing in Glioblastoma: When and How?

  1285. [09/01/2007] In Reply (to previous coment on Temodar)

  1286. [09/01/2007] The Fallacy of Single-Agent Chemotherapy for Cancer

  1287. [08/30/2007] Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells

  1288. [08/29/2007] MUSC Researchers Discover Garlic Kills Brain Cancer Cells

  1289. [08/29/2007] Efficacy of Temozolomide Is Correlated With 1p Loss and Methylation of the Deoxyribonucleic Acid Repair Gene MGMT in Malignant Gliomas.

  1290. [08/29/2007] Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.

  1291. [08/25/2007] Neuropathological postmortem evaluation of BNCT for GBM.

  1292. [08/24/2007] The First Annual Eclectic Electric Concert for the Cure benefiting the Charles Warren Brain Tumor Awareness Foundation, Inc. will be held September 29, 2007 at the Mable House Amphitheatre in Mableton, Georgia.

  1293. [08/24/2007] Overlook Hospital only site in tri-state to offer new brain tumor vaccine

  1294. [08/24/2007] Updated version of: Treatment Options For Glioblastoma and other Gliomas

  1295. [08/24/2007] Guidelines: Carmustine Implants and Temozolomide for Treatment of Newly Diagnosed High-Grade Glioma

  1296. [08/21/2007] Brain tumour stem cells: possibilities of new therapeutic strategies.

  1297. [08/21/2007] Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: Case report and review of the literature.

  1298. [08/21/2007] Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.

  1299. [08/21/2007] Angiogenesis Inhibition: The Next Frontier in Multimodal Therapy for Glioblastoma Multiforme

  1300. [08/21/2007] Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.


  1302. [08/17/2007] Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma.

  1303. [08/17/2007] Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.

  1304. [08/10/2007] Brain Cancer Zapper

  1305. [08/10/2007] Electric Fields Kill Tumors A promising device uses electric fields to destroy cancer cells in the brain.

  1306. [07/31/2007] Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

  1307. [07/28/2007] MIT IDs Link Between Brain Tumor Proteins Work Could Guide Drugs For Especially Aggressive Cancer

  1308. [07/28/2007] Experimental Device Used To Treat Deadly Brain Cancer

  1309. [07/27/2007] Cooking up a CURE volume 7! Your recipes are needed!

  1310. [07/09/2007] Worlds First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland

  1311. [07/06/2007] Peregrine Pharma Begins Patient Enrollment In New Cotara Brain Cancer Trial [PPHM]

  1312. [06/29/2007] Canadian recommendations for the treatment of glioblastoma multiforme.

  1313. [06/24/2007] Anti-inflammatory shows promise in brain tumor treatment

  1314. [06/22/2007] Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

  1315. [06/20/2007] Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.

  1316. [06/20/2007] Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

  1317. [06/20/2007] Temozolomide-associated organizing pneumonitis.

  1318. [06/20/2007] Fractionated stereotactic radiotherapy boost and weekly Paclitaxel in malignant gliomas clinical and pharmacokinetics results.

  1319. [06/16/2007] Phase I Trial of Tipifarnib (R115777) Concurrent with Radiotherapy in Patients with Glioblastoma Multiforme.

  1320. [06/16/2007] Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium with Standard Radiotherapy in Patients with Glioblastoma Multiforme.

  1321. [06/16/2007] Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.

  1322. [06/16/2007] Phase I Trial of Gross Total Resection, Permanent Iodine-125 Brachytherapy, and Hyperfractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme.

  1323. [06/16/2007] Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.

  1324. [06/16/2007] Temozolomide and thalidomide in the treatment of glioblastoma multiforme.

  1325. [06/16/2007] Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

  1326. [06/16/2007] Vorinostat shows anti-cancer activity in recurrent gliomas

  1327. [06/11/2007] Rock Beats Cancer

  1328. [06/06/2007] Alternating electric fields arrest cell proliferation in animal tumor model and human brain tumors

  1329. [05/30/2007] Innovative device to treat brain cancer shows promise in early studies

  1330. [05/16/2007] Phase I Trial for ImmunoCellular Therapeutics Brain Tumor Vaccine Commences

  1331. [05/16/2007] Multifocal Glioblastoma Multiforme: Prognostic Factors and Patterns of Progression.

  1332. [04/29/2007] New mechanism identified for resistance to targeted lung cancer drugs

  1333. [04/20/2007] New vaccine trial for newly diagnosed glioblastoma multiforme

  1334. [04/20/2007] AstraZeneca brain tumor drug shows promise

  1335. [04/20/2007] Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

  1336. [04/20/2007] Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1.

  1337. [04/20/2007] Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.

  1338. [04/20/2007] Antiangiogenic Agent Shows Promise against Glioblastoma

  1339. [04/18/2007] Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

  1340. [04/18/2007] Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  1341. [04/18/2007] A novel lipoxygenase inhibitor Nordy attenuates malignant human glioma cell responses to chemotactic and growth stimulating factors.

  1342. [04/18/2007] Establishment of experimental glioma models at the intrinsic brainstem region of the rats.

  1343. [04/18/2007] Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR Annual Meeting 2007

  1344. [04/18/2007] NICE finally approves glioma drugs after finding error in its calculations

  1345. [04/18/2007] Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

  1346. [04/18/2007] Bothell biotech sees opportunity in Switzerland - Northwest Biotherapeutics wants to sell its brain cancer treatment, currently in clinical trials in the U.S., in the European nation.

  1347. [04/13/2007] Radiotherapy for Glioblastoma in the Elderly.

  1348. [03/29/2007] Protherics starts trial of brain cancer therapy

  1349. [03/29/2007] NeoPharm plunges on FDA request

  1350. [03/23/2007] Stanford brain tumor vaccine to be tested nationally

  1351. [03/22/2007] Area doctor free of brain tumor for 22 months

  1352. [03/10/2007] Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

  1353. [03/10/2007] Complications of a temozolomide overdose: a case report.

  1354. [03/10/2007] Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.

  1355. [03/09/2007] Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer

  1356. [03/09/2007] Northwest Biotherapeutics Adds UCLA as a Site to Its Pivotal Phase II Brain Cancer Trial

  1357. [02/23/2007] Fighting brain cancer with electricity

  1358. [02/17/2007] Electrodes fight brain cancer

  1359. [02/15/2007] Light Sciences Oncology Initiates Phase II Trial of Litx(TM) Therapy in Patients with Glioma

  1360. [02/15/2007] First Patients Undergo Surgery in Northwest Biotherapeutics` Phase II Brain Cancer Trial

  1361. [02/08/2007] Celtic Pharma halts study of cancer drug

  1362. [01/26/2007] Advances in the Management of Glioblastoma Multiforme: An Expert Interview With Dr. Renato La Rocca From 2006 SNO

  1363. [01/17/2007] Experiment at Stony Brook delivers drugs into arteries that feed the brain, targeting aggressive tumors

  1364. [01/16/2007] Creating a new kind of cancer treatment

  1365. [01/13/2007] New Anti-angiogenesis Treatment: Combination Therapy Obliterates New Vessel Growth In Tumors And Retinopathy

  1366. [01/07/2007] Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme1

  1367. [01/07/2007] Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy.

  1368. [12/23/2006] EntreMed`s Panzem(R) Demonstrates Antitumor Activity In Brain Tumor Model

  1369. [12/21/2006] EntreMed`s Panzem(R) Demonstrates Antitumor Activity in Brain Tumor Model

  1370. [12/20/2006] Researchers identify genes that allow brain cancer-causing stem cells to resist treatment

  1371. [12/20/2006] Making Glioblastomas Starve - First Clinical Trials In The USA And Germany

  1372. [12/14/2006] Sangamo BioSciences and City of Hope Announce License Agreement and Research Collaboration to Develop Treatment for Brain Cancer

  1373. [12/14/2006] NEOPHARM Announces Efficacy Results for Phase 3 PRECISE Trial

  1374. [12/11/2006]

  1375. [12/07/2006] Drug that can fight brain cancer discovered

  1376. [11/28/2006] Bradmer Contracts With Prologue Research to Manage Multi-Center Pivotal Trial of Neuradiab in Brain Cancer

  1377. [11/28/2006] Northwest Biotherapeutics Receives Institutional Review Board Approval to Accrue Patients in Phase II Brain Cancer Trial

  1378. [11/28/2006] Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas.

  1379. [11/28/2006] Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities.

  1380. [11/22/2006] Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol)

  1381. [11/22/2006] Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

  1382. [11/22/2006] The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

  1383. [11/22/2006] The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas

  1384. [11/22/2006] Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

  1385. [11/22/2006] Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

  1386. [11/22/2006] Increased expression of 5-lipoxygenase in high-grade astrocytomas.

  1387. [11/22/2006] Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. [Editor`s Note: bevacizumab is the generic name for Avastin}

  1388. [11/22/2006] Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.

  1389. [11/22/2006] Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.

  1390. [11/22/2006] Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.

  1391. [11/22/2006] A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.

  1392. [11/21/2006] University Evaluates New Device To Treat Brain Tumors

  1393. [11/20/2006] NEOPHARM AnNOUNCES Presentation of FINAL SAFETY DATA FROM PHASE 1 TRIAL OF CINTREDEKIN BESUDOTOX for Newly Diagnosed Malignant Glioma

  1394. [11/20/2006] Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting

  1395. [11/18/2006] Mayo Clinic Cancer Center -- Harnessing the Measles Virus to Attack Cancer

  1396. [11/10/2006] Northwest Biotherapeutics Discusses Results From Clinical Trials In Brain Cancer At Two Conferences

  1397. [11/10/2006] Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas.

  1398. [11/10/2006] Reata Announces Presentation of Interim Results for Phase 1 Study of RTA 744 in Treatment of Advanced Brain Tumors

  1399. [10/30/2006] Northwest Biotherapeutics Discusses Results From Clinical Trials in Brain Cancer at Two Conferences

  1400. [10/30/2006] Mayo Clinic Cancer Center -- Harnessing the Measles Virus to Attack Cancer Seeking a Cure for Glioblastoma Multiforme, Other Deadly Cancers

  1401. [10/18/2006] Research Yields Clues to Radiation-Resistant Brain Cancer

  1402. [10/17/2006] Monitoring the effects of BCNU chemotherapy Wafers (Gliadel((R))) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.

  1403. [10/17/2006] Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.

  1404. [10/17/2006] Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.

  1405. [10/17/2006] Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.

  1406. [10/17/2006] PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium.

  1407. [10/17/2006] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

  1408. [10/17/2006] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

  1409. [10/13/2006] Peregrine Pharma Gets Regulatory Approval To Test Cotara Brain Cancer Therapy In India - Update

  1410. [09/26/2006] Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

  1411. [09/18/2006] NEOPHARM Presents Updated CINTREDEKIN BESUDOTOX Phase I/II Median Survival Data at European Association of Neuro-Oncology (EANO) Meeting

  1412. [09/15/2006] New vaccine helps doctor fight brain cancer

  1413. [09/14/2006] U.S. to map genes of brain, ovarian and lung cancer

  1414. [09/14/2006] Experimental Brain Tumor Treatment

  1415. [09/13/2006] Cholesterol Carrier to Fight Brain CA?

  1416. [08/28/2006] Northwest Biotherapeutics Updates Brain Cancer Clinical Data

  1417. [08/28/2006] Updated version of Ben Williams`s paper:` Treatment Options For Glioblastomas` posted on


  1419. [08/05/2006] Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

  1420. [08/05/2006] Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

  1421. [07/31/2006] Panzem Gets Orphan Drug Status for Glioblastoma Multiforme

  1422. [07/25/2006] O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.

  1423. [07/20/2006] Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

  1424. [07/20/2006] Protox acquires Phase II cancer program from Neurocrine and U.S. Public Health Service

  1425. [07/05/2006] A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

  1426. [06/27/2006] Etoposide Nanocarriers Suppress Glioma Cell Growth by Intracellular Drug Delivery and Simultaneous P-Glycoprotein Inhibition

  1427. [06/27/2006] NeoPharm places big bet on brain medicine

  1428. [06/26/2006] The Samantha Dickson Research Trust has become the largest funder of laboratory based brain tumour research in the UK, and offers a vital support link for brain tumour patients and their families or carers.

  1429. [06/21/2006] Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities (Editor`s Note: This article says that Decadron makes Temodar less effective)

  1430. [06/12/2006] Early necrosis following concurrent temozolomide and radiotherapy in adult patients with glioblastoma.

  1431. [06/12/2006] Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma--Toxicity and Efficacy.

  1432. [06/12/2006] Hana Biosciences Receives Orphan Drug Status For Drug In Treatment Of Brain Tumor - Update

  1433. [06/07/2006] Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6-year experience.

  1434. [06/07/2006] A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

  1435. [06/07/2006] Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

  1436. [06/07/2006] Phase I/II Trial of Twice-Daily Temozolomide and Celecoxib for Treatment of Relapsed Malignant Glioma: Final Data

  1437. [06/06/2006] Phase II Trial of Gliadel Plus O6-Benzylguanine (O6-BG) for Patients With Recurrent Glioblastoma Multiforme

  1438. [06/05/2006] Study Demonstrates Safety of Promising Investigational Treatment for Deadly Brain Cancer; Results Establish Safe Dosages for Larger-Scale Study of 131I-TM-601 in Treatment of High-Grade Gliomas

  1439. [05/25/2006] Northwest Biotherapeutics gives brain cancer trial update

  1440. [05/09/2006]  M. D. Anderson: Setting the Benchmark in Brain Tumor Treatment

  1441. [05/09/2006]  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

  1442. [05/03/2006] Matthew Fullerton guest speaker at NJ support group

  1443. [05/03/2006] An Evening with David M. Bailey

  1444. [05/03/2006] Northwest Biotherapeutics to Present Updated Brain Cancer Data at the International Society for Cellular Therapy Annual Meeting

  1445. [05/02/2006] Scientist works to improve treatment for brain tumors

  1446. [05/02/2006] Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation( bigstar).


  1448. [04/25/2006] Brain Tumor Vaccine Shows Promise


  1450. [04/18/2006] FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.

  1451. [04/18/2006] Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

  1452. [04/05/2006] A new approach to treating cancer

  1453. [04/05/2006] A new hope for brain tumor patients

  1454. [04/04/2006] Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

  1455. [04/04/2006] Antihistamine and Anti-inflammatory Drug Use Associated Differently for High-Grade Versus Low-Grade Gliomas: Abstract No. 486

  1456. [04/03/2006] EntreMed Presents Preclinical Results at AACR for Panzem(R) and ENMD-1198

  1457. [04/03/2006] A a homeopathic cure for brain cancer, long practiced by a family of Indian homeopaths may finally secure its rightful place in the medical texts.

  1458. [04/03/2006] Preclinical Studies Presented at AACR Meeting Show Potential of Peregrine`s Tarvacin(TM) Plus Radiation or Chemotherapy to Increase Survival in Resistant Breast Cancer and Brain Cancer

  1459. [03/31/2006] MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.

  1460. [03/29/2006] Radiotherapy Advance Points Way To Noninvasive Brain Cancer Treatment


  1462. [03/21/2006] Recent advances in the treatment of malignant astrocytoma.


  1464. [03/16/2006] Laureate Pharma and Bradmer Pharmaceuticals Announce Their Development and Manufacturing Agreement on a Therapeutic Monoclonal Antibody Product for Treatment of Brain Cancer

  1465. [03/14/2006] Prolonged Lymphopenia Common with Long-Term Temozolomide for Glioma

  1466. [03/09/2006] Eli Lilly Launches Phase III Study Of Enzastaurin For Brain Tumor Treatment - Update

  1467. [03/08/2006] Gliadel(R) Wafer Demonstrates Long-Term Survival Benefit for Patients with High-Grade Malignant Gliomas

  1468. [03/07/2006] PCV chemotherapy for recurrent glioblastoma.

  1469. [03/07/2006] Adding Chloroquine to Conventional Chemotherapy and Radiotherapy for Glioblastoma Multiforme

  1470. [03/03/2006] Temodal To Be Funded For Newly Diagnosed Brain Cancer Patients

  1471. [02/27/2006] Genes May Influence Response to Brain-Tumor Treatments : Brain tumors with a particular gene composition are more responsive to a specific class of drugs, researchers are reporting.

  1472. [02/21/2006] Researchers at UPCI Studying New Approach to Attacking Brain Tumors

  1473. [02/12/2006] In fight for life, insurer no help

  1474. [02/02/2006] Canada OKs Schering-Plough Cancer Drug

  1475. [01/31/2006] Surviving glioblastoma for more than 5 years: the patient`s perspective.

  1476. [01/30/2006] HEALING HIMSELF

  1477. [01/23/2006] Distinct transcription profiles of primary and secondary glioblastoma subgroups.

  1478. [01/23/2006] Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).

  1479. [01/23/2006] Experimental treatment for brain tumors tested in Valhalla

  1480. [01/19/2006] EntreMed Commences Phase 2 Studies with Panzem(R) NCD - Duke University Medical Center to Conduct Brain Cancer Trial

  1481. [01/15/2006] Target for Therapeutic Drugs to Fight Most Common Adult Brain Cancer

  1482. [01/15/2006] UVa doctors work to improve deadly tumor treatment

  1483. [01/14/2006] Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

  1484. [01/12/2006] Concerts for a CURE, presents David Bailey in concert (Philly, PA).

  1485. [01/11/2006] Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages.

  1486. [01/11/2006] Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors (Tarceva and Iressa)

  1487. [01/11/2006] Researchers at Vanderbilt-Ingram Cancer Center uncover clue to explain invasive brain tumors

  1488. [01/05/2006] Virus-Drug Combination May Have Synergistic Effect Against Glioblastoma

  1489. [01/05/2006] Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

  1490. [01/03/2006] Ecopia Announces Filing of Clinical Trial Application for ECO-4601

  1491. [12/31/2005] Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme.

  1492. [12/31/2005] Tumor Necrosis Factor-{alpha}-Induced Protein 3 As a Putative Regulator of Nuclear Factor-{kappa}B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas.


  1494. [12/22/2005] Study: New brain tumor therapy

  1495. [12/21/2005] Report of GBM metastasis to the parotid gland.

  1496. [12/10/2005] NeoPharm Announces Completion of PRECISE Trial Enrollment as Per Special Protocol Assessment Agreement

  1497. [12/07/2005] Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme.

  1498. [12/07/2005] Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

  1499. [12/07/2005] Study suggests a way to eliminate glioblastoma

  1500. [12/02/2005] Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma.

  1501. [12/02/2005] Tenascin-C protein is induced by Transforming Growth Factor-ss1 but does not correlate with time to tumor progression in high-grade gliomas.

  1502. [12/02/2005] A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999.

  1503. [11/29/2005] Tailoring tumor therapy - Targeted treatment for brain cancer shows promise

  1504. [11/21/2005] First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics` Oncophage Cancer Vaccine in Glioma


  1506. [11/16/2005] Technology to Be Used to Study MGMT Methylation Status in Glioblastoma Multiforme Brain Cancer Patients Treated with TEMODAR(R) (Temozolomide) - Schering-Plough and ONCOMETHYLOME Sciences (OMS) Announce License and Collaboration Agreement For Use of OMS Pharmacogenomic Technology

  1507. [11/10/2005] `Personalized` Therapy Targets Brain Tumors


  1509. [11/01/2005] Temozolomide Improves Survival in Glioma: Presented at ECCO

  1510. [11/01/2005] Wake Forest University Baptist Medical Center - Novel treatment target for deadly brain tumors identified

  1511. [11/01/2005] Research shows protein can slow cancer

  1512. [10/28/2005] Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.

  1513. [10/28/2005] Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate (Gleevec) Therapy.

  1514. [10/28/2005] Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme.

  1515. [10/26/2005] Exploring Avastin`s effects on brain cancer

  1516. [10/26/2005] Three new genetic mutations in brain tumors identified

  1517. [10/20/2005] Genentech in collaboration to explore Avastin for brain cancer treatment

  1518. [10/19/2005] NeoPharm Investigators Present Preliminary Phase I Data of Cintredekin Besudotox in the Treatment of Malignant Glioma at Initial Diagnosis

  1519. [10/19/2005] Brain cancer patients fight an unseen enemy Advice and updated information offered at recent area conference

  1520. [10/18/2005] O6–BG May Help Re-Sensitize Cancer Cells to Temodar® in Brain Cancer

  1521. [10/06/2005] Attacking Brain Cancer At Tumor Site Extends Survival

  1522. [10/05/2005] Stereotactically Guided Fractionated Re-irradiation in Recurrent Glioblastoma Multiforme.

  1523. [10/03/2005] Key Genetic Mutations in Brain Tumors Identified by Scientists From J. Craig Venter Institute, Ludwig Institute for Cancer Research, and The Johns Hopkins University School Of Medicine

  1524. [09/27/2005] Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme.

  1525. [09/22/2005] Essential role for Ras signaling in glioblastoma maintenance.

  1526. [09/21/2005] Northwest Biotherapeutics Announces Clinical Advisory Board for Brain Cancer Program

  1527. [09/21/2005] Combination of Gleevec® and Hydrea® Offers Promise for Glioblastoma Multiforme

  1528. [09/08/2005] Intracavitary Chemotherapy (paclitaxel/Carboplatin Liquid Crystalline Cubic Phases) for Recurrent Glioblastoma - Clinical Observations.

  1529. [09/08/2005] Marital status, treatment, and survival in patients with glioblastoma multiforme.

  1530. [08/31/2005] Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. *note: clotrimazole is the generic name of Gyne-Lotrimin, Lotrimin and Mycelex - which are commonly used for fungal and yeast infections

  1531. [08/29/2005] Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.

  1532. [08/29/2005] The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

  1533. [08/29/2005] Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Initiate Cotara(R) Brain Cancer Trial

  1534. [08/20/2005] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

  1535. [08/17/2005] Experimental Drug Gives New Hope For Brain Cancer

  1536. [08/15/2005] Researchers find that combined gene therapy eliminates glioblastoma multiforme in lab studies

  1537. [08/09/2005] Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

  1538. [08/09/2005] HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

  1539. [08/09/2005] Caspase 8 is absent or low in many ex vivo gliomas.

  1540. [08/02/2005] Northwest Biotherapeutics Announces Appointment of Paul Zeltzer, MD as Medical Director - Personalized Vaccine for Brain Cancer Entering Phase II Clinical Trials

  1541. [07/27/2005] Treatment Options For Malignant Glioma - update

  1542. [07/27/2005] MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.

  1543. [07/27/2005] Researchers to look at genetic composition of Pratt tumors

  1544. [07/27/2005] UAB discovers treatment for brain cancer

  1545. [07/16/2005] Asthma gene variants may cut risk of brain cancer

  1546. [07/12/2005] Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.

  1547. [07/12/2005] Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: North Central Cancer Treatment Group.

  1548. [07/05/2005] The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years.

  1549. [07/02/2005] Pinpointing response to brain cancer drug

  1550. [07/02/2005] How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience (Editor`s Note: Also results of one week on, one week off dosage schedule)


  1552. [06/23/2005] New hope for brain cancer patients

  1553. [06/15/2005] Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma.

  1554. [06/15/2005] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.

  1555. [06/15/2005] P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.

  1556. [06/15/2005] The contribution of Magnetic Resonance Spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours.

  1557. [06/15/2005] Phase I study examines biomarkers for response to erlotinib (Tarceva) in glioma

  1558. [06/13/2005] Chemotherapy for Brain Tumors is Boosted After Vaccine

  1559. [06/10/2005] Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients.

  1560. [06/10/2005] Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

  1561. [06/10/2005] TEMODAL(R) Approved in European Union For Treatment of Newly Diagnosed Glioblastoma Multiforme

  1562. [06/02/2005] Gene Variant Predicts Brain Tumor Survival Enzyme Related to Chromosome Length Holds the Key

  1563. [06/01/2005] Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials

  1564. [05/31/2005] Molecule May Be Target for Treatment of Malignant Glioma

  1565. [05/26/2005] NeoPharm: brain tumor agent may struggle to overtake Temodar NeoPharm has announced a review of safety data for the ongoing PRECISE trial.

  1566. [05/20/2005] YM BioSciences and CIMAB achieve clinical milestone - Data for TheraCIM h-R3 in High Grade Malignant Glioma presented at ASCO 2005 -

  1567. [05/20/2005] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors.

  1568. [05/18/2005] ASCO: Pipeline Drug Said to Shrink Recurrent Brain Tumors

  1569. [05/18/2005] Mayo Clinic Researchers Develop New Treatment For Incurable Recurring Form Of Adult Brain Cancer

  1570. [05/17/2005] Guilford Pharmaceuticals Announces Promising Results at ASCO in Study of Newly Diagnosed High Grade Malignant Glioma

  1571. [05/11/2005] Virus Targets and Kills Brain Tumors

  1572. [05/11/2005] Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults.

  1573. [05/11/2005] Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.

  1574. [05/09/2005] Research suggests molecular approaches to brain tumor treatment

  1575. [05/08/2005] International brain tumour advocacy group established

  1576. [05/05/2005] EGFR tyrosine kinase domain mutations in human gliomas.

  1577. [05/05/2005] Antisoma Reviews Portfolio: Drops AS1405 to Accelerate AS1411 - [Editor`s note: Brain tumor trial to close immediatley!]

  1578. [05/04/2005] Molecular change occurring during brain tumor progression also evident in breast cancer

  1579. [05/03/2005] History of Chickenpox and Shingles and Prevalence of Antibodies to Varicella-Zoster Virus and Three Other Herpesviruses among Adults with Glioma and Controls

  1580. [04/30/2005] Antisense Pharma Completes Patient Recruitment for AP 12009 Phase II Trial

  1581. [04/26/2005] European Union`s CHMP Recommends Approval of TEMODAL(R) (Temozolomide) for the Most Common and Aggressive Form of Brain Cancer

  1582. [04/26/2005] Is older age associated with a worse prognosis due to different patterns of care? A long-term study of 1346 patients with glioblastomas or brain metastases.

  1583. [04/18/2005] Hana Biosciences to Present Positive Pre-Clinical Data on IPdR at AACR Meeting - Pre-clinical study shows IPdR demonstrates effective dose-responsive radiotherapy sensitization and direct inhibition of human gliobastoma tumors in xenografts


  1585. [04/18/2005] Call for Participants: MALIGNANT BRAIN TUMOR SYMPTOMS STUDY

  1586. [04/18/2005] Spectrum Pharmaceuticals Presents Data on EOquin(TM) as a Radiation Sensitizer at the Annual Meeting of American Association of Cancer Research (AACR) in Anaheim, California

  1587. [04/13/2005] Scientists identify protein that controls cancer cells

  1588. [04/06/2005] Glioblastoma multiforme metastasis to the axis. Case report.

  1589. [03/28/2005] The Brad Kaminsky Foundation for Brain Tumor Research Brings its Fourth Annual Heroes of Hope Silent Auction “on-line”

  1590. [03/22/2005] website redesigned to reflect new FDA approved indication for newly diagnosed glioblastoma multiforme!

  1591. [03/21/2005] Wake Forest University Baptist Medical Center Scientist works on innovative treatments for brain tumors

  1592. [03/17/2005] MGMT gene silencing and benefit from temozolomide in glioblastoma.

  1593. [03/16/2005] Schering-Plough Brain Cancer Drug Wins Expanded OK

  1594. [03/15/2005] The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo.

  1595. [03/10/2005] UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

  1596. [03/10/2005] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.

  1597. [03/10/2005] Inotek Pharmaceuticals Announces Commencement of Enrollment in Phase 1b/2a Trial for Glioblastoma Multiforme

  1598. [03/10/2005] New hope against brain tumors

  1599. [02/15/2005] Glioblastoma multiforme-report of 267 cases treated at a single institution.

  1600. [02/15/2005] Increased resistance of glioma cell lines to extracellular ATP cytotoxicity.

  1601. [02/15/2005] Dr. S. R. Burzynski Gives Presentation at ICACT in Paris

  1602. [02/14/2005] Xenova Group plc -- TransMID Obtains Orphan Drug Designation in Japan

  1603. [02/02/2005] Rethinking the war on brain tumors - JAMA editorial finds treatments too scattershot

  1604. [02/01/2005] Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

  1605. [02/01/2005] Molecular mechanisms of glioma cell migration and invasion.

  1606. [02/01/2005] Genetic and hypoxic regulation of angiogenesis in gliomas.

  1607. [01/27/2005] OHSU study: Protein stops growth of brain tumor - Herstatin blocks signaling inside cells that leads to deadly glioblastoma growth

  1608. [01/25/2005] Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2004 fourth quarter and full year.

  1609. [01/22/2005] Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receive Approval for Cotara(R) Brain Cancer Protocol

  1610. [01/21/2005] Poway Woman First To Try Experimental Brain Cancer Treatment

  1611. [01/18/2005] Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas.

  1612. [01/17/2005] Doctors at Fort Lauderdale convention honor neurosurgeon recovering from crash

  1613. [01/10/2005] Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.

  1614. [01/10/2005] Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.

  1615. [01/10/2005] Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.

  1616. [01/03/2005] New weapons target deadly brain cancer

  1617. [12/28/2004] The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells.

  1618. [12/28/2004] Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

  1619. [12/21/2004] Protein Delivered Via Genetically Engineered Virus Slowed Glioblasoma Multiforme Growth

  1620. [12/20/2004] Early results show encouragement in treatment of glioblastoma brain tumors.

  1621. [12/20/2004] Daily topotecan blocks glioblastoma growth in animal models.

  1622. [12/20/2004] Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.

  1623. [12/19/2004] LIFELINE FOR TUMOUR DAD (

  1624. [12/16/2004] Protein Delivered Via Genetically Engineered Virus Slowed Glioblasoma Multiforme Growth

  1625. [12/12/2004] NHS refuses to pay for cancer drug which could extend man`s life

  1626. [12/09/2004] Cancer Killer

  1627. [12/09/2004] Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

  1628. [12/07/2004] TransMolecular Successfully Completes Phase I/II Clinical Trial With its Targeted Oncology Therapeutic

  1629. [12/06/2004] Protein Upped Immune Cells, Slowed Growth of Glioblastoma Multiforme

  1630. [12/06/2004] Silencing of Monocarboxylate Transporters via Small Interfering Ribonucleic Acid Inhibits Glycolysis and Induces Cell Death in Malignant Glioma: An in Vitro Study.

  1631. [12/06/2004] Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  1632. [11/25/2004] SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.

  1633. [11/25/2004] Role of synaptojanin 2 in glioma cell migration and invasion.


  1635. [11/23/2004] Guilford Pharmaceuticals Inc. (GLFD) Presents New GLIADEL(R) Wafer Data At The Society For Neuro-Oncology Annual Meeting

  1636. [11/23/2004] Dr. S. R. Burzynski Presents Preliminary Research On Antineoplastons A10 and AS2-1 For Treatment of Deadly Brain Tumors to the Society For Neuro-Oncology

  1637. [11/19/2004] Positive Results Reported in Phase II Study of Cervene - TP-38 - To Treat Brain Cancer; Data Presented at Society for Neuro-Oncology Meeting in Toronto

  1638. [11/19/2004] Pharmacyclics Announces Presentation of Results From Two Phase 1 Clinical Trials Evaluating Xcytrin Plus Cranial Irradiation for Aggressive Brain Tumors

  1639. [11/16/2004] Erlotinib (Tarceva®) Produces Responses in Glioblastoma Multiforme

  1640. [11/12/2004] Tarceva® Produces Responses in Recurrent Glioblastoma Multiforme

  1641. [11/11/2004] Correlation of N-cadherin expression in high grade gliomas with tissue invasion.

  1642. [11/11/2004] Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.

  1643. [11/09/2004] Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Enter Collaboration to Treat Brain Cancer Patients

  1644. [11/04/2004] Oncolytics Biotech Inc. Announces 2004 Third Quarter Results

  1645. [11/04/2004] Xenova Group PLC -- Third Quarter Results, 2004

  1646. [11/02/2004] Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study.

  1647. [10/29/2004] Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study

  1648. [10/29/2004] Schering-Plough Reports FDA Grants Priority Review to TEMODAR(R) (Temozolomide) Supplemental New Drug Application for Gliomas (Brain Tumors)

  1649. [10/28/2004] Two drugs for a hitherto fatal brain cancer are giving patients a new lease on life.

  1650. [10/26/2004] NYU Cancer Center Features New System by BSD Medical

  1651. [10/26/2004] BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.

  1652. [10/23/2004] Lab study defines and blocks mechanism that lets brain tumors sidetrack immune response

  1653. [10/21/2004] Newcastle Disease Virus

  1654. [10/21/2004] Data on GliaSite Radiation Therapy System for Recurrent Brain Tumors Presented at Neurological Surgeons Meeting

  1655. [10/20/2004] How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.

  1656. [10/20/2004] Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas.

  1657. [10/20/2004] Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.

  1658. [10/20/2004] Adult glioma incidence trends in the United States, 1977-2000.

  1659. [10/14/2004] Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts)

  1660. [10/12/2004] Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.

  1661. [10/12/2004] Genetic pathways to glioblastoma: a population-based study.

  1662. [10/12/2004] Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.

  1663. [10/05/2004] Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit.

  1664. [10/03/2004] Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme (GBM)

  1665. [09/29/2004] Trial shows which brain cancer patients benefit from temozolomide

  1666. [09/28/2004] Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.

  1667. [09/27/2004] Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer

  1668. [09/27/2004] CombinatoRx and ABC2 Initiate Brain Cancer Collaboration

  1669. [09/21/2004] Decoupling the Control of Brain Cancer Cells

  1670. [09/16/2004] Guilford Pharmaceuticals Receives European Marketing Authorization for Expanded Use of GLIADEL(R) Wafer - GLIADEL(R) Approved to Treat Newly-Diagnosed Patients with Malignant Glioma

  1671. [09/16/2004] Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme

  1672. [09/16/2004] Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas

  1673. [09/16/2004] Decoupling the control of brain cancer cells to find better treatments

  1674. [09/16/2004] Brain cancer rate in normal range, study finds

  1675. [09/07/2004] Survival trends in elderly patients with glioblastoma multiforme: resective surgery, radiation, and chemotherapy.

  1676. [08/31/2004] Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors.

  1677. [08/31/2004] Recombinant humanised anti-HER2/neu antibody (Herceptin((R))) induces cellular death of glioblastomas.

  1678. [08/27/2004] Vaccination and Chemotherapy Appear to Work Together to Increase Survival in Patients with Glioblastoma

  1679. [08/24/2004] The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme.

  1680. [08/24/2004] Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.

  1681. [08/24/2004] Association between laminin-8 and glial tumor grade, recurrence, and patient survival.

  1682. [08/22/2004] Researchers Expand Scope of Cancer Study

  1683. [08/22/2004] Accelerate Brain Cancer Cure and National Brain Tumor Foundation Co-Fund Brain Cancer Genetics Research at UCSF

  1684. [08/14/2004] Cannabis may block growth of brain cancer

  1685. [08/09/2004] New treatment strategy for brain cancer

  1686. [08/06/2004] Scientists encode gene to help fight brain cancer

  1687. [08/05/2004] Five brain cancers linked to single gene

  1688. [08/05/2004] Molecular therapeutics advance fight against brain cancer

  1689. [08/05/2004] Smart drug that targets cancer cells in the brain following removal of a tumor


  1691. [08/04/2004] Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure


  1693. [08/03/2004] Gene Mutations Behind Some Brain Cancers

  1694. [08/01/2004] Study shows that fluorescence spectroscopy can distinguish brain tumor from normal tissue

  1695. [07/25/2004] Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content.

  1696. [07/20/2004] Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.

  1697. [07/20/2004] HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells.

  1698. [07/17/2004] Chemo wafers used to treat brain tumor directly

  1699. [07/15/2004] EXPERIMENTAL VACCINE - New way to fight brain cancer

  1700. [07/10/2004] Adding Temozolomide (Temodar®) to Radiation Increases Survival in Glioblastoma Multiforme

  1701. [07/08/2004] Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.

  1702. [07/08/2004] TransMID drug adheres to cells in brain tumors

  1703. [07/01/2004] Geron Announces Publication of Data on GRN163, a Telomerase Inhibitor, in Animal Models of Human Brain Tumors

  1704. [06/30/2004] `Tour of the California Alps` fundraiser for brain tumor research!

  1705. [06/22/2004] Journal Cancer: Protein shift predicts brain cancer grade, recurrence and patient survival

  1706. [06/22/2004] Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis

  1707. [06/17/2004] Research Gives Brain Tumor Patients Hope Radiologist Outlives Life Expectancy

  1708. [06/15/2004] SciClone`s ZADAXIN Shows Promising Effects in Treating Brain Cancer in Animal Model Study

  1709. [06/15/2004] One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

  1710. [06/11/2004] Healthcast: Drug For Brain Tumor Patients

  1711. [06/08/2004] Drug treatment is first major improvement in brain cancer in decades

  1712. [06/08/2004] The familiality of primary brain tumors as studied in the Utah Population Database (UPDB).

  1713. [06/08/2004] Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: Phase I/II-study.

  1714. [06/08/2004] Temozolomide (TMZ) and lomustine (CCNU) in high grade glioma (HGG) patients: Phase I study.

  1715. [06/08/2004] Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009.

  1716. [06/08/2004] Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group).

  1717. [06/08/2004] Radiotherapy and concomitant weekly carboplatin and daily etoposide for patients with inoperable biopsy proven glioblastoma multiforme.

  1718. [06/08/2004] Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG).

  1719. [06/08/2004] Phase II trial of functional imaging-optimized stereotactic fractionated radiotherapy plus temozolomide for recurrent high-grade glioma.

  1720. [06/08/2004] Phase II trial of copper depletion as angiosuppressive treatment in newly diagnosed Glioblastoma Multiforme: Final report.

  1721. [06/08/2004] Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma.

  1722. [06/08/2004] Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme (GBM).

  1723. [06/08/2004] Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.

  1724. [06/08/2004] PCV and/or TMZ chemotherapy in 255 gliomas. Analysis of the clinical experience from a neuro-oncology data-base.

  1725. [06/08/2004] One week on/one week off regimen of temozolomide for recurrent glioblastoma: A phase II study.

  1726. [06/08/2004] NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).

  1727. [06/08/2004] NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.

  1728. [06/08/2004] Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

  1729. [06/08/2004] Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.

  1730. [06/08/2004] Intensity modulated radiotherapy in high grade gliomas: Clinical and dosimetric results.

  1731. [06/08/2004] Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials.

  1732. [06/08/2004] Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts).

  1733. [06/08/2004] Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy.

  1734. [06/08/2004] High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study.

  1735. [06/08/2004] Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1.

  1736. [06/08/2004] Adjuvant chemotherapy with temozolomide and pegylated liposomal doxorubicin in the first-line therapy of patients with glioblastoma ¨C a phase-II trial.

  1737. [06/08/2004] A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs.

  1738. [06/08/2004] A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021.

  1739. [06/08/2004] A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM).

  1740. [06/08/2004] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).

  1741. [06/08/2004] Histopathological findings in autopsied glioblastoma patients treated by mixed neutron beam BNCT.

  1742. [06/08/2004] Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group.


  1744. [06/04/2004] `Tour of the California Alps` fundraiser for brain tumor research!

  1745. [06/01/2004] Phildadelphia’s Most Renowned Chefs “Cook Up” Over $12,000 for Brain Tumor Research.

  1746. [05/18/2004] Role of estrogen receptor-related antigen in initiating the growth of human glioma cells.

  1747. [05/18/2004] Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.

  1748. [05/17/2004] Guilford Pharmaceuticals Expands Marketing and Distribution Agreement for GLIADEL(R) Wafer With Link Pharmaceuticals

  1749. [05/13/2004] Life sciences researchers see uses for synchrotron

  1750. [05/11/2004] Xenova and FDA reach agreement on SPA Phase III trial programme for TransMIDTM
    Enrolment to Begin Immediately


  1752. [05/05/2004] Mechanism That Enables Stem Cells to Track Migrating Brain Tumor Cells

  1753. [05/04/2004] First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

  1754. [04/18/2004] Targeted radiotherapy of brain tumours

  1755. [04/15/2004] Measurement of tamoxifen-induced apoptosis in glioblastoma by cytometric bead analysis of active caspase-3.

  1756. [04/15/2004] Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

  1757. [04/15/2004] MTH-68/H oncolytic viral treatment in human high-grade gliomas.

  1758. [04/15/2004] Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells.

  1759. [04/15/2004] Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.

  1760. [04/15/2004] Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

  1761. [04/15/2004] Prediction of neurocognitive outcome in adult brain tumor patients.

  1762. [04/15/2004] Clinical Cases in Neurology From Johns Hopkins Case 5: Altered Mental Status and Fever After Resection of Glioblastoma Multiforme

  1763. [04/12/2004] A New York City First: Brain Cancer Patient Receives Unique Liquid Radiation Treatment at NewYork-Presbyterian/Weill Cornell

  1764. [04/07/2004] Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial.

  1765. [04/07/2004] Expression and activation of signal regulatory protein alpha on astrocytomas.

  1766. [04/07/2004] Molecular classification and survival prediction in human gliomas based on proteome analysis.

  1767. [04/03/2004] Cancer cluster inquiry begins

  1768. [03/30/2004] Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

  1769. [03/30/2004] Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.

  1770. [03/26/2004] Cancer rates spur inquiry

  1771. [03/22/2004] New tumor suppressor may play important role in deadly brain tumors

  1772. [03/19/2004] Rebecca Libutti, 48, cancer`s tough foe

  1773. [03/10/2004] Local Group Publishes Third Cookbook to Fight Cancer

  1774. [03/10/2004] Third Annual Heroes of Hope Fundraising Golf Tournament Scheduled for Saturday, April 17th

  1775. [02/23/2004] A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease.

  1776. [02/07/2004] Thalidomide prolongs disease stabilization in those with recurrent glioblastoma.

  1777. [02/05/2004] NeoPharm Reaches Agreement with FDA on Phase III ``Precise`` Trial

  1778. [01/29/2004] Pharmacyclics Initiates Phase 1 Clinical Trial of Xcytrin Plus Temodar for the Treatment of Refractory Brain Tumors

  1779. [01/27/2004] Surgical Outcome following Resection of Contrast-Enhanced Pediatric Brainstem Gliomas.

  1780. [01/25/2004] Run/walk benefits Florida Brain Tumor Association

  1781. [01/22/2004] Brain tumor action week - request for memorial hats!

  1782. [01/09/2004] Rohm and Haas finds no environmental link in 15 brain-tumor cases

  1783. [01/06/2004] Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.

  1784. [01/06/2004] Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton.

  1785. [01/06/2004] Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

  1786. [01/06/2004] Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.

  1787. [01/02/2004] Phase II Trial of Gefitinib in Recurrent Glioblastoma

  1788. [12/28/2003] 12 with brain tumors tied to Rohm & Haas - A study, to be released, is to provide clues to the mystery.

  1789. [12/15/2003] Salvage therapy in patients with glioblastoma.

  1790. [12/10/2003] Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.

  1791. [12/10/2003] Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.

  1792. [12/10/2003] Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

  1793. [12/10/2003] Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

  1794. [12/02/2003] Phase II Trial of Gefitinib in Recurrent Glioblastoma.

  1795. [12/02/2003] Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.

  1796. [12/02/2003] Genetic analysis of a multifocal glioblastoma multiforme: a suitable tool to gain new aspects in glioma development.

  1797. [11/27/2003] New drugs show promise in brain tumors

  1798. [11/26/2003] Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas

  1799. [11/20/2003] Scientists Report on Promising New Approaches to Induce Cancer Cell Suicide

  1800. [11/20/2003] Trial Drugs Offer Hope for Brain Cancer

  1801. [11/20/2003] Jefferson scientists find radiation and blood vessel inhibitor more effective against brain tumors

  1802. [11/19/2003] Brain Cancer Research Moves Forward

  1803. [11/18/2003] Age-Related Outcomes, Immune Response in Patients with Brain Tumors Linked to Thymic Cells

  1804. [11/18/2003] Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing.

  1805. [11/18/2003] Expression of the b7-related molecule b7-h1 by glioma cells: a potential mechanism of immune paralysis.

  1806. [11/18/2003] Prognostic significance of annexin VII expression in glioblastomas multiforme in humans.

  1807. [11/17/2003] NeoPharm and Collaborators Present IL13-PE38QQR Clinical Data in Brain Cancer

  1808. [11/17/2003] Current status of malignant glioma chemotherapy - hype or hope?

  1809. [11/17/2003] Vincristine, ACNU, Carboplatin and Interferon Beta with Radiation (VAC-FERON-R) for Newly Diagnosed Glioblastoma Multiforme

  1810. [11/17/2003] The Hypoxia-Inducible Cell Death Gene BNIP3 In Malignant Gliomas

  1811. [11/17/2003] Stimulation Of Glioblastoma And Cerebral Microvascular Endothelial Cell Migration By Tumor-Associated Growth Factors

  1812. [11/17/2003] Pseudopalisading Cells In Glioblastoma Are Hypoxic And Could Represent A Rapidly Migrating Population

  1813. [11/14/2003] ARIAD Reports Its Lead Oncology Product, AP23573, Potently Blocks Brain Tumor Cell Growth; Presentation At Society for Neuro-Oncology Meeting

  1814. [11/14/2003] FOR THE LOVE OF COLYN: A Rockville Centre Lions Club Partnership Fundraising Event

  1815. [11/04/2003] To Operate - Or Not
    One family`s tough decision when good doctors differed

  1816. [11/03/2003] Temozolomide Stops Growth of Gliomas in Long-term Study

  1817. [11/03/2003] The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme.

  1818. [10/25/2003] First Viruses, Now Tumors: AIDS drug shows promise against brain cancers

  1819. [10/22/2003] Leukemia drug a treatment for brain cancer: Study

  1820. [10/21/2003] Research says drug may treat brain cancer

  1821. [10/20/2003] Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?

  1822. [10/20/2003] In lab studies, blocking expression of gene reduces invasion of deadly brain tumor cells

  1823. [10/13/2003] Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma.

  1824. [10/13/2003] Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.

  1825. [10/03/2003] Benchmark study of brain tumors points to resection over biopsy as one key to survival

  1826. [09/27/2003] ALF has history of attacking labs
    Previous victims call animal-rights group terrorists

  1827. [09/25/2003] Antigen targeted in therapy for melanoma also prompts immune response in brain tumor cells

  1828. [09/17/2003] Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997.

  1829. [09/17/2003] Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas.

  1830. [09/10/2003] Nanoparticles to Fight Cancer from the Inside

  1831. [09/09/2003] Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

  1832. [09/09/2003] Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

  1833. [09/09/2003] Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression.

  1834. [09/09/2003] Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.

  1835. [08/30/2003] Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma

  1836. [08/20/2003] Announcement of new online brain tumor journal

  1837. [08/12/2003] Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.

  1838. [08/06/2003] Treatment helps patient beat rare cancer

  1839. [07/27/2003] Tumor-free survival of 7 years after gene therapy for recurrent glioblastoma.

  1840. [07/22/2003] Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.

  1841. [07/22/2003] Second tumors after radiosurgery: tip of the iceberg or a bump in the road?

  1842. [07/20/2003] Precision instrument: MIT-Beth Israel trial targets tumors

  1843. [07/14/2003] Geron Reports on Preclinical Safety Studies of GRN163, an Inhibitor of Telomerase for the Treatment of Cancer

  1844. [07/08/2003] A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

  1845. [06/24/2003] Psychometric- and quality-of-life assessment in long-term glioblastoma survivors.

  1846. [06/24/2003] Glioblastoma in kidney transplant recipients. Report of five cases.

  1847. [06/24/2003] Wafer attacks tumors

  1848. [06/24/2003] Ken Stover is riding his bike in the Tour of the California Alps to raise money for the Musella Foundation.

  1849. [06/16/2003] Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study.

  1850. [06/16/2003] Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas.

  1851. [06/16/2003] Michael T. Glass Glioblastoma Research Foundation will be hosting a fundraiser at DIP (416 3rd Avenue between 29th and 30th) from 6:30 p.m.-9:30 p.m.

  1852. [06/14/2003] A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme

  1853. [06/14/2003] Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90

  1854. [06/14/2003] Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas

  1855. [06/14/2003] Phase II trial of fenretinide in patients with recurrent malignant gliomas - A North American Brain Tumor Consortium study

  1856. [06/14/2003] Phase II trial of ZD1839 for patients with first relapse glioblastoma

  1857. [06/14/2003] Temozolomide plus celecoxib for treatment of malignant gliomas

  1858. [06/14/2003] Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy

  1859. [06/14/2003] Survival analysis for patients with primary brain tumors treated with temozolomide

  1860. [06/14/2003] A phase II trial of temozolomide and oral VP-16 for adults with recurrent malignant glioma

  1861. [06/14/2003] C11-methionine PET in radiotherapy planning of glioma

  1862. [06/14/2003] Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database

  1863. [06/14/2003] A phase I trial of CC-5103, a potent thalidomide analog, in patients with recurrent high-grade gliomas and other refractory CNS malignancies

  1864. [06/14/2003] Safety and efficacy of temozolomide concomitant and sequential to radiotherapy in glioblastoma multiforme: Results of a phase II multicentric study

  1865. [06/14/2003] STI 571/hydroxyurea in progressive, pretreated glioblastoma (GB) patients (pts.)

  1866. [06/14/2003] Intracavitary placement of lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

  1867. [06/14/2003] Combination temozolomide (T) and pegylated liposomal doxorubicin (C) in patients with recurrent glioblastoma multiforme (GBM)

  1868. [06/14/2003] Preradiation combination of temozolomide (TMZ) and BCNU as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)

  1869. [06/14/2003] Phase II trial of daily oral temozolomide and thalidomide in newly diagnosed glioblastoma multiforme before radiation therapy

  1870. [06/14/2003] Temozolomide in glioblastoma: 4 years` experience with monthly or fortnigthly schedule

  1871. [06/14/2003] Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

  1872. [06/11/2003] Chemists unlock secret to activating tumor suppressor gene

  1873. [06/10/2003] Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

  1874. [06/08/2003] Altered cold virus kills brain tumors in mice

  1875. [06/03/2003] NeoPharm and Collaborators Present New IL13-PE38QQR Clinical Data In Brain Cancer

  1876. [05/27/2003] Glioblastoma and Cerebral Microvascular Endothelial Cell Migration in Response to Tumor-associated Growth Factors.

  1877. [05/22/2003] Use of a Vaccine Strain of Measles Virus Genetically Engineered to Produce Carcinoembryonic Antigen as a Novel Therapeutic Agent against Glioblastoma Multiforme.

  1878. [05/22/2003] Synergistic Down-Regulation of Urokinase Plasminogen Activator Receptor and Matrix Metalloproteinase-9 in SNB19 Glioblastoma Cells Efficiently Inhibits Glioma Cell Invasion, Angiogenesis, and Tumor Growth.

  1879. [05/22/2003] Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden.

  1880. [05/22/2003] Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.

  1881. [05/22/2003] MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen.

  1882. [05/07/2003] Altered Cold Virus Kills Tumors in Mice Genetically Altered Cold Virus Can Kill Brain Tumors and Spare Healthy Tissue, Researchers Say

  1883. [05/06/2003] Cancer patient`s courage gives hope - Calgarian pioneered drug trials

  1884. [04/30/2003] NeoPharm Announces New Clinical Trial Data for IL13-PE38QQR in Brain Cancer

  1885. [04/29/2003] Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  1886. [04/27/2003] Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394.

  1887. [04/08/2003] Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.

  1888. [04/02/2003] Therapy of Glioblastoma Multiforme Improved by the Antimutagenic Chloroquine

  1889. [04/01/2003] Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.

  1890. [03/19/2003] Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.

  1891. [03/19/2003] Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.

  1892. [03/19/2003] Chemosensitivity of glioblastoma cells during treatment with the organo-tin compound triethyltin(IV)lupinylsulfide hydrochloride.

  1893. [03/15/2003] Treatment Benefits Elderly Brain Cancer Patients

  1894. [03/12/2003] A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.

  1895. [03/12/2003] Symptomatic Spinal Dissemination of Malignant Astrocytoma

  1896. [03/11/2003] Extraneural metastases of paediatric brain tumours

  1897. [02/26/2003] FDA Approves Expanded Use Of Gliadel Wafer (Polifeprosan 20 With Carmustine Implant) For Primary Malignant Brain Cancer

  1898. [02/25/2003] Peregrine Pharmaceuticals Receives FDA Approval for its Cotara(TM) Phase III Registration Trial Design for Brain Cancer

  1899. [02/25/2003] Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.

  1900. [02/25/2003] High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.

  1901. [02/11/2003] Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.

  1902. [02/04/2003] A prospective study on glioblastoma in the elderly.

  1903. [02/04/2003] Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data.

  1904. [01/21/2003] A prospective study on glioblastoma in the elderly

  1905. [01/21/2003] The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review.

  1906. [01/14/2003] Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas.

  1907. [01/07/2003] Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated whole-brain radiation therapy.

  1908. [01/07/2003] Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.

  1909. [01/07/2003] Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand.

  1910. [01/07/2003] Eradication of glioblastoma, and breast and colon carcinoma xenografts by hsp70 depletion.

  1911. [01/07/2003] Tumor-Tracking Missiles: Researchers Develop a Possible New Treatment Strategy for Deadly Brain Tumors

  1912. [12/30/2002] Combination Chemotherapy Using Carboplatin (JM-8) and Etoposide (JET Therapy) for Recurrent Malignant Gliomas: A Phase II Study.

  1913. [12/28/2002] Induction of Glioblastoma Apoptosis Using Neural Stem Cell-mediated Delivery of Tumor Necrosis Factor-related Apoptosis-inducing Ligand1

  1914. [12/28/2002] Eradication of Glioblastoma, and Breast and Colon Carcinoma Xenografts by Hsp70 Depletion1

  1915. [12/18/2002] Wistar Institute-Developed Antibody Shows Promise Against Brain Tumors in Drexel University Trial

  1916. [11/26/2002] NeoPharm Presents Phase I/II Data for IL13-PE38 at the 7th Annual Society Of Neuro-Oncology (SNO) Annual Meeting

  1917. [11/25/2002] Methodist Foresees Fruits of Lab Seeding research to aid patients

  1918. [11/12/2002] Local chemotherapy with cisplatin-depot for glioblastoma multiforme.

  1919. [11/12/2002] Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma.


  1921. [10/23/2002] Potential of the Conditionally Replicative Adenovirus Ad5-Delta24RGD in the Treatment of Malignant Gliomas and Its Enhanced Effect with Radiotherapy.

  1922. [10/22/2002] Oates` cancer has not returned

  1923. [10/17/2002] Direct Therapeutics Receives Approval to Begin European Trial Of New Brain Cancer Drug - Trial Will Evaluate DTI-015 in Patients With Newly Diagnosed High-Grade Glioma, the Most Aggressive and Deadly Form of Brain Cancer

  1924. [10/14/2002] Preliminary data show good results at Studsvik`s BNCT clinic

  1925. [09/27/2002] New Hope for Patients With Brain Tumors

  1926. [09/25/2002] High-Dose Measles Vaccine Could Fight Brain Tumors

  1927. [09/25/2002] Man-Made Molecule May Thwart Brain Cancer

  1928. [09/24/2002] Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.

  1929. [09/24/2002] Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme.


  1931. [09/18/2002] Spatial expression of VEGF-A in human glioma.

  1932. [09/18/2002] Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.

  1933. [09/16/2002] Active Matrix Metalloproteinase 9 Expression Is Associated with Primary Glioblastoma Subtype1

  1934. [09/10/2002] Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis.

  1935. [09/10/2002] MRI of high-grade astrocytic tumors: early appearance and evolution.

  1936. [09/09/2002] NeoPharm Announces Additional Clinical Data for IL13-PE38 at European Association of Neuro-Oncology (EANO) Congress Encouraging Preliminary Data From Ongoing Phase I/II Trial Presented On Potential New Treatment for Deadly Brain Cancer

  1937. [08/25/2002] New drug may hold answer to cancer

  1938. [08/15/2002] Temozolomide as second-line chemotherapy for relapsed gliomas.

  1939. [08/15/2002] Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. Editor`s note: this article shows that genistein - which is a health food supplement - found in soy beans, may improve the results of BCNU chemotherapy.. at least in the test tube!

  1940. [08/15/2002] Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

  1941. [08/15/2002] Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Editor`s note: this is an experimental new blood test for glioblastomas!

  1942. [07/22/2002] Glioblastoma Distance Healing Project NOW RECRUITING PATIENTS WITH GLIOBLASTOMA

  1943. [07/16/2002] Pratt & Whitney leaves behind a trail of cancer.

  1944. [07/15/2002] Oncolytics Phase I/II Reolysin Glioma Trial Begun

  1945. [07/03/2002] Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (‘Oncolytics’) has started a Phase I/II brain cancer clinical trial with REOLYSIN®.

  1946. [06/01/2002] SuperGen`s Partaject(TM)-Delivered Busulfan is Safe and Effective in Patients with Neoplastic Meningitis
    Results from Phase I clinical trial presented at 38th Annual Meeting of the American Society of Clinical Oncology (ASCO)

  1947. [05/26/2002] Phase II trial of motexafin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) Motexafin gadolinium in combination with cranial radiation is tolerable for GBM patients; early follow-up shows a 6 month survival of 84%

  1948. [05/26/2002] Use of magnetic resonance spectroscopy (MRS) in malignant gliomas treated with temozolomide (TMZ) MRS may increase sensitivity of traditional MRI techniques for detecting tumor progression or response and our observations of tumor response by MRI suggest that multi-voxel MRS is crucial to evaluating response for inhomogeneous tumors (such as oligodendrogliomas).

  1949. [05/26/2002] The role of 3-step radioimmunotherapy (RIT) as adjuvant treatment in malignant gliomas Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival.

  1950. [05/26/2002] A phase I study of temozolomide (Temodar) and escalating doses of oral VP-16 for adults with recurrent malignant glioma The maximum tolerated dose of this combination in this heavily treated group of patients with recurrent malignant glioma is temozolomide 150 mg/m2/d for 5 days + oral VP-16 50 mg/m2/d for 12 days.

  1951. [05/26/2002] First line chemotherapy with cisplatin plus fractionated temozolomide (bid) in recurrent glioblastoma (GBM). This new regimen of DDP plus bid TMZ is effective in chemonaive recurrent GBM, with acceptable toxicity

  1952. [05/26/2002] Phase II study of temozolomide (TMZ) without radiotherapy in newly diagnosed glioblastoma multiforme (GBM) in an elderly population TMZ without radiotherapy may offer a safe, convenient, and efficient therapeutic alternative in elderly patients with newly diagnosed GBM.

  1953. [05/26/2002] Phase II trial with carboplatin (CBCDA) and etoposide (VP-16) in recurrent high grade gliomas In this clinical trial CBCDA + VP-16 has shown activity in recurrent AA and GBM, with a good toxicity profile.

  1954. [05/26/2002] A phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral etoposide combined with radiation therapy in the treatment of glioblastoma (GBM) No significant improvement in survival rate with this pre-irradiation chemotherapy.

  1955. [05/26/2002] Comparison of mixed anaplastic oligoastrocytoma and high-grade astrocytoma in North Central Cancer Treatment Group (NCCTG) clinical trials of high-grade glioma Study breaks down survival rate based on category of tumor.

  1956. [05/26/2002] Five years of glioblastoma multiforme (GBM) phase II trials at the radiation therapy oncology group (RTOG) Comparison of five experimental chemotherapies to BCNU results over 5 years.

  1957. [05/26/2002] Role of temozolomide (TMZ) for brain relapsed tumors: preliminary results Use of temodar as sole chemotherapy agent showed positive results in pts who had already had surgery, radiotherapy and chemotherapy and had recurrence of tumor.

  1958. [05/26/2002] Concurrent chemoradiotherapy in chemo- naive operated glioblastoma multiforme: a phase II study Pts given Docetaxel on first treatment day of each radiotherapy (RT) week with survival rate comparable to treatment plan of chemotherapy after RT.

  1959. [05/26/2002] Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy No significant difference between survival rate of pt treated with temodar + prinomastat vs temodar + placebo.

  1960. [05/26/2002] Safety profile and activity of high-dose temozolomide given daily x 3 every 2 weeks in patients with primary brain tumors. Temador was given safely at escalated dosages on days 1-3 and 14-16 every 28 days.

  1961. [05/26/2002] Overexpression of c-kit oncogene in human brain tumors Positive correlation between c-kit, a transdermal glycoprotein and more aggressive brain malignancy could lead to c-kit targeted therapies to treat high grade gliomas

  1962. [05/26/2002] Gliomas following organ transplantation: a tumor registry analysis: No evidence that primary brain tumors are found more frequently in transplant recipients relative to population.

  1963. [05/24/2002] Convection-enhanced intra-tumoral delivery of taxol for recurrent glioblastoma. Results of a phase I clinical study.
    Conclusion: Significant antitumor responses were seen.

  1964. [04/11/2002] Oncolytics Gets OK to Start Canadian Cancer Study (Dow Jones)
    CALGARY -(Dow Jones)- Oncolytics Biotech Inc. (ONCY) has received approval from Health Canada to start a Phase I/II clinical trial to investigate the use of REOLYSIN as a treatment for patients with recurrent malignant glioma, the most aggressive form of brain cancer.
    - Apr 11 8:03 AM ET

  1965. [12/19/2001] Drug May Give Brain Cancer Patients More Time (Cleveland - NewsNet5)
    Doctors have a new weapon in their fight to help treat the nearly 18,000 Americans who are diagnosed each year with a brain tumor.
    - Dec 18 5:57 PM ET

  1966. [12/07/2001] Guilford gets partial support for new Gliadel use (Reuters Securities)
    Guilford Pharmaceuticals Inc.(NasdaqNM: GLFD - news ) received partial support on Thursday from a U.S. advisory panel for the company`s push to expand approved uses for its Gliadel Wafer to treat certain brain tumors.
    - Dec 06 7:09 PM ET

  1967. [12/07/2001] Guilford Gets Partial Support for New Gliadel Use (Reuters)
    Guilford Pharmaceuticals Inc. received partial support on Thursday from a U.S. advisory panel for the company`s push to expand approved uses for its Gliadel Wafer to treat certain brain tumors.
    - Dec 06 7:12 PM ET

  1968. [12/04/2001] Older Age Dampens Response to Radiation Therapy (Reuters)
    Old age may limit the response to radiation therapy in patients with a certain type of brain cancer, suggesting that additional therapies should be investigated for older patients, according to researchers.
    - Dec 03 6:10 PM ET

  1969. [11/27/2001] Oates to Have Surgery for Brain Tumor (AP)
    Former Texas Rangers manager Johnny Oates, diagnosed this month with a brain tumor, will undergo surgery Tuesday.
    - Nov 19 7:36 PM ET

  1970. [11/27/2001] Ex-Rangers Manager Oates Undergoes Brain Surgery (Reuters)
    Former major league manager Johnny Oates underwent surgery for a brain tumor Tuesday at Johns Hopkins Hospital and is listed in good condition.
    - Nov 20 9:04 PM ET

  1971. [11/27/2001] Ex-Manager Oates Has Brain Surgery (AP)
    Former major league manager Johnny Oates underwent surgery Tuesday for a brain tumor and was listed in good condition at Johns Hopkins Hospital.
    - Nov 21 9:55 AM ET

  1972. [11/09/2001] Ex-Rangers Manager Has Brain Tumor (AP)
    Former Texas and Baltimore manager Johnny Oates has been diagnosed with the most aggressive form of primary brain tumors.
    - Nov 09 12:42 PM ET

  1973. [11/08/2001] Former Rangers Manager Oates Diagnosed with Brain Tumor (Reuters)
    Former Texas Rangers and Baltimore Orioles manager Johnny Oates has been diagnosed with a brain tumor and will undergo surgery at the end of the month in Virginia.
    - Nov 08 7:25 PM ET

  1974. [11/08/2001] Ex-Manager Oates Has Brain Tumor (AP)
    Former Texas manager Johnny Oates has been diagnosed with a brain tumor and will undergo surgery later this month.
    - Nov 08 7:16 PM ET

  1975. [11/07/2001] Pharmacyclics Announces Baseline Characteristics From Xcytrin Phase III Trial At ASTRO Meeting (PR Newswire)
    Pharmacyclics, Inc., today announced baseline results from its pivotal prospective, randomized, controlled Phase III clinical trial with its lead investigational agent, Xcytrin(R) Injection, for the potential treatment of brain metastases.
    - Nov 07 7:32 AM ET

  1976. [11/02/2001] Pharmacyclics Announces Six Xcytrin Abstracts to Be Presented at ASTRO Annual Meeting Next Week (PR Newswire)
    ... company`s pivotal 429-patient Phase III clinical trial of Xcytrin for the potential treatment of brain metastases.......That study will report on the strong correlation between tumor size and neurocognitive function, further validating one of the study`s two co-primary endpoints....... highlight Xcytrin`s potential utility in glioblastoma multiforme (i.e., GBM or primary brain tumors) and further elucidate Xcytrin`s unique mechanism of action....
    - Nov 02 7:30 AM ET

  1977. [11/01/2001] Cancer-Linked Gene Also Controls Stem Cells: Study (Reuters)
    A gene that helps suppress tumors also controls the proliferation of stem cells in the brains of mice, scientists have found. They say the discovery could help them better understand--and possibly treat--aggressive tumors of the brain and other types of cancer in humans.
    - Nov 01 5:44 PM ET

  1978. [11/01/2001] Pharmacyclics Reports First Quarter Results (PR Newswire)
    ... Phase III clinical trial of Xcytrin® (motexafin gadolinium) Injection for the treatment of brain metastases....... company`s Xcytrin Phase II clinical trial for treatment of glioblastoma multiforme (primary brain tumor)....
    - Nov 01 7:31 AM ET

  1979. [11/01/2001] Neurocrine Biosciences Reports Positive Third Quarter 2001 Results; Neurocrine Awarded SBIR Grant From NIH for GnRH Antagonist Program (PR Newswire)
    ... largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis,...
    - Nov 01 7:33 AM ET

  1980. [10/10/2001] Peregrine gets fast-track for brain cancer drug (Reuters Securities)
    Drug developer Peregrine Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration will give the company`s antibody-based brain cancer drug an expedited review if it is submitted for approval.
    - Oct 10 4:13 PM ET

  1981. [10/10/2001] FDA Grants Peregrine Pharmaceuticals Fast Track Review Status For Cotara in Brain Cancer (Business Wire)
    ...Cotara is Peregrine`s Tumor Necrosis Therapy (TNT) drug.......It is a radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out.......Cotara is currently being studied in a multi-center Phase II study for brain cancer....
    - Oct 10 11:01 AM ET

  1982. [10/04/2001] Mouse Model Developed for Deadly Brain Cancer (Reuters)
    An important advance in the frustrating battle against deadly brain cancers was reported here this week at the annual meeting of the American Neurological Association.
    - Oct 04 1:34 PM ET

  1983. [10/01/2001] Neurocrine Biosciences Announces Additional Positive Phase II Results With NBI-34060 in 331 Subjects With Transient Insomnia (PR Newswire)
    ... largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis,...
    - Oct 01 5:50 AM ET

  1984. [09/10/2001] NeoPharm Announces It is Seeking Orphan Drug Status for IL13-PE38 (Business Wire)
    NeoPharm, Inc. announced today that it has submitted an Orphan Drug Application for IL13-PE38 for the treatment of malignant glioma, a lethal form of brain cancer that includes glioblastoma multiforme and anaplastic astrocytoma.
    - Sep 10 7:06 AM ET

  1985. [09/07/2001] Genes That Sustain Cancer Found (HealthSCOUT)
    ...The researchers say the finding doubles the number of genes now known to help tumors build up a network of blood vessels to help themselves thrive....... the researchers screened more than 24,500 genes turned on in a kind of brain tumor called glioblastoma multiforme, which grow with oxygen levels about 15 times lower than...
    - Sep 07 2:40 AM ET

  1986. [08/30/2001] Researcher Finds Way to Slow Spread of Brain Tumors (PR Newswire)
    A New York Medical College neurophysiologist is closer to proving a new and non-invasive treatment for patients with glioblastomas. These common and virulent brain tumors are actively killing normal brain tissue to support their own growth.
    - Aug 30 5:00 PM ET

  1987. [08/23/2001] Pharmacyclics Reports Fourth Quarter and Fiscal 2001 Financial Results (PR Newswire)
    ... Phase III clinical trial of Xcytrin (motexafin gadolinium) Injection for the treatment of brain metastases....... company`s Xcytrin Phase II clinical trial for treatment of glioblastoma multiforme (primary brain tumor)....
    - Aug 23 7:30 AM ET

  1988. [08/13/2001] Geron Corporation Announcement: Kyowa Hakko Selects Telomerase Inhibitor Compound for Development (Business Wire)
    ... potent and specific telomerase inhibitory activity in vitro and exhibits significant anti-tumor activity against multiple types of human cancer cells.......In vivo studies in rodents demonstrated activity against human malignant glioblastoma (brain cancer)....... the most pathogenic features of cancer cells is their loss of growth control, which allows tumors to invade and grow in normal tissue, causing loss of organ function and in many cases,...
    - Aug 13 7:32 AM ET

  1989. [08/02/2001] Pharmacyclics Completes Patient Enrollment in Xcytrin Phase II Clinical Trial For Primary Brain Tumors (PR Newswire)
    Pharmacyclics, Inc. today announced the company has completed patient enrollment in a Phase II clinical trial to evaluate its lead investigational product, Xcytrin(R) Injection, for the potential treatment of glioblastoma multiforme, the most common primary central nervous system tumor in adults.
    - Aug 02 7:31 AM ET

  1990. [08/02/2001] INTRABEAM(TM) Trial at Children`s Memorial Hospital, Chicago May Offer New Hope to Children With Brain Tumors (PR Newswire)
    Photoelectron Corporation, a technology company dedicated to developing, manufacturing and marketing micro adaptive x-ray systems for multiple market applications, announced today that the Falk Brain Tumor Center at Children`s Memorial Hospital, Chicago has begun a program of treatments which the hospital believes may offer new hope to children with brain tumors.
    - Aug 02 8:15 AM ET

  1991. [07/31/2001] Neurocrine Biosciences Reports Second Quarter 2001 Results; Company Expands Clinical Development Efforts (PR Newswire)
    ...Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers,...
    - Jul 31 7:30 AM ET

  1992. [07/20/2001] Direct Therapeutics Awarded Patent for Medical Injection Device (Business Wire)
    ... anti-cancer product designed for direct injection to brain and liver tumors....... of anti-cancer agents in water-miscible, organic, tumor-penetrating solvent vehicles....
    - Jul 20 1:02 PM ET

  1993. [07/18/2001] Merck Granted Additional Six Months of Marketing Exclusivity for Mevacor-R- (Business Wire)
    ... studies demonstrated that lovastatin crosses the blood-brain and placental barriers.......Tumor increases were not seen at 20 and 100 mg/kg/day,...
    - Jul 18 3:52 PM ET

  1994. [07/19/2001] METVAN Effective in Neutralizing the Growth and Spread of Breast and Brain Cancer Tumors (PR Newswire)
    In a study described in the July issue of Clinical Cancer Research, researchers at the Parker Hughes Cancer Center found that the compound bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV){METVAN [VO(SO(4))(Me(2)-Phen)(20]} is effective in neutralizing the growth and spread of breast and brain cancer tumors.
    - Jul 19 9:40 AM ET

  1995. [07/16/2001] Gene May Predict Speed of Brain Tumor Recurrence (Reuters)
    The discovery of a gene that is overactive in an aggressive type of brain tumor may lead to better understanding of how such cancer spreads and help doctors predict how quickly tumors are likely to recur after treatment, according to a new report.
    - Jul 16 2:58 PM ET

  1996. [07/13/2001] Brain Cancer Vaccine Under Way (KGTV
    Brain tumors are one of the fastest growing cancers today.
    - Jul 13 6:23 PM ET

  1997. [06/19/2001] Common Virus May Fight Brain Tumors (Associated Press)
    In research that may offer new hope for treating an aggressive and lethal cancer, doctors say an injection of a common virus into the brains of mice caused tumors to shrink without causing other disease.
    - Jun 19 7:00 PM ET

  1998. [06/11/2001] Direct Therapeutics Awarded SBIR Grant (Business Wire)
    Direct Therapeutics Inc.,, a privately-held drug development company, today announced that the National Institutes of Health has awarded the company a Small Business Innovation Research grant for the development of techniques to evaluate the distribution of its DTI-015 product candidate for the treatment of brain tumors.
    - Jun 11 5:24 PM ET

  1999. [06/06/2001] Guilford`s Supplemental New Drug Application for GLIADEL(R) Wafer Accepted For Review by the FDA (PR Newswire)
    ...The first new therapy to be approved for the treatment of brain cancer in over two decades, GLIADEL® Wafer received marketin......GLIADEL® Wafers can be implanted in the cavity created when a brain tumor is surgically removed....
    - Jun 06 10:41 AM ET

  2000. [05/16/2001] Some Tumors Spread with Heart or Lung Transplants (Reuters)
    ...For donors with a tumor involving the nervous system, or neurologic tumors,......No tumor transmission occurred with donors who had brain tumor types known as astrocytomas or glioblastomas,...
    - May 16 5:17 PM ET

  2001. [05/16/2001] Clinical Trial Results Reported at ASCO on the Use of Celgene`s THALOMID(R) (Thalidomide) for the Treatment of Renal Cell Carcinoma and Glioblastoma (PR Newswire)
    ...This study evaluated patient response rate and tumor perfusion changes for a median of three cycles (1 cycle = 28 days) of treatment.......About Glioblastoma Multiforme Glioblastoma multiforme is the most aggressive form of the primary brain tumors known collectively as gliomas....
    - May 16 7:30 AM ET

  2002. [05/14/2001] Peregrine Announces Preliminary Results From Phase II Brain Cancer Trial (Business Wire)
    Peregrine Pharmaceuticals Inc. today announced Dr. Sunil Patel, associate professor of neurosurgery at the Medical University of South Carolina, presented preliminary efficacy and safety results from a Phase II brain cancer trial using Cotara(TM), Peregrine`s Tumor Necrosis Therapy drug.
    - May 14 3:30 PM ET

  2003. [05/14/2001] AEterna`s Neovastat shows ability to increase the angiostatin level in mice with implanted human brain cancer cells (Canada NewsWire)
    Today, AEterna Laboratories Inc. presented new data showing that Neovastat/AE-941 is able to increase the level of angiostatin in mice with implanted human glioblastoma, a form of brain cancer.
    - May 14 7:30 AM ET

  2004. [05/14/2001] AEterna`s Neovastat shows ability to increase the angiostatin level in mice with implanted human brain cancer cells (PR Newswire)
    Today, AEterna Laboratories Inc. presented new data showing that Neovastat/AE-941 is able to increase the level of angiostatin in mice with implanted human glioblastoma, a form of brain cancer.
    - May 14 7:32 AM ET

  2005. [05/14/2001] Pharmacyclics Reports Positive Clinical Results With Xcytrin for Treatment Of Brain Tumors and Other Cancers at ASCO Meeting (PR Newswire)
    Pharmacyclics, Inc. today reported results from several clinical trials with its lead product, Xcytrin(R) Injection, demonstrating that the investigational agent is well tolerated and may have clinical utility in a variety of cancers, including glioblastoma multiforme, childhood gliomas, pancreatic cancer and brain metastases, i.e., tumors that have spread to the brain from another part of the body.
    - May 14 9:01 AM ET

  2006. [05/11/2001] Breakthrough Cancer Drug Lifts Novartis Shares (Reuters)
    ...Attention now turns to initial trial results due on Monday that may give clues about how well the innovative leukemia drug can handle solid cancerous tumors as well.......Novartis says it also inhibits two other proteins: the c-kit receptor linked to GIST and small cell lung cancers, and the PDG-F receptor, active in some kinds of brain, prostate and soft tissue cancer....
    - May 11 7:21 AM ET

  2007. [05/08/2001] AstraZeneca Completes Enrollment in Phase III Non-Small Cell Lung Cancer Clinical Trial Program For IRESSA(R) (ZD1839) (PR Newswire)
    ...Clinical studies are ongoing regarding the use of IRESSA for other solid tumors.......The National Cancer Institute (NCI) or oncology cooperative groups are accruing patients into clinical trials with IRESSA in renal cell, bladder, glioblastoma and brain cancers.......Expression and overexpression of EGFR is found in many tumor types and clinical data suggests that excessive levels of EGFR are linked to poor prognosis,...
    - May 08 10:38 AM ET

  2008. [05/08/2001] National Brain Tumor Foundation Recognizes Pharmacyclics and Schering-Plough With Merit Award for Advancing Brain Tumor Research (PR Newswire)
    The National Brain Tumor Foundation announced today that its first annual Award of Merit will be given jointly to Pharmacyclics, Inc. and Schering-Plough Corporation for their contributions and ongoing commitment to researching and developing treatments for brain tumors.
    - May 08 7:30 AM ET

  2009. [05/08/2001] Pharmacyclics Receives National Brain Tumor Foundation`s Award of Merit for Advancing Brain Tumor Research (PR Newswire)
    Pharmacyclics, Inc. announced today that The National Brain Tumor Foundation has given its first annual Award of Merit jointly to Pharmacyclics, Inc. and Schering-Plough Corporation for their scientific and clinical contributions and ongoing commitment to researching and developing treatments for brain tumors.
    - May 08 7:31 AM ET

  2010. [05/07/2001] National Brain Tumor Awareness Week 2001; Innovative Wafer Therapy Has Enhanced Treatment Options, Renewed Hope (PR Newswire)
    This year more than 185,000 Americans will be diagnosed with primary or metastatic brain tumors, now the leading cause of solid tumor cancer death in children younger than age 20, and the third leading cause of cancer death in young adults between the ages of 20 to 39.
    - May 07 8:32 AM ET

  2011. [05/03/2001] Pharmacyclics Reports Third Quarter Results (PR Newswire)
    ...(motexafin gadolinium) Injection for the treatment of brain metastases.......Xcytrin is also being evaluated in a recently initiated Phase II clinical trial for treatment of glioblastoma multiforme (primary brain tumor)....
    - May 03 7:30 AM ET

  2012. [05/03/2001] Pharmacyclics Reports Third Quarter Results (PR Newswire)
    ...(motexafin gadolinium) Injection for the treatment of brain metastases.......Xcytrin is also being evaluated in a recently initiated Phase II clinical trial for treatment of glioblastoma multiforme (primary brain tumor)....
    - May 03 7:30 AM ET

  2013. [04/26/2001] Light Therapy Tested for Brain Tumors (Reuters)
    Brain tumors may be the next target for photodynamic therapy (PDT), which combines drugs and light to treat cancer and other conditions.
    - Apr 26 1:56 PM ET

  2014. [04/17/2001] Compound Shrinks Brain Tumors in Mice (Reuters)
    An experimental compound appears promising as a treatment for an incurable form of brain cancer, according to a study in animals. In experiments in mice, treatment with the drug stopped tumors from growing in some animals and shrank tumors in others.
    - Apr 17 2:21 PM ET

  2015. [04/11/2001] Publication of Preclinical IL13-PE38 Data Shows Potential of Neopharm Agent Against Glioblastoma Tumors (Business Wire)
    NeoPharm, Inc. announced today publication of data on its product IL13-PE38, a chimeric protein composed of human interleukin-13 and a truncated form of Pseudomonas exotoxin. In an experimental, preclinical tumor study, recently published in International Journal of Cancer, IL13-PE38 evidenced significant regression of glioblastoma tumors when injected into such tumors.
    - Apr 11 7:01 AM ET

  2016. [04/11/2001] NeoPharm Study Shows Effect on Tumors (Reuters)
    Biopharmaceutical company NeoPharm Inc. (NEOL.O) said on Wednesday that a study on its IL13-PE38 drug showed a significant regression of brain tumors.
    - Apr 11 7:49 AM ET

  2017. [04/11/2001] NeoPharm says drug study shows effect on tumors (Reuters Securities)
    Biopharmaceutical company NeoPharm Inc. said on Wednesday that a study on its IL13-PE38 drug showed a significant regression of brain tumors.
    - Apr 11 7:48 AM ET

  2018. [04/10/2001] Pharmacyclics Announces Start of Xcytrin Phase II Clinical Trial in Primary Brain Tumors (PR Newswire)
    Pharmacyclics, Inc. today announced the initiation of a Phase II clinical trial to evaluate the company`s investigational lead product, Xcytrin(R) Injection, for treatment of glioblastoma multiforme, the most common primary central nervous system tumor in adults.
    - Apr 10 7:30 AM ET

  2019. [04/05/2001] Doctors Using Tumors To Stop Brain Cancer (Cleveland - NewsNet5)
    The number of patients with brain cancer is on the rise, and usually, the outlook for survival is not good.
    - Apr 05 8:56 PM ET

  2020. [03/28/2001] MGI PHARMA Presents Further Data On Irofulven`s Anti-Tumor Activity at AACR Meeting (PR Newswire)
    MGI PHARMA, INC. today announced that six poster presentations on irofulven`s anti-tumor activity and mechanism of action were made at this year`s American Association for Cancer Research meeting held in New Orleans from March 24-28, 2001.
    - Mar 28 7:45 AM ET

  2021. [03/27/2001] Genaera Presents Data for Squalamine in Cancer at AACR (PR Newswire)
    ...Squalamine blocks the formation of blood vessels associated with tumors, and it is being developed clinically for the treatment of several advanced cancers.......I look forward to our planned clinical trial evaluating squalamine and radiation therapy for the treatment of glioblastoma multiforme brain tumors that will be conducted by the Radiation Therapy Oncology Group.``...
    - Mar 27 8:03 AM ET

  2022. [03/27/2001] AEterna Laboratories: Research Results Confirm Additional Mechanism of Action of its Lead Compound, Neovastat/AE-941 (PR Newswire)
    AEterna Laboratories Inc., today announced new results showing that its lead product, Neovastat/AE-941, specifically activates apoptosis of endothelial cells. Previous research had also shown that Neovastat has two other mechanisms of action inhibiting matrix metalloproteinases and Vascular Endothelial Growth Factor, all aimed at stopping a cancerous tumor`s growth, by blocking the formation of new blood vessels.
    - Mar 27 7:31 AM ET

  2023. [03/27/2001] AEterna Laboratories: Research Results Confirm Additional Mechanism of Action of its Lead Compound, Neovastat/AE-941 (Canada NewsWire)
    CNW/ - AEterna Laboratories Inc., today announced new results showing that its lead product, Neovastat/AE-941, specifically activates apoptosis of endothelial cells. Previous research had also shown that Neovastat has two other mechanisms of action inhibiting matrix metalloproteinases and Vascular Endothelial Growth Factor, all aimed at stopping a cancerous tumor`s growth, by blocking the formation of new blood vessels.
    - Mar 27 7:30 AM ET

  2024. [03/27/2001] Northwest Biotherapeutics Presents Information On Its Prostate and Brain Cancer Initiatives (PR Newswire)
    ...It also presented preclinical validation findings supporting the suitability of its DCVax(TM) platform as a possible treatment for advanced brain cancer.......we were able to demonstrate both CD8+ and CD4+ T cell reactivity with only two stimulations in vitro and demonstrated tumor-specific cytolytic activity and cytokine secretion.``...
    - Mar 27 10:29 AM ET

  2025. [03/14/2001] Brain Cancer Patients Get Hope From Pill (KITV
    According to the Brain Tumor Society, more than 100,000 Americans will be diagnosed with a brain tumor over the next year. In children and young adults, brain tumors are the second leading cause of cancer death. The cause is unknown, but certain factors can increase its risk, such as exposure to radiation or having an impaired immune system. In rare cases, brain tumors run in families.
    - Mar 14 10:22 PM ET

  2026. [03/07/2001] Genetic Discoveries May Aid Brain Tumor Treatment (Reuters)
    The identification of four genes overproduced by brain tumors may lead to a greater understanding of the causes of brain cancer and to better brain tumor diagnosis and treatments.
    - Mar 07 2:16 PM ET

  2027. [02/14/2001] Allos Therapeutics, Inc. Announces Year End 2000 Results (PR Newswire)
    ...-- Initiated its first pivotal Phase 3 trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13, and received Fast Track Status from the Food and Drug Administration for this indication....
    - Feb 14 7:45 AM ET

  2028. [02/07/2001] Panacea Pharmaceuticals, Inc. Announces Collaboration with Massachusetts Institute of Technology Utilizing Breakthrough Technology for Engineering Ultra Affinity Antibodies (Business Wire)
    ..., which have demonstrated that the overexpression of AAH leads to the transformation of normal cells to cancer cells in liver, brain, colon, pancreatic, and breast cancers......., oligodendroglioma, and primitive neuroectodermal tumors have shown a marked overexpression of AAH....
    - Feb 07 10:03 AM ET

  2029. [02/06/2001] New Therapy Offers Hope for Brain Cancer Patients (Reuters)
    A new treatment that teaches a patient`s immune cells to recognize cancer cells offers hope for longer survival with a deadly brain cancer called glioblastoma.
    - Feb 06 5:55 PM ET

  2030. [02/05/2001] AVAX Technologies Receives Contract From French Army to Evaluate Gene Therapy Technology (PR Newswire)
    ...The company has completed initial Phase I testing of the TK suicide gene technology in 20 patients with glioblastoma, a malignant brain tumor, and 11 patients with late stage melanoma....
    - Feb 05 8:00 AM ET

  2031. [02/02/2001] Demegen Receives Grant to Expand Cancer Research (PR Newswire)
    ...``Funds will be directed towards development of products to treat glioblastoma, a form of brain tumor, and colorectal cancer,`` Demegen President Richard Ekstrom said.......Glioblastomas represent 23 percent of all primary brain tumors, the second leading cause of cancer death in children under age 15 and in young adults up to age 34....
    - Feb 02 10:06 AM ET

  2032. [01/16/2001] Allos Therapeutics Initiates Clinical Study of RSR13 Combined With Chemotherapy for Recurrent Brain Cancer (PR Newswire)
    Allos Therapeutics, Inc. announced today the start of a Phase Ib/II study evaluating the safety and efficacy of RSR13 administered with BCNU chemotherapy for the treatment of recurrent malignant glioma, a type of primary brain cancer.
    - Jan 16 8:02 AM ET

  2033. [01/10/2001] Brain Tumors on the Rise in New York (Reuters)
    The rates of at least two different types of brain tumors appear to have risen drastically over the last 20 years in the state of New York, according to a new study conducted at the State University of New York at Buffalo.
    - Jan 10 3:06 PM ET

  2034. [01/09/2001] Peregrine Pharmaceuticals Announces Interim Results From Brain Cancer Trial and Plans to Initiate Phase III Registration Trial (Business Wire)
    Peregrine Pharmaceuticals Inc., announced today favorable preliminary results from its ongoing Phase II clinical trial of Cotara(TM), its Tumor Necrosis Therapy drug, in patients with recurrent or unresectable malignant glioma.
    - Jan 09 7:30 AM ET

  2035. [12/14/2000] Direct Therapeutics Announces Completion of Private Placement (Business Wire)
    Direct Therapeutics Inc.,, a privately-held drug development company, today announced that it has successfully completed a private placement which will provide $6.0 million in working capital to DTI.
    - Dec 14 10:06 AM ET

  2036. [12/11/2000] NeoPharm Announces Initiation of IL13-PE38 Phase I/II Clinical Trial in Brain Cancers (Business Wire)
    NeoPharm announced today the initiation of Phase I/II clinical trials for IL13-PE38 for patients with refractory glioblastoma multiforme, a lethal form of brain cancer. The initial clinical trial is being conducted by the New Approaches to Brain Tumor Therapy, a research consortium sponsored by the National Cancer Institute.
    - Dec 11 7:03 AM ET

  2037. [12/03/2000] New Drug Said To Help Some Leukemia (Associated Press)
    A leukemia drug that patients say has fewer side effects than aspirin has shown surprising success in early trials, researchers at the University of Texas M.D. Anderson Cancer Center say.
    - Dec 03 8:00 PM ET

  2038. [11/14/2000] Panacea Pharmaceuticals, Inc. Proceeds with Pre-Clinical Studies on Antisense Compound PAN-346 for Treating Brain Cancers (Business Wire)
    Panacea Pharmaceuticals, Inc. announced today that it is proceeding with pre-clinical studies for PAN-346, its lead candidate for the treatment of brain tumors. The Company remains on schedule to take PAN-346 into clinical trials in 2001.
    - Nov 14 1:34 PM ET

  2039. [11/13/2000] Onyx Reports Progress with Diverse Portfolio of Novel, Targeted Anticancer Therapeutics (PR Newswire)
    Onyx Pharmaceuticals, Inc. announced today that new clinical and preclinical data demonstrating the breadth of the company`s promising approaches to treating cancer were presented at the 11th Annual NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, held last week in Amsterdam, Netherlands.
    - Nov 13 6:31 AM ET

  2040. [11/09/2000] Guilford Announces Phase III Clinical Trial Results for Gliadel(R) Wafer in First-Line Treatment of Malignant Glioma (PR Newswire)
    Guilford Pharmaceuticals Inc. announced today that GLIADEL(R) Wafer prolonged survival and improved neurological outcomes in patients who were enrolled in a Phase III clinical trial to investigate the treatment benefit of GLIADEL(R) Wafer when used at the time of initial surgery for the treatment of malignant glioma.
    - Nov 09 8:19 AM ET

  2041. [10/25/2000] Allos Therapeutics, Inc. Announces Extended Survival Data of RSR13 For Primary and Metastatic Brain Cancers at the American Society Of Therapeutic Radiation & Oncology (PR Newswire)
    Allos Therapeutics, Inc. announced today positive, extended survival data of two Phase II clinical trials of RSR13 combined with cranial radiation therapy in patients with glioblastoma multiforme and patients with brain metastases.
    - Oct 25 11:36 AM ET

  2042. [10/25/2000] Pharmacyclics Reports Promising Results From Lead-In Phase of Ongoing Phase III Trial of Xcytrin for Brain Metastases (PR Newswire)
    Pharmacyclics, Inc. today reported results from the lead-in phase of its ongoing randomized Phase III clinical trial of Xcytrin(R) Injection, for the treatment of cancer patients with brain metastases, i.e., tumors that have spread to the brain from another part of the body.
    - Oct 25 9:00 AM ET

  2043. [10/24/2000] Guilford Reacquires Commercial Rights to GLIADEL(R) Wafer - First Localized Treatment for Malignant Brain Cancer (PR Newswire)
    Guilford Pharmaceuticals Inc., developer of GLIADEL(R) Wafer, the first significant new treatment for malignant brain cancer in over 20 years, today announced that it has reacquired commercial rights to its flagship biopolymer product, GLIADEL(R) Wafer, from Aventis Pharma, the pharmaceutical company of Aventis S.A..
    - Oct 24 8:07 AM ET

  2044. [10/19/2000] Allos Therapeutics, Inc. Announces Third Quarter Financial Results (PR Newswire)
    Allos Therapeutics, Inc. announced today financial results for the third quarter ended September 30, 2000.
    - Oct 19 7:04 PM ET

  2045. [10/18/2000] AVAX Technologies` TK Suicide Gene Data Published in Peer Reviewed Journal Gene Therapy (PR Newswire)
    AVAX Technologies, Inc. today announced that new data relating to its thymidine kinase suicide gene program has been published in an article entitled, ~~~Transient control of a virus-induced immunopathology by genetic immunosuppression~~~ in the peer-reviewed journal, Gene Therapy (2000 Sep;7(18):1536-42).
    - Oct 18 8:06 AM ET

  2046. [10/03/2000] AVAX Technologies Provides Update On Genopoietic Development Timelines (PR Newswire)
    AVAX Technologies, Inc. today announced details on the cell and gene therapy products being developed at its Genopoietic subsidiary in France.
    - Oct 03 9:28 AM ET

  2047. [10/03/2000] Direct Therapeutics Announces Two Phase I/II Clinical Trials of DTI-015 in Brain Tumors (Business Wire)
    Direct Therapeutics, Inc., a privately held drug development company, today announced that enrollment has opened for two Phase I/II clinical trials using its DTI-015 drug candidate for the direct treatment of glioblastoma multiforme, the most common primary form of brain cancer.
    - Oct 03 8:10 AM ET

  2048. [09/25/2000] TransMolecular, Inc. Announces Issuance of Three U.S. Patents (Business Wire)
    TransMolecular, Inc., a neuroscience biotechnology company developing products to treat central nervous system disorders, reported today the issuance of U.S. Patents No. 5,905,027 and No. 6,028,174, which cover the use of peptide and recombinant toxins, based on chlorotoxin a component of scorpion venom, and monoclonal antibodies, which specifically bind to glial-derived or meningioma-derived tumor cells.
    - Sep 25 9:29 AM ET

  2049. [09/14/2000] Biopure to Make Detection Test Available for its Oxygen Therapeutic Drugs (PR Newswire)
    Biopure Corporation today announced that it would make available a proprietary laboratory test that detects the presence of its oxygen therapeutic drugs in human and animal blood.
    - Sep 14 7:30 AM ET

  2050. [09/07/2000] Pharmacyclics Announces Start of NCI-Sponsored Phase I Clinical Trials Of Xcytrin in Primary Lung Cancer and With Stereotactic Radiosurgery For Advanced Brain Tumors (PR Newswire)
    Pharmacyclics, Inc. today announced the initiation of two Phase I clinical trials with the company`s Xcytrin(R) Injection.
    - Sep 07 7:30 AM ET

  2051. [09/06/2000] Biopure Completes Patient Enrollment in Phase III Hemopure(R) Trial (PR Newswire)
    Biopure Corporation today announced it has completed enrolling patients in the pivotal Phase III clinical trial evaluating its investigational oxygen therapeutic drug, Hemopure(R) [hemoglobin glutamer - 250], as a universally compatible alternative to red blood cell transfusion in patients undergoing orthopedic surgery.
    - Sep 06 7:29 AM ET

  2052. [09/06/2000] Biopure Completes Patient Enrollment in Phase III Hemopure(R) Trial (PR Newswire)
    Biopure Corporation today announced it has completed enrolling patients in the pivotal Phase III clinical trial evaluating its investigational oxygen therapeutic drug, Hemopure(R) [hemoglobin glutamer - 250], as a universally compatible alternative to red blood cell transfusion in patients undergoing orthopedic surgery.
    - Sep 06 7:29 AM ET

  2053. [08/24/2000] AVAX Technologies Completes Acquisition of Genopoietic (PR Newswire)
    AVAX Technologies, Inc., a biotechnology company developing individualized cancer vaccines based on its AC Vaccine(TM) technology, today announced that it has completed its acquisition of Genopoietic S.A., Paris, France.
    - Aug 24 9:14 AM ET

  2054. [08/03/2000] Techniclone Expands Cotara Clinical Study to Include Northwestern University (Business Wire)
    Techniclone Corporation, today announced that the ongoing Phase II clinical study for the treatment of brain cancer has been expanded to include Northwestern University, Chicago, Illinois.
    - Aug 03 9:35 AM ET

  2055. [07/20/2000] Techniclone Expands Cotara Clinical Study To Include the Barrow Neurological Institute (Business Wire)
    Techniclone Corporation, today announced that the ongoing Phase II clinical study for the treatment of brain cancer has been expanded to include the Barrow Neurological Institute, Phoenix, Arizona.
    - Jul 20 7:34 AM ET

  2056. [06/06/2000] Panacea Pharmaceuticals, Inc. Announces the Licensing of Cancer Platform Technology and Signing of Collaborative Research Agreement with Rhode Island Hospital/Brown University (Business Wire)
    Panacea Pharmaceuticals, Inc. announced today the signing of both a License Agreement and a Collaborative Research Agreement with Rhode Island Hospital/Brown University for Human Aspartyl Beta-Hydroxylase.
    - Jun 06 2:17 PM ET

  2057. [06/01/2000] Investigational Oxygen Therapeutic Sustains Critically Ill Woman Unable to Receive Blood Transfusion (PR Newswire)
    A young woman suffering from a life-threatening form of anemia was stabilized with an investigational oxygen therapeutic drug after standard therapy failed to control her condition, military doctors reported in today`s issue of the New England Journal of Medicine.
    - Jun 01 9:29 AM ET

  2058. [05/23/2000] Allos Therapeutics, Inc. Announces Improved Survival Achieved With RSR13 Combined With Radiation Therapy in Patients With Glioblastoma Multiforme Brain Cancer, Presented at the American Society of Clinical Oncology Meeting (PR Newswire)
    Allos Therapeutics, Inc. announces positive Phase II survival results with RSR13 combined with cranial radiation therapy in patients with newly diagnosed glioblastoma multiforme brain cancer.
    - May 23 1:30 PM ET

  2059. [04/28/2000] American Brain Tumor Association Awards $680,000 for Cutting Edge Research (PR Newswire)
    The American Brain Tumor Association, a national organization which exists to eliminate brain tumors through research and to meet the needs of brain tumor patients and their families, announces a commitment of $680,000 to fund the research efforts of 12 scientists at renowned institutions in the United States and Canada.
    - Apr 28 4:59 PM ET

  2060. [04/27/2000] Allos Therapeutics, Inc. Announces RSR13 Phase II Clinical Results to Be Presented in Two Oral Presentations at ASCO (PR Newswire)
    Allos Therapeutics, Inc. announced today that the preliminary results of two Phase II clinical trials of RSR13 combined with cranial radiation therapy in patients with primary brain cancer and patients with brain metastases will be presented in oral presentations at the upcoming meeting of the American Society of Clinical Oncology to be held May 20-23, 2000 in New Orleans.
    - Apr 27 9:00 AM ET

  2061. [04/27/2000] Neurocrine Biosciences Reports First Quarter 2000 Results (Business Wire)
    Neurocrine Biosciences Inc. today announced its financial results for the first quarter ended March 31, 2000.
    - Apr 27 7:35 AM ET

  2062. [04/20/2000] FDA Grants Marketing Approval to CAMPTOSAR(R) for First-Line Treatment of Metastatic Colorectal Cancer (PR Newswire)
    Pharmacia Corporation announced today that the U.S. Food and Drug Administration approved CAMPTOSAR(R), as first-line therapy for the treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil/leucovorin.
    - Apr 20 5:10 PM ET

  2063. [04/19/2000] Neurocrine Biosciences Announces Positive Findings in Phase I/II Malignant Brain Tumor Clinical Trial (Business Wire)
    Neurocrine Biosciences Inc. Wednesday announced results from a Phase I/II clinical trial in patients with advanced malignant glioma.
    - Apr 19 7:30 AM ET

  2064. [04/11/2000] Guilford Receives Milestone Payment For Regulatory Approval of Gliadel(R) Wafer in Spain (PR Newswire)
    Guilford Pharmaceuticals Inc. today announced that it has received a $1 million milestone payment from Aventis S.A. for regulatory approval of GLIADEL(R) Wafer in Spain.
    - Apr 11 8:30 AM ET

  2065. [04/05/2000] Scientists Exploit Unconventional Route of Protein Transport Involved in Tumor Growth; Key Protein Sequence Identified (PR Newswire)
    Scientists at Ciblex Corporation reported today the identification of a key protein sequence that permits a protein called fibroblast growth factor 2 to exit cancer cells and stimulate blood vessel and tumor growth.
    - Apr 05 12:00 PM ET

  2066. [03/29/2000] Stem cells may help treat brain tumors (Reuters)
    Neural stem cells, which eventually specialize to form various cells in the central nervous system, hold promise as a treatment for a particularly aggressive form of brain cancer, study findings suggest. Injection with genetically modified stem cells boosted the survival of mice with brain tumors, researchers report.
    - Mar 29 5:06 PM ET

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557